

cencora

Publications list

Including posters, presentations, and conference abstracts

November 2024

PUBLICATIONS

[Go to Posters](#)

Publication links by year:									
2020		2021		2022		2023		Error! Reference source not found.	
2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
1999									

*Xcenda provided medical writing and editorial assistance for manuscripts marked with an asterisk.

2024

Appukkuttan S, Yao J, Partridge J, Kong SX, Parkin J, Freedland SJ. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients. *J Med Econ.* 2024;27(1):145-152. doi:10.1080/13696998.2023.2299179

Brisibe T, Hikmat Z, Hyderey T, Gorey C, Boswell K. Healthcare decision-maker perceptions and trends in the utilization of preapproval information for formulary decision-making. *J Manag Care Spec Pharm.* 2024;30(5):475-479. doi:10.18553/jmcp.2024.30.5.475

Chaplin S, van Stiphout J, Chen A, Li E. Budget impact analysis of including biosimilar adalimumab on formulary: a United States payer perspective. *J Manag Care Spec Pharm.* 2024:1-13. doi:10.18553/jmcp.2024.24036

Fan L, Stewart F, Ruiz K, Devani D, Fusco N, Gill M, Amber V, Su W, Gangi A, Hanvesakul R. Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: a systematic review. *Heliyon.* 2024:e36883. doi:10.1016/j.heliyon.2024.e36883

Farber RH, Stull DE, Witherspoon B, Evans CJ, Yonan C, Bron M, Dhanda R, Jen E, O'Brien C. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. *J Patient Rep Outcomes.* 2024;8(1):2. doi:10.1186/s41687-023-00679-4

Gärtner BC, Beier D, Gosch G, Klaus W, Wendt L, Forster L, Schmidt K, Schwarz T. Zellkulturbasierte influenzaimpfstoffe: eine effektive impfstoffoption für unter 60-jährige [Cell-based influenza vaccines: an effective vaccine option for under 60-year-olds]. *Wien Klin Wochenschr.* 2024;136(Suppl 2):35-42. doi:10.1007/s00508-024-02327-3

Gärtner BC, Kwetkat A, Beier D, Wahle K, Schmidt KJ, Schwarz TF. Reply to letter to editor by Yin et al. *Vaccine.* 2024;42(9):2115-2116. doi:10.1016/j.vaccine.2024.01.051

Ketkar A, Willey V, Glasser L, Dobie C, Wenziger C, Teng C, Dube C, Hirpara S, Cunningham D, Verduzco-Gutierrez M. Assessing the burden and cost of COVID-19 across variants in commercially insured immunocompromised populations in the United States: updated results and trends from the ongoing EPOCH-US Study. *Adv Ther.* 2024 Mar;41(3):1075-1102. doi:10.1007/s12325-023-02754-0

Kim H, Serbin M, Hansen R, Lee K, Haubenberger D, Klepitskaya O, Hinton SC, Jen E. The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington's disease. *J Med Econ*. 2024 Jan-Dec;27(1):1348-1357. doi: 10.1080/13696998.2024.2412470

Lei M, Li Q, O'Day K, Meyer K, Wang A, Jun MP. Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective. [Published correction appears in *Future Oncol*. 2024 Jul 9:1-4. doi:10.1080/14796694.2024.2375846] *Future Oncol*. 2024 Jun 24:1-13. doi:10.1080/14796694.2024.2354157

Mannino DM, Roberts MH, Mapel DW, Zhang Q, Lunacsek O, Grabich S, van Stiphout J, Meadors BL, Feigler N, Pollack MF. National and local direct medical cost burden of COPD in the United States from 2016 to 2019 and projections through 2029. *Chest*. 2024;165(5):1093-1106. doi:10.1016/j.chest.2023.11.040

Roberts MH, Mannino DM, Mapel DW, Lunacsek O, Amin S, Farrelly E, Feigler N, Pollack MF. Disease burden and health-related quality of life (HRQoL) of chronic obstructive pulmonary disease (COPD) in the US—evidence from the Medical Expenditure Panel Survey (MEPS) from 2016–2019. *Int J Chron Obstruct Pulmon Dis*. 2024;19:1033-1046. doi:10.2147/COPD.S446696

Stewart F, Kistler K, Du Y, Singh RR, Dean BB, Kong SX. Exploring kidney dialysis costs in the United States: a scoping review. *J Med Econ*. 2024;27(1):618-625. doi:10.1080/13696998.2024.2342210

Wink S, Schroader BK, Giglio T, Ward A. Impact of health system specialty pharmacies on total cost of care in cancer treatment, a multisite review. *J Oncol Pharm Pract*. 2024 Jul;30(5):884-892. doi:10.1177/10781552231190016

Xing S, Bullano M, Hale S, Lokhandwala T, Murty S. Clinical and economic burden of suspected thrombotic thrombocytopenic purpura in US hospitals. *Am J Health Syst Pharm*. 2024;11:zxae167. doi:10.1093/ajhp/zxae167

2023

[Return to Publications](#)

Charrière S, Maillot F, Bouée S, Douillard C, Jacob C, Schneider KM, Theil J, Arnoux JB. Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients—a nationwide study of health insurance claims data. *Mol Genet Metab*. 2023;139(3):107625. doi:10.1016/j.ymgme.2023.107625

Chepke C, Benning B, Cicero S, Hull M, Giraldo E, Yeaw J, Coyle K, Jen E, Bron M. Investigating real-world benzotropine usage patterns in movement disorders: claims analysis and health care provider survey results. *Prim Care Companion CNS Disord*. 2023;25(4):22m03472. doi:10.4088/PCC.22m03472

Dall'Era M, Kalunian K, Eaddy M, Ogonnaya A, Farrelly E, Turowski E, Birardi V, Solomons N, Randhawa S, Mina-Osorio P. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States. *J Manag Care Spec Pharm*. 2023 Jan;29(1):36-45. doi:10.18553/jmcp.2022.21496

Dodda S, Bannister B, Hydery T, Gorey C, Dunlap S, Mody L. Best practices in designing preapproval information engagements for US health care decision makers. *J Manag Care Spec Pharm*. 2023;29(3):245-250. doi:10.18553/jmcp.2023.29.3.245

Freedland SJ, Hong A, El-Chaar N, Murty S, Ramaswamy K, Coutinho AD, Nimke D, Morgans AK. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting. *Prostate Cancer Prostatic Dis*. 2023 Sep;26(3):523-530. doi:10.1038/s41391-022-00622-6

*Frühwein M, Schelling J, Wahle K, Beier D, Kwetkat A, Schwarz TF. Weiterentwickelte zielgruppenorientierte influenzaimpfstoffe: neue evidenz zeigt höhere effektivität in älteren erwachsenen [Enhanced targeted influenza

vaccines: new evidence shows higher effectiveness in older adults]. *Dtsch Med Wochenschr.* 2023;148(09):556-562.

Gaul C, Seidel K, Heuck A, Silaidos C, Mrosowsky T, Eberhardt A, Fritz B, Jacob C. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis. *J Med Econ.* 2023;26(1):667-678. doi:10.1080/13696998.2023.2207413

Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T, Lopez-Gonzalez L, Zhou ZY, Edwards ML, Monnette A, Ogbonnaya A, Deyoung K, Venkatasetty D, Shi P, Aton L, Huang H, Conkling PR, Gordan L. Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy. *Adv Ther.* 2023;40(10):4189-4215. doi:10.1007/s12325-023-02601-2

Hart L, Ogbonnaya A, Boykin K, Deyoung K, Bailey R, Heritage T, Lopez-Gonzalez L, Huang H, Gordan L. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: a retrospective study from community oncology practices. *Cancer Med.* 2023 Apr;12(8):10020-10030. doi:10.1002/cam4.5738

Ketkar A, Willey V, Pollack M, Glasser L, Dobie C, Wenziger C, Teng C-C, Dube C, Cunningham D, Verduzco-Gutierrez M. Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study. *Curr Med Res Opin.* 2023 Aug;39(8):1103-1118. doi:10.1080/03007995.2023.2233819

Konstanski M, Schmidt KJ, Rössel A, Rasch A, Mittendorf T. Ökonomische langzeiteffekte innovativer therapiekonzepte am beispiel von hepatitis C [Economic long-term effects of innovative therapy concepts using the example of hepatitis C]. *Monitor Versorgungsforschung.* 2023;2:61-65.

Kota V, Ogbonnaya A, Farrelly E, Schroader BK, Raju A, Kristo F, Dalal M. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. *Future Oncol.* 2023 Mar;29(3):237-243. doi:10.18553/jmcp.2023.29.3.237

Kota V, Ogbonnaya A, Farrelly E, Schroader BK, Raju A, Kristo F, Dalal M. Economic impact of transformation to acute myeloid leukemia among actively managed patients with higher-risk myelodysplastic syndromes in the United States. *Adv Ther.* 2023;40(4):1655-1669. doi:10.1007/s12325-022-02370-4

Lee P, Kistler KD, Douyon L, Volodarsky R, Young A, Karve S, Challagulla S. Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma. *Drugs Real World Outcomes.* 2023 Mar;10(1):11-22. doi:1007/s40801-022-00332-4

Linnerooth S, Penley B, Sauvageau G, Ha J, Beal A, Craven J, Feeney E, Taddei-Allen P, Thomas N, Watkins J, Hydere T. Methodology for conducting a comprehensive product review in managed care. *J Manag Care Spec Pharm.* 2023;29(3):237-243. doi:10.18553/jmcp.2023.29.3.237

Lokhandwala T, Aly A, Farrelly E, Willey JP, Lamerato LE, Healey M, Coutinho AD, Seal BS. Management of hepatocellular carcinoma from diagnosis in routine clinical practice. *Hepat Oncol.* 2023 Jan;9(4). <https://doi.org/10.2217/hep-2021-0011>

Mallick R, Carlton R, Van Stiphout J. A budget impact model of maintenance treatment of chronic inflammatory demyelinating polyneuropathy with IgPro20 (Hizentra) relative to intravenous immunoglobulin in the United States. *Pharmacoecon Open.* 2023 Mar;7(2):243-255. doi:10.1007/s41669-023-00386-2

Meyer JM, Chepke C, Bera RB, Perez-Rodriguez MM, Lundt L, Franey EG, Dhanda R, Benning B, Bron M, Yonan C. Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review. *MHC.* 2023;13(5):225-232. doi:10.9740/mhc.2023.10.225

Mody RR, Meyer KL, Ward JM, O'Day KB. Cost per patient achieving treatment targets and number needed to treat with tirzepatide versus semaglutide 1 mg in patients with type 2 diabetes in the United States. *Diabetes Ther.* 2023 Dec;14(12):2045-2055. doi:10.1007/s13300-023-01470-w

Musallam KM, Lombard L, Kistler KD, Arregui M, Gilroy KS, Chamberlain C, Zagadailov E, Ruiz K, Taher AT. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps. *Am J Hematol*. 2023 Sep;98(9):1436-1451. doi:10.1002/ajh.27006

Ortman E, Westrich K, Buelt L. Driving progress in US value assessment. January 2023. https://www.phrmafoundation.org/wp-content/uploads/2023/01/Driving-Progress-in-U.S.-Value-Assessment_PhRMA-Foundation.pdf

Phelps H, Lin D, Keenan A, Raju A, Huang D, Cheng C-Y, Benson C. Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. *J Manag Care Spec Pharm*. 2023;29(3):303-313. doi:10.18553/jmcp.2023.29.3.303

Raval AD, Kistler KD, Tang Y, Vincenti F. Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies. *Transpl Infect Dis*. 2023 Feb;25(1):e14000. doi:10.1111/tid.14000

Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho A, Rybowski S. Characteristics and outcomes in cases of US male patients with metastatic breast cancer receiving abemaciclib in routine clinical practice. *Adv Ther*. 2023 Mar 30;40(5):2515-2523. doi:10.1007/s12325-023-02471-8

Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho AD, Rybowski S. Real-world analysis of clinical and demographic characteristics, treatment patterns, and outcomes in predominantly older patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in routine clinical practice. *Drugs Real World Outcomes*. 2023;10(4):589-603.

Rosa Bolling K, Wahdan Y, Warnock N, Lott J, Schoendorf J, Pisa F, Gomez-Espinosa E, Kistler K, Maiese B. Utilisation, effectiveness, and safety of immediate postpartum intrauterine device insertion: a systematic literature review. *BMJ Sex Reprod Health*. 2023 Apr;49(2):e1. doi:10.1136/bmjshr-2022-201579

Sireci AN, Krein PM, Hess LM, Khan T, Willey J, Ayars M, Deyoung K, Bhaskar S, Mumuney G, Coutinho A. Real-world biomarker testing patterns in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in a US community-based oncology practice setting. *Clin Lung Cancer*. 2023;24(5):429-436. doi:10.1016/j.clcc.2023.03.002

Westrich K, Hydere T, Dharbhamalla V, Buelt L, Zheng C, Loo V, Graff J. Payer perceptions and use of value assessment tools in the United States. *J Manag Care Spec Pharm*. 2023;29(5):582-588.

Williamson T, Gomez-Espinosa E, Stewart F, Dean BB, Singh R, Cui J, Kong SX. Poor adherence to clinical practice guidelines: a call to action for increased albuminuria testing in patients with type 2 diabetes. *J Diabetes Complicat*. 2023;37(8):108548.

2022

[Return to Publications](#)

Ailawadhi S, Ogbonnaya A, Murty S, Cherepanov D, Schroader BK, Romanus D, Farrelly E, Chari A. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. *Cancer Medicine*. 2022 Sep 24; <https://doi.org/10.1002/cam4.5239>

*Cho SK, Bekaii-Saab T, Kavati A, Babajanyan S, Hocum B, Barzi A. Value-based analysis of therapies in refractory metastatic colorectal cancer in US. *Clin Colorectal Cancer*. 2022 Dec;21(4):277-284. <https://doi.org/10.1016/j.clcc.2022.09.003>

*Dorscheid DR, Lee JK, Ramesh W, Greenwald M, Del Carpio J. Guidance for administering biologics for severe asthma and allergic conditions. *Can Respir J*. 2022 Sep 10;2022:9355606. doi:10.1155/2022/9355606

Farej R, Rametta M, La Rose A, Quillen A, McLeod K. A prospective, observational, multicenter study assessing adherence to interferon beta-1b therapy and patient satisfaction using the BETACONNECT auto-injector. *Neurol Ther.* 2022 Mar;11(1):373-384. doi.org/10.1007/s40120-022-00323-1

Fusco N, Sils B, Graff JS, Kistler K, Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: a systematic literature review. *J Manag Care Spec Pharm.* 2022 Apr 7;1-13. doi:10.18553/jmcp.2022.21270

Gärtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, Schwarz TF. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective—a systematic review of recently published literature on real-world data. *Vaccine.* 2022;40(22):2999-3008. doi:10.1016/j.vaccine.2022.04.019

Grabich S, Farrelly E, Ortmann R, Pollack M, Sze-Jung Wu S. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–2018. *Lupus Sci Med.* 2022 May;9(1):e000640. doi:10.1136/lupus-2021-000640

Heresi GA, Dean BB, Castillo H, Lee HF, Classi P, Stafkey-Mailey D, Kantorovich A, Morland K, Sketch MR, Wu BS, King CS. Identifying patients with group 3 pulmonary hypertension associated with COPD or ILD using an administrative claims database. *Lung.* 2022;200(2):187-203.

Hohmann C, Lutz M, Vignali S, Borchert K, Seidel K, Braun S, Baldus S, Näbauer M. Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study. *Thromb J.* 2022;20(1):37. 2022 Jul 4;20(1):37. doi:10.1186/s12959-022-00395-x

Huntington SF, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment patterns of follicular lymphoma in the United States: a claims analysis. *J Health Econ Outcomes Res.* 2022;9(2):115-122. doi:10.36469/001c.38070

Huttner HB, Gerner ST, Kuramatsu JB, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, Zotova E, Altevers J, Andersohn F, Christoph MJ, Yue P, Stross L, Schwab S. Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care. *Stroke.* 2022;53(2):532-543. doi:10.1161/STROKEAHA.121.034572

Link H, Thompson SF, Tian M, Haas JS, Meise D, Christopher Maas C, Dimitrov S. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany. *Support Care Cancer.* 2022 Nov;30(11):9317-9327. doi:10.1007/s00520-022-07353-3

Lokhandwala T, Acharya M, Farrelly E, Coutinho AD, Bell CF, Svedsater H. Within-trial economic analysis of resource use from COMET-ICE: a phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression. *J Manag Care Spec Pharm.* 2022;28(11):1261-1271. doi:10.18553/jmcp.2022.28.11.1261

Mahtani R, Oestreich N, Lalla D, Ogbonnaya A, Saundankar V, Willey J, Coutinho AD, McCann K. Health care resource utilization and costs for metastatic breast cancer patients newly treated with human epidermal growth factor receptor 2 (HER2)-targeted agents. *Clin Breast Cancer.* 2022;22(4):e488-e496. doi:10.1016/j.clbc.2021.11.013

Mayer W, Kontekakis A, Maas C, Kuchenbecker U, Behlke S, Schennach H. Comparison of procedure times and collection efficiencies using integrated and multistep nonintegrated procedures for extracorporeal photopheresis. *J Clin Apher.* 2022;37(4):332-339. doi:10.1002/jca.21974

Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care: an invited review. *Muscle Nerve.* 2022 Jun;65(6):630-639. <https://doi.org/10.1002/mus.27476>

Raju A, Pimple P, Stafkey-Mailey D, Farrelly E, Shetty S. Healthcare costs and resource utilization associated with the use of empagliflozin versus other antihyperglycemic agents among patients with type 2 diabetes mellitus and cardiovascular disease: a real-world retrospective cohort analysis. *Diabetes Ther.* 2022;13(1):25-42. doi:10.1007/s13300-021-01173-0

Reuschenbach M, Mihm S, Wölle R, Schneider KM, Jacob C, Greiner W, Hampf M, Goodman E. Healthcare resource utilization and costs in 23-25-year-old women with human papillomavirus (HPV) associated anogenital diseases in Germany—a retrospective analysis of statutory health insurance claims data. *BMC Health Serv Res.* 2022;22(1):1002. doi:10.1186/s12913-022-08397-1

Reuschenbach M, Stephan AJ, Saxena K, Prabhu VS, Jacob C, Schneider KM, Greiner W, Wölle R, Hampf M. Burden of CIN2+ diagnoses and conizations in women aged 18–45 years—a retrospective secondary data analysis of German statutory health insurance claims data. *Arch Gynecol Obstet.* 2022 Dec;306(6):2077-2092. doi:10.1007/s00404-022-06548-7

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Health resource utilization and associated healthcare costs of biologic disease modifying antirheumatic drugs in German patients with psoriatic arthritis. *Arthritis Care Res (Hoboken).* 2022 Sep;74(9):1435-1443. doi:10.1002/acr.24598

Seymour EK, Daniel L, Pointer E, Julian J, Smith ST, Schiffer CA. How to effectively decrease patient co-payments of high-cost drugs through innovation: lessons from the Karmanos Specialty Pharmacy. *JCO Oncol Pract.* 2022;18(1):e137-e151. doi:10.1200/OP.21.00207

Stephan AJ, Reuschenbach M, Saxena K, Prabhu VS, Jacob C, Schneider KM, Greiner W, Wölle R, Hampf M. Healthcare costs and resource use associated with cervical intraepithelial neoplasia and cervical conization: a retrospective study of German statutory health insurance claims data. *J Health Econ Outcomes Res.* 2022;9(1):128-139. doi:10.36469/001c.35329

Velez FF, Huang D, Mody L, Malone DC. Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder. *Expert Rev Pharmacoecon Outcomes Res.* 2022;22(4):599-607. doi:10.1080/14737167.2022.2016396

Xcenda. Alopecia areata: a global perspective of a disease that extends beyond hair loss. 2022. <https://www.xcenda.com/insights/alopecia-areata-a-global-perspective-of-a-disease-that-extends-beyond-hair-loss>

Ziemssen T, Kurzeja A, Muresan B, Haas JS, Alexander J, Driessen MT. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. *Neurodegener Dis Manag.* 2022;12(2):93-107. doi:10.2217/nmt-2021-0031

2021

[Return to Publications](#)

*Ananthasubramaniam K, Kitt TM, Saxena A, Feng Q, Nimke D, Spalding JR, Xu Y. Healthcare resource utilization among patients receiving non-invasive testing for coronary artery disease in an outpatient setting: a cohort study reflecting daily practice trends. *J Nucl Cardiol.* 2022;29:1776-1787. doi:10.1007/s12350-021-02549-2

Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K. Number needed to treat and number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. *J Affect Disord.* 2021 April;285:112-119.

Babajanyan S, Pollack M, Castelo S, Kavati A, Bekaii-Saab TS. Sequenced treatment after regorafenib and survival in metastatic colorectal cancer: a qualitative clinical review. *Colorectal Cancer.* 2021;10(1):CRC37.

Bensink M, Shah S, Shah N, Desai P, Khan F, Rubin A, Ailani J, Dougherty C, McLeod K, Quillen A. Tracking migraine digitally: The future of migraine management. *J Nurse Pract.* 2021;17(4):462.

Canbay A, Kachru N, Haas J, Meise D, Ozbay A, Sowa J. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. *Ann Transl Med.* 2021;9(8):615.

Chick J, Andersohn F, Guillo S, Borchert K, Toussi M, Braun S, Haas J, Kuppan K, Lemming O, Reines E, Tubach F. Safety and persistence of nalmefene treatment for alcohol dependence. Results from two post-authorisation safety studies. *Alcohol Alcohol.* 2021;56(5):556-564.

Davies F, Rifkin R, Castello C, Morgan G, Usami S, Abonour F, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. *Ann Hematol.* 2021 Sep;100(9):2325-2337. doi:10.1007/s00277-021-04534-8

Feng XS, Farej R, Dean BB, Xia F, Gaiser A, Kong SX, Elliott J, Lindemann S, Singh R. CKD prevalence among patients with and without type 2 diabetes: regional differences in the United States. *Kidney Med.* 2021;4(1):100385. doi:10.1016/j.xkme.2021.09.003

Konstanski M, Mittendorf M, Kuchenbecker U, Bubendorfer-Vorwerk H. Add-on payments and price evolution for orphan drugs in oncology in Germany from 2011 to 2019. *Value Outcomes Spotlight* (online). 2021;7(4).

Laurenz M, von Eiff C, Borchert K, Jacob C, Seidel K, Schley K. Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change—a claims database analysis. *Vaccine.* 2021 June;39(24):3287-3295.

Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH. Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. *JCO Oncol Pract.* 2021 Aug;17(8):e1235-e1245. doi:10.1200/OP.20.01047

Lokhandwala T, Coutinho AD, Bell CF. Retrospective analysis of disease severity, health care resource utilization, and costs among patients initiating belimumab for the treatment of systemic lupus erythematosus. *Clin Ther.* 2021 Aug;43(8):1320-1335. <https://doi.org/10.1016/j.clinthera.2021.06.009>

Lokhandwala T, Yue B, Coutinho AD, Bell CF. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. *Lupus Sci Med.* 2021 Feb;8(1): e000438. doi:10.1136/lupus-2020-000438

Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, McCart M, Eaddy M. Hospital readmissions and mortality among intubated and mechanically ventilated adult subjects with pneumonia due to gram-negative bacteria. *Respir Care.* 2021 May;66(5):742-750.

McBride A, Campbell K, Li E, Schroader B, Campbell D, Wang W. Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis. *J Manag Care Spec Pharm.* 2021 Sep;27(9):1230-1238. doi:10.18553/jmcp.2021.21010

McCann W, Haas SL, Norrett K, Cameron A, Etschmaier M, Duhig A, Yu S. The peanut allergy burden study: real-world impact of peanut allergy on resource utilization and productivity. *World Allergy Organ J.* 2021;14(3): 100525. doi:10.1016/j.waojou.2021.100525

Morland K, Raina A, Nails A, Classi P, Etschmaier M, Frantz RP. Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension. *Pulm Circ.* 2021;11(4):20458940211046761. doi:10.1177/20458940211046761

O'Day K, Mezzio DJ. Demystifying ICER's equal value of life years gained metric. *Value & Outcomes Spotlight.* 2021;7(1): 26-28.

Parcher B, Coder M. Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use. *J Manag Care Spec Pharm*. 2021;27(4):536-538. doi:10.18553/jmcp.2021.27.4.536

Pollack M, Keating K, Wissinger E, Jackson L, Sarnes E, Cuffel B. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. *Curr Med Res Opin*. 2021 Jan;37(1):59-70.

Schwartz GF, Patel A, Naik R, Lunascek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. *Ophthalmol Glaucoma*. 2021 Mar-Apr;4(2):117-125.

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis—a retrospective database study. *Rheumatol Ther*. 2021 Mar;8(1):483-497.

Spargo A, Yost C, Squires P, Raju A, Schroader B, Brown JD. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia. *J Manag Care Spec Pharm*. 2021 May;27(5):554-564.

Trefz F, Muntau AC, Schneider KM, Altevers J, Jacob C, Braun S, Greiner W, Jha A, Jain M, Alvarez I, Lane P, Zeiss C, Rutsch F. Health economic burden of patients with phenylketonuria (PKU)—a retrospective study of German health insurance claims data. *Mol Genet Metab Rep*. 2021;27:100764. doi:10.1016/j.ymgmr.2021.100764

Velez FF, Luderer HF, Gerwien R, Parcher B, Mezzio D, Malone DC. Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. *Postgrad Med*. 2021 May;133(4):421-427.

von der Schulenburg JG, Braun S, Zeidler J. Note from the editor, January 2021. *Health Econ Rev*. 2021;11(1):12. doi:10.1186/s13561-021-00311-5

*Weidner S, Diaz M, Schaedig C, Gordan L. Observations regarding the average sales price reimbursement methodology. *Evidence-Based Oncol*. 2021 June;27(4):SP156-SP160.

Wohlfahrt P, Nativi-Nicolau J, Zhang M, Selzman CH, Greene T, Conte J, Biber JE, Hess R, Mondesir FL, Wever-Pinzon O, Drakos SG, Gilbert EM, Kemeyou L, LaSalle B, Steinberg BA, Shah RU, Fang JC, Spertus JA, Stehlik J. Quality of life in patients with heart failure with recovered ejection fraction. *JAMA Cardiol*. 2021;6(8):957-962. doi:10.1001/jamacardio.2021.0939

Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. *J Manag Care Spec Pharm*. 2021 June;27(6):743-752.

2020

[Return to Publications](#)

Ataga KI, Gordeuk VR, Agodoa I, Colby JA, Gittings K, Allen IE. Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: a systematic literature review and meta-analysis. *PLoS One*. 2020 Apr 3;15(4):e0229959.

Borchert K, Jacob C, Wetzel N, Jänicke M, Eggers E, Sauer A, Marschner N, Altevers J, Mittendorf T, Greiner W. Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry. *Health Econ Rev*. 2020 Dec; 19(1):40. doi:10.1186/s13561-020-00297-6

- Bruno AS, Wilson JL, Opalinska JM, Nelson JJ, Lunascek OE, Stafkey-Mailey DR, Wiley JP. Recent real-world treatment patterns and outcomes in US patients with relapsed, refractory multiple myeloma. *Expert Rev Hematol*. 2020 Sep;13(9):1017-1025.
- Canbay A, Kachru N, Haas JS, Sowa J-P, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2020 Oct;52(7):1185-1194.
- Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. *Expert Rev Hematol*. 2020 Mar;9:1-13.
- Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2020 Jan;20(1):8-17.e16.
- Coleman C, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B. Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume Medicare and Medicaid physician providers. *J Mark Access Health Policy*. 2020;8(1). doi:10.1080/20016689.2020.1829883
- Costa OS, Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Specialist physician perspectives on non-medical switching of prescription medications. *J Mark Access Health Policy*. 2020;8(1):1-10.
- Dean BB, Saundankar V, Stafkey-Mailey D, Anguiano RH, Nelsen AC, Gordon K, Classi P. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. *Drugs Real World Outcomes*. 2020 Sep;7(3):229-239.
- Haas JS, Krinke K-S, Maas C, Hardt T, Barck I, Braun S. The burden of hyperkalemia in Germany—a real world evidence study assessing the treatment and costs of hyperkalemia. *BMC Nephrol*. 2020 Aug;21(1):332. doi:10.1186/s12882-020-01942-2
- Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/ polymyositis. *Open Access Rheumatol*. 2020 Feb;12:21-28.
- Jesudian AB, Ahmad M, Bozkya D, Migliaccio-Walle K. Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy. *J Manag Care Spec Pharm*. 2020 Jun;26(6):750-757.
- Kudrow D, Munjal S, Bensimon L, Lokhandwala T, Yue B, Coutinho AD, Silberstein SD. Treatment patterns of patients diagnosed with major headache disorders: a retrospective claims analysis. *Cephalalgia Reports*. 2020;3:1-12.
- Lin HM, Pan X, Biller A, Covery KJ, Huang H, Sugarman R, Scipione F, West H. Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. *Lung Cancer Manag*. 2020. <https://doi.org/10.2217/lmt-2020-0018>
- Lodise TP, Tilotson GS, Spargo A, Bozkaya D, Massey J. The role of delafloxacin in patients with community-acquired bacterial pneumonia in the outpatient setting: a budget impact model. *Clin Drug Investig*. 2020 Oct;40(10):961-971.
- Lopes S, O'Day K, Meyer K, Van Stiphout J, Puneekar Y, Radford M, Haas J. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany. *Pharmacoepidemiol Drug Saf*. 2020;29(3):270-278.
- Morrison VA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Galaznik A. Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma—use of non-R-CHOP alternative therapies and impact of

comorbidities on treatment choices and outcome: a Humedica database retrospective cohort analysis, 2007–2015. *J Geriatr Oncol*. 2020 Jan;11(1):41-54. doi:10.1016/j.jgo.2019.07.025

Reuschenbach M, Mihm S, Wölle R, Schneider KM, Jacob C, Braun S, Greiner W, Hampl M. Burden of HPV related anogenital diseases in young women in Germany—an analysis of German statutory health insurance claims data from 2012 to 2017. *BMC Infect Dis*. 2020 Apr; 20(1):297. doi:10.1186/s12879-020-05002-w

Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Communication of medication nonmedical switching policies and procedures by insurance companies: results of an e-survey. *Clin Ther*. 2020;42(6):1077-1086.

Salam T, Duhig A, Patel AA, Cameron A, Voelker J, Bookhart B, Coleman CI. Physicians' perspectives regarding non-medical switching of prescription medications: results of an internet e-survey. *PLoS One*. 2020;15(1):e0225867. doi:10.1371/journal.pone.0225867

Schultz NM, O'Day K, Sugarman R, Ramaswamy K. Budget impact of enzalutamide for nonmetastatic castration-resistant prostate cancer. *J Manag Care Spec Pharm*. 2020;26(4):538-549. doi:10.18553/jmcp.2020.19329

Shiozawa A, Hopson S, Fuldeore R, Stoelzel M, Ng D, Hairston J. Increased healthcare resource utilization and direct and indirect costs in patients with depression and comorbid overactive bladder: evidence from a retrospective, matched case-control cohort analysis. *Adv Ther*. 2020 Nov;37(11):4599-4613.

2019

[Return to Publications](#)

Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. *Clinicoecon Outcomes Res*. 2018 Aug;10:443-456.

Christensen S, Wolf E, Altevers J, Diaz-Cuervo H. Comorbidities and costs in HIV patients: a retrospective claims database analysis in Germany. *PLOS ONE*. 2019;14(11):e0224279.

Citrome L, Jain R, Tung A, Landsman-Blumberg PB, Kramer K, Ali S. Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder. *J Affect Disord*. 2019;249:378-384. doi:10.1016/j.jad.2019.01.044

Diel R, Ewig S, Blaas S, Jacob C, Juelich F, Korfmann G, Sohrab S, Sutharsan S, Rademacher J. Incidence of patients with non-cystic fibrosis bronchiectasis in Germany—a healthcare insurance claims data analysis. *Respir Med*. 2019;151:121-127.

François C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla B, Yue B, Orloski L, Kymes SM. Six-month use of droxidopa for neurogenic orthostatic hypotension. *Mov Disord Clin Pract*. 2019;6(3):235-242. doi:10.1002/mdc3.12726

Gordan L, Blazer M, Saundankar V, Kazzaz D, Weidner S, Eaddy M. Cost differential of immuno-oncology therapy delivered at community versus hospital clinics. *Am J Manag Care*. 2019 Mar;25(3):e66-e70.

Guptill JT, Runken MC, Eaddy M, Lunacsek OE, Fuldeore RM. Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis. *Am Health Drug Benefits*. 2019;12(3):127-135.

Guptill JT, Runken MC, Eaddy M, Lunacsek OE, Fuldeore RM, Blanchette CM, Zacherle E, Noone JM. Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US. *Patient Prefer Adherence*. 2019;13:649-655.

Hari P, Blazer M, Raju A, Farrelly E, Labotka R, Skacel T, Romanus D. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. *Expert Rev Hematol*. 2019 Jan;12(1):71-79.

Jacob C, Altevers J, Barck I, Hardt T, Braun S, Greiner W. Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. *ESC Heart Failure*. 2019;6(4):840-855.

Krinke K, Tangermann U, Amelung V, Krauth C. Public preferences for primary care provision in Germany—a discrete choice experiment. *BMC Family Practice*. 2019;20(1):80.

*Li J, Walker DR, Biesbrock G, Kristy RM, Yang H, Gao E, Koenigsberg S, Spalding JR, Kitt TM. Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: a survey of patients, imaging center staff, and physicians. *J Nucl Cardiol*. 2019 Aug 29. doi:10.1007/s12350-019-01863-0

Mathai SC, Hemnes AR, Manaker S, Anguiano RH, Dean BB, Saundankar V, Classi P, Nelsen AC, Gordon K, Ventetuolo CE. Identifying patients with pulmonary arterial hypertension using administrative claims algorithms. *Ann Am Thorac Soc*. 2019;16(7):797-806.

Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. *Future Oncol*. 2019;15(9):1021-1034.

Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A. Treatment patterns and survival outcomes in patients with follicular lymphoma: a 2007 to 2015 Humedica database study. *Clin Lymphoma Myeloma Leuk*. 2019 Apr;19(4):e172-e183. doi:10.1016/j.clml.2018.12.017

Murray B, Hessami SH, Gulyaev D, Lister J, Dmochowski R, Gillard KK, Stanistic S, Tung A, Boer R, Kaplan S. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. *J Comp Eff Res*. 2019;8(1):61-71. doi:10.2217/ce-2018-0079

Regal RE, Ren SP, Paige G, Alaniz C. Evaluation of vancomycin dosing in patients with cirrhosis: beginning deliveries about a new nomogram. *Hosp Pharm*. 2019;54(2):125-129. doi:10.1177/0018578718772266

Runken MC, Caraceni P, Fernandez J, Zipprich A, Carlton R, Bunke M. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. *Health Econ Rev*. 2019 Jul;9(1):22. doi:10.1186/s13561-019-0237-7

Schroader B, Kong S, Anderson S, Williamson T, Sireci A, Shields K. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers. *Expert Rev Anticancer Ther*. 2019 Nov;19(11):929-938. doi:10.1080/14737140.2019.1682554

Slater JD, Eaddy M, Butts CM, Meltser I, Murty S. The real-world economic impact of home-based video electroencephalography: the payer perspective. *J Med Econ*. 2019 Oct;22(10):1030-1040.

Trefz K, Muntau A, Kohlscheen K, Altevers J, Jacob C, Braun S, Greiner W, Jha A, Jain M, Alvarez I, Lane P, Schröder C, Rutsch F. Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities—a retrospective study of German health insurance claims data. *Orphanet J Rare Dis*. 2019;14(1):181.

Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. *Cephalalgia*. 2019;39(5):608-616.

- Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. *Clinicoecon Outcomes Res*. 2018 Aug;10:443-456.
- Alemayehu B, Speiser J, Bloudek L, Sarnes E. Costs associated with long-acting insulin analogues in patients with diabetes. *Am J Manag Care*. 2018 Jul;24(8 Spec No.):SP265-SP272.
- Bell CF, Coutinho AD, Farrelly E, Lokhandwala T, Landsman-Blumberg P. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care. *J Med Econ*. 2018 Jun 3;21(6):629-638.
- Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. *Leuk Lymphoma*. 2018 Jun;60(1):49-59.
- Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV. Economic burden of patients treated for higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States. *Pharmacoecoon Open*. 2019 Jun;3(2):237-245.
- Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. *Leuk Res*. 2018 Aug;71:27-33.
- Campbell D, O'Day K, Hertel N, Penrod JR, Manley Daumont M, Lees M. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions. *Popul Health Metr*. 2018 Nov 26;16(1):17.
- Carlton R, Coppolecchia R, Khalaf-Gillard K, Lennert B, Moradi A, Williamson T, Cameron J. Budget impact of appropriate low-dose aspirin use for primary and secondary cardiovascular event prevention in the managed care setting. *J Manag Care Spec Pharm*. 2018 Nov;24(11):1102-1111. doi:10.18553/jmcp.2018.24.11.1102
- Clark R, Bozkaya D, Levenberg M, Faulkner S, Smith TW, Gerberd RA. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2%. *J Med Econ*. 2018 May;21:1-8.
- Corren J, Kavati A, Ortiz B, Vegesna A, Colby JA, Ruiz K, Panettieri RA Jr. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. *Curr Med Res Opin*. 2018 Jan;34(1):65-80.
- Coutinho AD, Gandhi K, Fuldeore RM, Landsman-Blumberg PB, Gandhi S. Long-term opioid users with chronic noncancer pain: assessment of opioid abuse risk and relationship with healthcare resource use. *J Opioid Manag*. 2018 Mar/Apr;14(2):131-141.
- Coutinho AD, Raju AD, Wang W, Stafkey-Mailey D, Shetty S, Sander SD. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. *Curr Med Res Opin*. 2018 Jun;34(6): 1005-1012.
- Gordan L, Blazer M, Saundankar V, Kazzaz D, Weidner S, Eaddy M. Cost differences associated with oncology care delivered in a community setting versus a hospital setting: a matched-claims analysis of patients with breast, colorectal, and lung cancers. *J Oncol Pract*. 2018 Oct;14(12):e729-e738.
- Hari P, Blazer M, Raju A, Farrelly E, Labotka R, Skacel T, Romanus D. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. *Expert Rev Hematol*. 2019 Jan;12(1):71-79.

Hari P, Romanus D, Luptakova K, Blazer M, Yong C, Raju A, Farrelly E, Labotka R, Morrison VA. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. *J Geriatr Oncol*. 2018 Mar;9(2):138-144.

Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. *Clin Lymphoma Myeloma Leuk*. 2018 Feb;18(2):152-160.

Note: This article has been cited in clinical practice guidelines (ASCO/Cancer Care Ontario 2019 Joint Clinical Practice Guidelines for the treatment of multiple myeloma).

Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM, Zielinski MA, Frajzyngier V, Gerber RA. Patient impact and economic burden of mild-to-moderate atopic dermatitis. *Curr Med Res Opin*. 2018 Dec;34(12):2177-2185.

Humphries TJ, Rule B, Ogonnaya A, Eaddy M, Lunacsek O, Lamerato L, Pocoski J. Cardiovascular comorbidities in a United States patient population with hemophilia A: a comprehensive chart review. *Adv Med Sci*. 2018 Jul;63(2):329-333.

Krüger K, Von Hinüber U, Meier F, Tian H, Böhm K, Jugl S, Borchert K, Miese D, König C, Braun S. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. *Rheumatol Int*. 2018 Nov;38(11):2121-2131.

Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. *PLoS One*. 2018;13(5):e0197905.

Lamerato L, Price K, Szymialis R, Eaddy M, Ogonnaya A, Shih HC, Ahmad H. Comparative evaluation of treatment patterns and healthcare utilization of newly-diagnosed rheumatoid arthritis patients by anti-cyclic citrullinated peptide antibody status. *J Med Econ*. 2018 Mar;21(3):231-240.

Makhija D, Alscher MD, Becker S, D'Alonzo S, Mehrotra R, Wong L, McLeod K, Danek J, Gellens M, Kudelka T, Sloand JA, Laplante S. Remote monitoring of automated peritoneal dialysis patients: assessing clinical and economic value. *Telemed J E Health*. 2018;24(4):315-323. doi:10.1089/tmj.2017.0046

Mezzio DJ, Nguyen VB, Kiselica A, O'Day K. Evaluating the presence of cognitive biases in health care decision making: a survey of US formulary decision makers. *J Manag Care Spec Pharm*. 2018;24(11):1173-1183. doi:10.18553/jmcp.2018.24.11.1173

Morrison VA, Bell JA, Hamilton L, Ogonnaya A, Shih HC, Hennenfent K, Eaddy M, Shou Y, Galaznik A. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. *Future Oncol*. 2018;14(25):2627-2642.

Neufeld EJ, Sidonio RF Jr, O'Day K, Runken MC, Meyer K, Spears J. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. *J Med Econ*. 2018 Aug;21(8):762-769.

Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2301-2311. doi:10.2147/COPD.S163795

Shetty S, Stafkey-Mailey D, Yue B, Coutinho AD, Wang W, Del Parigi A, Sander SD, Coleman CI. The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. *Curr Med Res Opin*. 2018;34(6):1081-1087. doi:10.1080/03007995.2018.1445620

Song TT, Brown D, Karjalainen M, Lehnigk U, Lieberman P. Value of a second dose of epinephrine during anaphylaxis: a patient/caregiver survey. *J Allergy Clin Immunol Pract*. 2018;6(5):1559-1567. doi:10.1016/j.jaip.2018.01.019

Song TT, Brown D, Lehnigk U, Corvino FA, Lieberman P. Anaphylaxis care guidelines and the effect on health care resource use in the United States. *Ann Allergy Asthma Immunol*. 2018;121(1):132-134.e3. doi:10.1016/j.anai.2018.03.018

Stein J, Haas J, Ong S, Borchert K, Hardt T, Lechat E, Nip K, Foerster D, Braun S, Baumgart DC. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany: a real-world evidence analysis. *Clinicoecon Outcomes Res*. 2018 Feb;10:93-103.

2017

[Return to Publications](#)

Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. *J Med Econ*. 2017;20(3):297-302. doi:10.1080/13696998.2016.1258366

Cairo MS, Thompson S, Tangirala K, Eaddy M. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. *Clin Lymphoma Myeloma Leuk*. 2017 Mar;17(3):173-178.

Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, Panettieri RA Jr. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. *Allergy Asthma Proc*. 2017 Jul 1;38(4):250-263.

Fazeli Farsani S, Brodovicz KG, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis in adults with type 1 diabetes: a systematic literature review. *BMJ Open*. 2017 Aug 1;7(7):e016587.

Note: This article has been cited in a consensus report (2021 Continuous Ketone Monitoring Consensus Report 2021) and in a chapter in the book, "Acid-Base Balance," 2021.

François C, Biaggioni I, Shihao C, Ogbonnaya A, Shih HC, Farrelly E, Ziemann A, Duhig A. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease. *J Med Econ*. 2017 May;20(5):525-532. doi:10.1080/13696998.2017.1284668

François C, Stern JM, Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A, Shen V, Tan R. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome. *J Mark Access Health Policy*. 2017 Jan 1;5(1):1318691.

Gordan L, Grogg A, Blazer M, Fortner B. Unintended consequences in cancer care delivery created by the Medicare Part B proposal: is the clinical rationale for the experiment flawed? *J Oncol Pract*. 2017 Feb;13(2):e139-e151.

Jacob C, Haas JS, Bechtel B, Kardos P, Braun S. Assessing asthma severity based on claims data: a systematic review. *Eur J Health Econ*. 2017;18(2):227-241.

Lokhandwala T, Bittoni MA, Dann RA, D'Souza AO, Johnson M, Nagy RJ, Lanman RB, Merritt RE, Carbone DP. Costs of diagnostic assessment for lung cancer: a Medicare claims analysis. *Clin Lung Cancer*. 2017 Jan;18(1):e27-e34.

Maiese BA, Pham AT, Shah MV, Eaddy MT, Lunacsek OE, Wan GJ. Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) plus other IV analgesics or IV opioid monotherapy for postoperative pain. *Adv Ther*. 2017;34(2):421-435.

Note: This article has been cited in clinical practice guidelines (2021 Guidelines for Opioid Prescribing After Analgesia After Common Otolaryngology Operations from the American Academy of Otolaryngology—Head and Neck Surgery).

Marino J, Ruban C, Saunders W, Blanchette CM. Examining the rate of exacerbations amongst COPD Medicare population with type 2 diabetes. *J Health Econ Outcomes Res*. 2017;5(2):183-193.

Orange JS, Johnson M, Lennert B, Shields K, Eaddy M. Multispecialty rating of evidence-based conditions for intravenous immunoglobulin therapy using a 3-axis prioritization algorithm. *Am Health Drug Benefits*. 2017 May;10(3):134-142.

Theidel U, Vaatainen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. *ESC Heart Fail*. 2017;4(3):274-281.

Vega C, Becker RV, Mucha L, Lorenz BH, Eaddy MT, Ogbonnaya AO. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder. *Curr Med Res Opin*. 2017 Oct;33(10):1879-1889.

Watson C, Prosser C, Braun S, Landsman-Blumberg PB, Gleissner E, Naoshy S. Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany. *Clinicoecon Outcomes Res*. 2017;9:85-97.

Weatherall J, Bloudek L, Buchs S. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine. *Curr Med Res Opin*. 2017 Feb;33(2):231-238.

Ziemssen T, Prosser C, Haas JS, Lee A, Braun S, Landsman-Blumberg P, Kempel A, Gleißner E, Patel S, Huang MY. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. *BMC Neurol*. 2017 Mar 27;17(1):62.

2016

[Return to Publications](#)

Altevers J, Lukaschek K, Baumert J, Kruse J, Meisinger C, Emeny RT, Ladwig KH. Poor structural social support is associated with an increased risk of Type 2 diabetes mellitus: findings from the MONICA/KORA Augsburg cohort study. *Diabet Med*. 2016;33(1):47-54.

Andersohn F, Claes AK, Kulp W, Mahlich J, Rockstroh JK. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison. *BMC Infect Dis*. 2016;16(1):10.

Boswell K, Sarnes E, Meyer K, Grossman F, Rajagopalan K, Hassan M. Review of outcomes associated with restricted access to atypical antipsychotics. *Am J Manag Care*. 2016;22(6):e208-e214.

Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. *J Med Econ*. 2016 Jul;19(7):649-654.

Bramley T, Antao V, Lunacsek O, Hennenfent K, Masaquel A. The economic burden of end-of-life care in metastatic breast cancer. *J Med Econ*. 2016 Nov;19(11):1075-1080.

Bui CN, O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, Popelar B, Tang H, Balk M. Budget impact of enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer. *J Manag Care Spec Pharm*. 2016;22(2):163-170.

Campbell C, Eaddy M, Raju A, Carlton R, Boswell K, Mallick R, Wright D. Treatment patterns and outcomes in patients with varicose veins. *Am Health Drug Benefits*. 2016;9(8):455-465.

Choti MA, Thomas M, Wong SL, Eaddy M, Pawlik TM, Hirose K, Weiss MJ, Kish J, Green MR. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. *Ann Surg Oncol*. 2016 Feb;23(2):375-381.

- Coutinho A, Lokhandwala T, Boggs RL, Landsman-Blumberg P, Priest J, Stempel DA. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. *Int J Chron Obstruct Pulmon Dis*. 2016 Jun 8;11:1223-1231.
- Damm K, Volk J, Horn A, Allam JP, Troensegaard-Petersen N, Serup-Hansen N, Winkler T, Thiessen I, Borchert K, Wüstenberg EG, Mittendorf T. Patient preferences in allergy immunotherapy (AIT) in Germany—a discrete-choice-experiment. *Health Econ Rev*. 2016;6(1):32.
- Damm O, Witte J, Wetzka S, Prosser C, Braun S, Welte R, Greiner W. Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. *Int J Public Health*. 2016;61(7):847-860.
- Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, Piau-Louis E, Doody RS, Galasko D, Gauthier S, Frank L; Patient-Reported Outcome Consortium's Cognition Working Group. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: the qualitative research phase. *Alzheimers Dement*. 2016;12(1):75-84. doi:10.1016/j.jalz.2015.04.008
- Haas J, Braun S, Wutzler P. Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013. *Eur J Health Econ*. 2016;17(6):669-679.
- Jacob C, Annoni E, Haas JS, Braun S, Winking M, Franke J. Burden of disease of reoperations in instrumental spinal surgeries in Germany. *Eur Spine J*. 2016;25(3):807-813.
- Jacob C, Bechtel B, Engel S, Kardos P, Linder R, Braun S, Greiner W. Healthcare costs and resource utilization of asthma in Germany: a claims data analysis. *Eur J Health Econ*. 2016;17(2):195-201.
- Jacob C, Haas J, Bechtel B, Kardos P, Braun S. Assessing asthma severity based on claims data: a systematic review. *Eur J Health Econ*. 2016;18(2):227-241.
- Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. *Expert Rev Hematol*. 2016 Jul;9(7):707-717.
- Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC. Measures of outcome for stimulant trials: ACTION recommendations and research agenda. *Drug Alcohol Depend*. 2016;158:1-7. doi:10.1016/j.drugalcdep.2015.11.004
- Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. *Clin Ophthalmol*. 2016;10:2443-2453.
- Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. *J Med Econ*. 2016 Mar;19(3):203-212.
- Lunacsek O, Ravelo A, Coutinho AD, Hazard S, Green MR, Willey J, Eaddy M, Goertz HP. First-line treatment with bevacizumab and platinum doublet combination in non-squamous non-small cell lung cancer: a retrospective cohort study in US oncology community practices. *Drugs Real World Outcomes*. 2016 Sep;3(3):333-343.
- Marre C, Riggs K, Colby J, Aigbogun MS, Hartry A, Tan R, Duhig A, McLaughlin T. The role of dependence in Alzheimer's disease dementia: a systematic literature review. *Alzheimers Dement*. 2016 Jul;12(7):P1009.
- Morland K, Carroll C, Brizner D, Meltzer E, Munzel U, Lipworth B. Implication of alternative minimal clinically important difference threshold estimation methods on technology assessment. *Int J Technol Assess Health Care*. 2016 Jan;32(6):371-375.

Nichols KK., Bacharach J, Holland E, Kislan T, Shettle L, Lunacsek O, Lennert B, Burk C, Patel V. Impact of dry eye disease on work productivity, and patients satisfaction with over-the-counter dry eye treatments. *Invest Ophthalmol Vis Sci*. 2016 Jun 1;57(7):2975-2982.

O'Day K, Levy WC, Johnson M, Jacobson AF. Cost-effectiveness analysis of iodine-123 meta-iodobenzylguanidine imaging for screening heart failure patients eligible for an implantable cardioverter defibrillator in the USA. *Appl Health Econ Health Policy*. 2016 Jun;14(3):361-373.

Patel V, Schwartz GF, Landsman-Blumberg PB, Lunacsek OE, Wong W. Adherence and persistence of bimatoprost in prior latanoprost users. *Am J Pharm Benefits*. 2016;8(6):e101-e107.

Raju A, Mallick R, Campbell C, Carlton R, O'Donnell T, Eaddy M. Real-world assessment of interventional treatment timing and outcomes for varicose veins: a retrospective claims analysis. *J Vasc Intervent Radiol*. 2016 Jan;27(1):58-67. doi:10.1016/j.jvir.2015.10.001

Sarnes E, Boswell K. Achieving balance with the AMCP Format for Formulary Submissions, Version 4.0: a dossier producer's perspective. *J Manag Care Spec Pharm*. 2016;22(5):447. doi:10.18553/jmcp.2016.16095

Theidel U, von der Schulenburg JM. Benefit assessment in Germany: implications for price discounts. *Health Econ Rev*. 2016;6(1):33.

Yaldo A, Wen L, Ogbonnaya A, Valderrama A, Kish J, Eaddy M, Kreilick C, Tangirala K, Shields K. Opioid use among metastatic prostate cancer patients with skeletal-related events. *Clin Ther*. 2016 Aug;38(8): 1880-1889.

2015

[Return to Publications](#)

Abdel-Sattar M, Krauth D, Anglemeyer A, Bero L. The relationship between risk of bias criteria, research outcomes, and study sponsorship in a cohort of preclinical thiazolidinedione animal studies: a meta-analysis. *Evid Based Preclin Med*. 2015 Jan;1(1):11-20.

Bell K, Parasuraman S, Raju A, Shah M, Graham J, Denno M. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population. *J Manag Care Spec Pharm*. 2015 Mar;21(3):220-228.

Bloudek L, Eaddy MT, Makenbaeva D. Anticipated impact of generic imatinib market entry on the costs of tyrosine kinase inhibitors. *Am Health Drug Benefits*. 2015;8(9):472-480.

Claes AK, Zhou JY, Philpott DJ. NOD-Like receptors: guardians of intestinal mucosal barriers. *Physiology (Bethesda)*. 2015 May;30(3):241-250.

Dalal AA, Patel J, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. *J Manag Care Spec Pharm*. 2015 Jul;21(7):575-583.

Diette GB, Dalal AA, D'Souza AO, Lunacsek OE, Nagar SP. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. *Int J Chron Obstruct Pulmon Dis*. 2015 Feb 24;10:415-422.

Fernandez-Lopez S. US clears approval pathway for biosimilars: considerations for your practice. *AmerisourceBergen Oncologistics Magazine*. Spring 2015;14(1).

Fernandez-Lopez S, Kazzaz D, Bashir M, McLaughlin T. Assessment of pharmacists' views on biosimilar naming conventions. *J Manag Care Spec Pharm*. 2015;21(3):188-195.

Haas J, Braun S, Wutzler P. Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013. *Eur J Health econ*. 2015;17(6):669-679.

Huh WK, Williams E, Huang J, Bramley T, Poulos N. Cost effectiveness of human papillomavirus—16/18 genotyping in cervical cancer screening. *Appl Health Econ Health Policy*. 2015;13(1):95-107.

Jacob C, Annoni E, Scarlet Haas J, Braun S, Winking M, Franke J. Burden of disease of reoperations in instrumental spinal surgeries in Germany. *Eur Spine J*. 2015;25(3):807-813.

Jacob C, Bechtel B, Engel S, Kardos P, Linder R, Braun S, Greiner W. Healthcare costs and resource utilization of asthma in Germany: a claims data analysis. *Eur J Health Economics*. 2015;17(2):195-201.

Kuhlmann A, Treskova M, Braun S, Graf von der Schulenburg JM. The role of decision-analytic modelling in German health technology assessments. *Health Econ Rev*. 2015;5:7.

Law A, McCoy M, Lynen R, Curkendall SM, Gatwood J, Juneau PL, Landsman-Blumberg P. Costs of newborn care following complications during pregnancy and delivery. *Matern Child Health J*. 2015 Sep;19(9):2081-2088.

Law A, McCoy M, Lynen R, Curkendall SM, Gatwood J, Juneau PL, Landsman-Blumberg P. The additional cost burden of preexisting medical conditions during pregnancy and childbirth. *J Womens Health (Larchmt)*. 2015;24(11):924-932. doi:10.1089/jwh.2014.4951

Leibson CL, Long KH, Ransom JE, Roberts RO, Hass SL, Duhig AM, Smith CY, Emerson JA, Pankratz VS, Petersen RC. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. *Alzheimers Dement*. 2015 Aug;11(8):917-932.

Mytelka D, Li L, Stafkey-Mailey D, Liepa A, Hess L, Farrelly E, Eaddy M. Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. *Hematology*. 2015 Sep;20(8):442-448.

Nag A, Stanford RH, D'Souza AO. Demographic characteristics of asthma subjects associated with stepping down from fluticasone propionate/salmeterol combination therapy. *Am J Pharm Benefits*. 2015;7(3):e73-e80.

O'Donnell TF, Eaddy M, Raju A, Boswell K, Wright D. Assessment of thrombotic adverse events and treatment patterns associated with varicose vein treatment. *J Vasc Surg: Venous Lym Dis*. 2015;3(1):27-34.

Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, Klok R, Gruen ES, Weycker D. Rates of pneumonia among children and adults with chronic medical conditions in Germany. *BMC Infect Dis*. 2015;15:470.

Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. *Expert Rev Pharmacoecon Outcomes Res*. 2015 Jun;15(3):545-550.

Roy S, Carlton R, Weisberg M, Clark R, Migliaccio-Walle K, Chapa H. Economic impact of the use of an absorbable adhesion barrier in preventing adhesions following open gynecologic surgeries. *J Long Term Eff Med Implants*. 2015;25(3):245-252. doi:10.1615/jlongtermeffmedimplants.2015012140

Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. *J Clin Epidemiol*. 2015 Jan;68(1):102-107.

Seal B, Sullivan SD, Ramsey S, Asche CV, Shermock KM, Sarma S, Zagadailov E, Farrelly E, Eaddy M. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. *Future Oncol*. 2015;11(3):439-447.

Sutton SS, Hardin JW, Bramley TJ, D'Souza AO, Bennett CL. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. *Am J Manag Care*. 2016 Apr;22(4):242-248.

Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. *J Natl Cancer Inst.* 2014;106(2):djt371. doi:10.1093/jnci/djt371

Andersohn F, Bornemann R, Damm O, Frank M, Mittendorf T, Theidel U. Vaccination of children with a live-attenuated, intranasal influenza vaccine—analysis and evaluation through a health technology assessment. *GMS Health Technol Assess.* 2014;10:Doc03.

Carlton R, Lunacsek O, Regan T, Carroll CA. Healthcare costs among patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy. *Am Health Drug Benefits.* 2014;7(6):334-340.

Changolkar A, Menditto L, Shah M, Puto K, Farrelly E. Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery. *Am J Health Syst Pharm.* 2014;71(7):562-569. doi:10.2146/ajhp120711

Claes AK, Steck N, Schultz D, Zähringer U, Lipinski S, Rosenstiel P, Geddes K, Philpott DJ, Heine H, Grassl GA. Salmonella enterica serovar Typhimurium Δ msbB triggers exacerbated inflammation in Nod2 deficient mice. *PLoS One.* 2014;9(11):e113645.

Kreissl M, Jacob C, Führer D, Karges W, Luster M, Lux M, Mann K, Mittendorf T, Schott M, Spitzweg C, Schmoll HJ. Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel. *Oncol Res Treat.* 2014;37(6):316-322.

Kruep EJ, Phillips E, Hogue S, Eaddy M. Early symptom improvement and discontinuation of 5- α -reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH). *Ann Pharmacother.* 2014 Mar;48(3):343-348.

Lalla D, Carlton R, Santos E, Bramley T, D'Souza A. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. *SpringerPlus.* 2014;3:350 (July 10, 2014).

Lange A, Kasperk C, Alvares L, Sauermann S, Braun S. Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data. *Spine.* 2014;39(4):318-326.

Lange A, Zeidler J, Braun S. One-year disease-related health care costs of incident vertebral fractures in osteoporotic patients. *Osteoporos Int.* 2014;25(10):2435-2443.

Minkowitz HS, Gruschkus SK, Shah M, Raju A. Adverse drug events among patients receiving postsurgical opioids in a large health system: risk factors and outcomes. *Am J Health Syst Pharm.* 2014;71(18):1556-1565. doi:10.2146/ajhp130031

Minkowitz HS, Scranton R, Gruschkus SK, Nipper-Johnson K, Menditto L, Dandappanavar A. Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events. *J Manag Care Pharm.* 2014;20(8):948-958.

Neubauer S, Cifaldi M, Mittendorf T, Ganguli A, Wolff M, Zeidler J. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. *Health Econ Rev.* 2014;4(1):32.

Polonsky WH, Thompson S, Wei W, Riddle MC, Chaudhari S, Jackson J, Bruno AS. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. *Diabetes Obes Metab.* 2014 Nov;16(11):1121-1127.

Sadlo A, Altevers J, Peplies J, Kaltz B, Classen M, Bauer A, Koletzko S, Timmer A. Measuring satisfaction with health care in young persons with inflammatory bowel disease—an instrument development and validation study. *BMC Health Serv Res*. 2014;14:97.

Saleh MN, Haislip S, Sharpe J, Hess T, Gilmore J, Jackson J, Sail KR, Ericson SG, Chen L. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. *Curr Med Res Opin*. 2014 Apr;30(4):529-536.

Scholz S, Mittendorf T. Modeling rheumatoid arthritis using different techniques—a review of model construction and results. *Health Econ Rev*. 2014;4(1):18.

Schreiber S, Lugert T, Mittendorf T, Mrowietz U, Müller-Ladner U, Schroder J, Stallmach A, Bokemeyer B. Evolution of biologicals in inflammation medicine—biosimilars in gastroenterology, rheumatology and dermatology. [Evolution von biologika in der entzündungsmedizin—biosimilars in der gastroenterologie, rheumatologie und dermatologie.] *Dtsch Med Wochenschr [German Medical Weekly]*. 2014;139(47):2399-2404.

Seal B, Sullivan S, Ramsey S, Ache C, Shermock K, Sarma S, Zagadailov E, Farrelly E, Eaddy M. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. *Appl Health Econ Health Policy*. 2014 Oct;12(5):547-557.

2013

[Return to Publications](#)

Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AM, Berto P, Franczok E, Lobban T, Zamorano JL. Patient perspective on the management of atrial fibrillation in five European countries. *BMC Cardiovasc Disord*. 2013;13:108.

Bokemeyer B, Hardt J, Huppe D, Prenzler A, Conrad S, Duffelmeyer M, Hartmann P, Hoffstadt M, Klugmann T, Schmidt C, Weismüller J, Mittendorf T, Raspe H. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. *J Crohns Colitis*. 2013;7(5):355-368.

Braun S, Russo L, Zeidler J, Linder R, Hodgkins P. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany. *Clin Ther*. 2013;35(5):673-685.

Braun S, Zeidler J, Linder R, Engel S, Verheyen F, Greiner W. Treatment costs of attention deficit hyperactivity disorder in Germany. *Eur J Health Econ*. 2013;14(6):939-945.

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. *Clin Ther*. 2013 Nov;35(11): 1744-1751.

Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. *Health Econ Rev*. 2013;3(1):1-10.

Denno M, Brown L, Jackson J. Impact of the NCCN biomarkers compendium on managed care pharmacy. *J Manag Care Pharm*. 2013 Jan/Feb;19(1):68-69.

Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR. The role of biosimilars in the treatment of rheumatic diseases. *Ann Rheum Dis*. 2013;72(3):322-328.

Esposito D (editor), Migliaccio-Walle K (assistant editor), Madsen E (managing editor). *Reliability and Validity of Data Sources for Outcomes Research & Disease and Health Management Programs*. Lawrenceville, NJ: ISPOR, 2013.

- Frank M, Mittendorf T. Gesundheitsökonomische Aspekte einer stratifizierten Medizin für rheumatoide Arthritis. [Health economic aspects of stratified medicine in rheumatoid arthritis.] *Z Rheumatol [J Rheumatol]*. 2013;72(1):12-19.
- Frank M, Mittendorf T. Influence of pharmacogenomic profiling to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness: a systematic review. *Pharmacoeconomics*. 2013;31(3):215-228.
- Horn J, Damm O, Kretzschmar MEE, Delere Y, Wichmann O, Kaufmann AM, Garbe E, Krämer A, Greiner W, Mikolajczyk RT. Estimating the long-term effects of HPV vaccination in Germany. *Vaccine*. 2013;31(19): 2372-2380.
- Jain G, Roy A, Harikrishnan V, Yu S, Dabbous O, Lawrence C. Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: results from a survey of full-time employees in the United States. *J Occup Environ Med*. 2013 Mar;55(3):252-258.
- Klose K, Witte J, Kreimeier S, Greiner W. Quality of life as a competitive advantage in the early benefit assessment. *Public Health Forum*. 2013;21(81):14-15.
- Kruep E, Goodwin B, Chaudhari S. Evaluation of recent trends in treatment patterns among men with benign prostatic hyperplasia. *Am J Mens Health*. 2013 May;7(3):214-219.
- Lawrence C, Roy A, Harikrishnan V, Yu S, Dabbous O. Association between severity of depression and self-perceived cognitive difficulties among full-time employees. *Prim Care Companion CNS Disord*. 2013;15(3): PCC.12m01469. doi:10.4088/PCC.12m01469
- Lennert B, Farrelly E, Sacco P, Pira G, Frost M. Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. *J Child Neuro*. 2013 Apr;28(4):461-469.
- Leppert F, Dockweiler C, Eggers N, Webel K, Hornberg C, Greiner W. Relevance and impact of financial factors on the acceptance of telemonitoring applications by service providers. *Medical future verlag*. 2013:289-297.
- Lieberthal RD, Dudash K, Axelrod R, Goldfarb NI. An economic model to value companion diagnostics in non-small-cell lung cancer. *Per Med*. 2013;10(2):139-147. doi:10.2217/pme.13.7
- O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. *Clinicoecon Outcomes Res*. 2013 Sep;5:459-470.
- Ollendorf DA, Migliaccio-Walle K, Colby JA, Pearson SD. Management options for children with attention deficit hyperactivity disorder: a regional perspective on value. *J Comp Eff Res*. 2013 May;2(3):261-271.
- Parker K, Zagadailov E, Bruno A, Wiland A. Transplant coordinators' perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy. *J Transplant*. 2013:1-7.
- Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. *J Med Econ*. 2013 Jul;16(7):951-961.
- Rajagopalan K, O'Day K, Meyer K, Pikalov A, Loebel A. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. *J Med Econ*. 2013 Aug;16(8):987-996.
- Roy S, Bramley TJ, Hinoul P, Migliaccio-Walle K, Li H. Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence. *J Long Term Eff Med Implants*. 2013;23(1):1-8.
- Ruof J, Schwartz FW, Schulenburg JM, Dintsios CM. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. *Eur J Health Econ*. 2013;15(6):577-589.

Seal B, Asche C, Puto K, Allen P. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review. *Value Health*. 2013 Jul-Aug;16(5):872-890.

Shah M, Winfree K, Peterson K, Gruschkus S, Eaddy M, Green M. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. *Lung Cancer*. 2013 Oct;82(1):121-127.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. *Pharmacoeconomics*. 2013 May;31(5):427-444.

Stanford R, Shah M, D'Souza A. Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma. *J Asthma Allergy*. 2013;6:1-10.

Stanford R, Shah M, D'Souza A, Schatz M. Predicting asthma outcomes in patients within commercially insured and Medicaid populations. *Am J Manag Care*. 2013 Jan;19(1):60-67.

Theidel U, Asseburg C, Giannitsis E, Katus H. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. *Clin Res Cardio*. 2013;102(6):447-458.

Theidel U, Braem A, Ruckinger S. Ermittlung von impfquoten für pneumokokken-konjugatimpfstoffe bei kindern auf basis von routinedaten der gesetzlichen krankenkassen. [Determination of vaccination quotas for pneumococcal conjugate vaccine in children on the basis of routine data of the statutory health insurance.] *Gesundheitswesen [Healthcare]*. 2013;75(5):309-316.

Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany—an analysis of statutory health insurance data on more than 850 000 individuals. *Deutsches Ärzteblatt Int*. 2013;110(44):743-750.

Zagadailov E, Fine M, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. *Am Health Drug Benefits*. 2013 Jul;6(5):264-274.

Zeidler J, Lange A, Braun S, et al. Die berechnung indikationsspezifischer kosten für die GKV-routinedatenanalyse am beispiel ADHD. Ein methodenvergleich. [The calculation of indication-specific costs for GKV routine data analyzes using the example of ADHD. A method comparison.] *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz [Federal Health Gazette - Health Research - Health Protection]*. 2013;56(3):430-438.

2012

[Return to Publications](#)

Bokemeyer B, Helwig U, Schmidt C, Teich N, Halle R, Düffelmeyer M, Raspe H, Prenzler A, Mittendorf T, Hartmann H, Nikolaus S, Schreiber S. Adherence to national guidelines for therapy of Crohn's disease in Germany. *J Crohns Colitis*. 2012;6(1):S72.

Boswell KA, Cook CL, Burch SP, Eaddy MT, Cantrell RC. Associating medication adherence with improved outcomes: a systematic literature review. *Am J Pharm Benefits*. 2012;4(4):e97-e108.

Boswell KA, Wang X, Shah MV, Apro MS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature. *Breast*. 2012;21:701-706.

Brown L. Gain a solid understanding of compendia and its impact on patient access. *Formulary*. 2012 Jul;47:2-6.

- Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal A. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. *Respir Res*. 2012 Feb 17;13(1):15.
- Dalal A, Shah M, D'Souza A, Crater G. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. *Respir Med*. 2012;106(6):829-837.
- Dalal A, Shah M, D'Souza AO, Chaudhari S, Crater G. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. *Int J Chron Obstruct Pulmon Dis*. 2012 Jan 18;7:11-19.
- Dalal A, Shah M, D'Souza A, Dhamane A, Crater G. Outcomes associated with timing of maintenance treatment for COPD exacerbation. *Am J Manag Care*. 2012;18(9):e338-e345.
- Dalal A, Shah M, D'Souza A, Lunacsek O, Nagar S, Crater G. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. *Respir Res*. 2012;13:41.
- Damm K, Jacob C, Mittendorf T, Schulenburg JM. Quality of life measurement in lung cancer clinical trials—overview from the ClinicalTrials database. *PharmacoEconomics German Research Articles*. 2012;10(1):3-15.
- Damm K, Lange A, Zeidler J, Braun S, Schulenburg JM. Introduction of the new job key and its application in GKV routine data analysis—possibilities and limitations. [*Einführung des neuen stellenschlüssels und dessen anwendung in der GKV-routinedatenanalyse—Möglichkeiten und grenzen.*] *Bundesgesundheitsblatt – Gesundheitsforschung - Gesundheitsschutz [Federal Health Gazette - Health Research - Health Protection]*. 2012;55(2):238-244.
- Dupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence. *Patient Prefer Adherence*. 2012;6:499-507.
- Eaddy M, Cook C, O'Day K, Burch S, Cantrell R. How patient cost-sharing trends affect adherence and outcomes, a literature review. *P T*. 2012 Jan;37(1):45-55.
- Eaddy M, Kruep E, Lunacsek O, Goodwin B. Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients. *Expert Opin Pharmacother*. 2012;13(18):2593-2600.
- Eaddy M, Seal B, Tangirala K, Davies E, O'Day K. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. *Appl Health Econ Health Policy*. 2012;10(6):431-440.
- Epstein J, Xiong Y, Luo M, Li-McLeod J. Benefits associated with a broad selection of dosage strengths for recombinant factor VIII products. *Haemophilia*. 2012 Mar;18(2):182-186.
- Feinberg B, Gilmore A, Haislip S, Gilmore J, Jain G, Whyte JL. Hemoglobin trends and anemia treatment due to concomitant chemotherapy in community oncology clinics. *J Oncol*. 2012 Jan;8(1):18-23.
- Gerlach FM, Greiner W, Hauibtz M, Schaeffer D, Thürmann P, Thüsing G, Wille E. Special Report 2010: Competition at the interface between outpatient and inpatient health care. Göttingen: Hogrefe; 2012.
- Green M, Brown L. The promising outlook with immunoconjugate therapy. *Oncol Bus Rev*. 2012 Jul;22-25.
- Greiner W. Health technology assessment (HTA). In: O S, JM S, eds. Health economic evaluations. Heidelberg: Springer-Verlag; 2012:457-479.
- Greiner W. Methods of health economic evaluation. In: K H, O R, eds. Handbook health sciences. Weinheim und Basel: Beltz Juventa; 2012:375-402.
- Greiner W. Ökonomische herausforderungen der individualisierten medizin. [Economic challenges of individualized medicine.] *FORUM*. 2012;27(3):2023-2208.

Greiner W. Price and quality competition in times of health insurance surpluses. Are surpluses a financing problem? *ifo Schnelldienst*. 2012;65(23):13-16.

Greiner W. The EQ-5D of the EuroQol Group. In: O S, JM S, eds. Health economic evaluations. Heidelberg: Springer-Verlag; 2012:411-422.

Greiner W, Damm O. Calculation of costs and benefits. In: O S, JM S, eds. Health economic evaluations. Heidelberg: Springer-Verlag; 2012:23-42.

Greiner W, Filonenko A, Schöffski O. The transferability of international results to national issues. In: O S, JM S, eds. Health economic evaluations. Heidelberg: Springer-Verlag; 2012:481-499.

Greiner W, Knittel M. Economic potentials of individualized medicine. *Gesundheit und Gesellschaft [Health and Society]*. 2012;12(1):20-26.

Greiner W, Schöffski O. Basic principles of an economic feasibility study. In: O S, JM S, editors. Gesundheitsökonomische Evaluationen. Heidelberg: Springer-Verlag; 2012:155-180.

Gruschkus S, Poston S, Eaddy M, Chaudhari S. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia. *P T*. 2012 Aug;37:8:464-470.

Hastings A, Byers C, Bercu B. Chapter 11: Navigating the IRB for Investigators. In: Melnyk BM, Morrison-Beedy D, eds. *Intervention Research Designing Conducting, Analyzing, and Funding*. New York, NY: Springer Publishing Company, LLC; 2012:169-191. <http://www.springerpub.com/product/9780826109576>

Howell P. How much cheaper will biosimilars be? *FiercePharma*. 2012 Mar 2. <http://www.fiercepharma.com/story/how-much-cheaper-will-biosimilars-be/2012-03-02>

Howel P, Burich M. Biosimilars: an uncertain path to promise. As the costs of drugs rise, will biosimilars fulfill their promise of affordability? *Pharmpro*. 2012 Oct:36-37.

Kirchhoff TD, Mittendorf T, Schmidt RE, Jablonka A, Merkesdal S. Cost-effectiveness of TNF-alpha inhibition in active ankylosing spondylitis: a systematic appraisal of the literature. *Expert Rev Pharmacoecon Outcomes Res*. 2012;12(3):307-317.

Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JM. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. *Health Econ Rev*. 2012;2(1):4.

LaBounty TM, Shah M, Raman SV, Lin FY, Berman DS, Min JK. Within-hospital and 30-day outcomes in 107,994 patients undergoing invasive coronary angiography with different low-osmolar iodinated contrast media. *Am J Cardiol*. 2012 Jun 1;109(11):1594-1599.

Lange A, Braun S, Greiner W. Economic aspects of integrated care. [Ökonomische Aspekte der integrierten Versorgung.] *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz [Federal Health Gazette - Health Research - Health Protection]*. 2012;55(5):643-651.

Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O'Day K, Bramley T. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. *J Urol*. 2012 Dec;188(6):2114-2119.

Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. *Am Health Drug Benefits*. 2012 Sep/Oct;5(6):347-357.

Miller R, Happe L, Meyer K, Spear R. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. *J Manag Care Pharm*. 2012 Jan/Feb;18(1):54-62.

Moore Simas T, Warings M, Liao X, Garrison A, Sullivan G, Howard A, Hardy J. Prepregnancy weight, gestational weight gain, and risk of growth affected neonates. *J Womens Health*. 2012;21(4):410-417.

Nagel A, Witte J, Hodek JM, Greiner W. Relationship between multimorbidity and direct healthcare costs in an advanced elderly population. Results of the PRISCUS study. *Z Gerontologie Geriatrie*. 2012;45(2):146-154.

Nuijten M, Mittendorf T. The health economic impact of oral nutritional supplements (ONS) in Germany. *Aktuelle Ernährungsmedizin*. 2012;37(3):126-133.

Patel A, Lennert B, Macomson B, Nelson W, Owens G, Mody S, Schein J. Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. *Am Health Drug Benefits*. 2012;5(5):291-298.

Ruhe AK, Greiner W. Outcome assessment in rehabilitation—an empirical study of the quality of life of rehabilitees with orthopedic diseases. *Pharmaco Economics German Research Articles*. 2012;10(1):29-41.

Schöffski O, Greiner W. The QUALY concept as the most prominent representative of cost-benefit analysis. In: O S, JM S, eds. *Gesundheitsökonomische Evaluationen*. Heidelberg: Springer-Verlag; 2012:71-110.

Schwarzbach C, Forstl H, Nocon M, Mittendorf T. Why is it so difficult to evaluate nursing interventions in dementia? *Dement Geriatr Cogn Dis Extra*. 2012;2(1):146-159.

Stanford R, Manan S, Chaudhari S. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 years. *Open Respir Med J*. 2012;6:37-43.

Stanford R, Shah M, D'Souza A, Dhamane A, Schatz M. Short-acting β -agonist use and its ability to predict future asthma-related outcomes. *Ann Allergy Asthma Immunol*. 2012 Dec;109(6):403-407.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and the Netherlands. *J Infect*. 2012;64(1):54-67.

Tanner N, Gomez M, Rainwater C, Nietert P, Simon G, Green M, Silvestri G. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. *J Thorac Oncol*. 2012 Feb;7(2):365-369.

Theidel U, Braem A, Rückinger S. Determination of the vaccination rate of pneumococcal vaccination in infants using routine GKV data (May 2008 to September 2009). In: Institut RK, ed. *Epidemiologisches Bulletin*. 2012:301-310.

Ye X, Rupnow M, Hammond J, Shah M, Farrelly E. Readmission rates and hospital costs associated with fibrin sealant use among patients undergoing orthopedic surgery. *J Orthopaedics*. 2012;9(1):e11.

Zeidler J, Mittendorf T, Muller R, von Kempis J. Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. *Health Econ Rev*. 2012;2(1):20.

Zeidler J, Zeidler H, Graf con der Schulenburg JM. Therapie der rheumatoiden arthritis mit methotrexat. Analyse von pflegeaspekten auf basis von GKV-routinedaten. [Therapy for rheumatoid arthritis with methotrexate. Analysis of care aspects based on GKV routine data.] *Zeitschrift für Rheumatologie [J Rheumatol]*. 2012;71(10):900-907.

2011

[Return to Publications](#)

Agashivala N, Dastani H, Carlton R, Sarnes E. Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis. *Am J Pharm Benefits*. 2011;3(6):320-328.

Allen P, Fuentes R, Hoopes M, Susla G. Evaluation of drug adverse event intake and reporting in a medical information service. *Drug Info J*. 2011;45(6):767-773.

Asseburg C, Frank M, Kohne CH, Hartmann JT, Griebisch I, Mohr A, Osowski U, Schulten J, Mittendorf T. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. *Clin Ther*. 2011;33(4):482-497.

Bonnet P, Gringeri A, Gomperts E, Leissing CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia A and high-titer inhibitors. *Am Health Drug Benefits*. 2011;4(4):219-229.

Bordoni R, Feinberg B, Gilmore J, Haislip S, Jackson J, Farrelly E, Kim E, Buchner D. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice. *Clin Lymphoma Myeloma Leuk*. 2011 Aug;11(4):350-354.

Bowles D, Damm O, Greiner W. Health-related health services research using GKV routine data—limitations exemplified by the prophylaxis of venous thromboembolism in hip and knee joint arthroplasty. *Gesundheitsökonomie & Qualitätsmanagement*. 2011;16(2):96-107.

Breckenkamp J, Spallek J, Kraywinkel K, et al. Abgleich von verwaltungsdaten des medizinischen dienstes der krankenkassen mit krebsregisterdaten. [Comparison of administrative data of the medical service of the health insurance with cancer registry data.] *Das Gesundheitswesen [Healthcare]*. 2011;74(7):e52-e60.

Brown L, Pih J. Payers and providers agree: realistic expectations and cost-effective analyses are key. *Oncol Bus Rev*. 2011 Jul:8-14.

Busse T, Leppert F, Hodek JM, Greiner W. Mergers in the statutory health insurance—on the way to the optimum? *Pharmaco Economics German Research Articles*. 2011;9(1):31-44.

Dalal AD, Shah M, D'Souza A, Mapel DW. COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies. *Am J Manag Care*. 2011 Mar;17(3):e55-e65.

Dalal A, Shah M, D'Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. *Respir Med*. 2011 Mar;105(3):454-460.

Dalal A, Shah M, Lunacsek O, Hanania N. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. *COPD*. 2011;8:293-299.

Damm K, Barth I, Greiner W, Kreienberg R, Maass N, Riederer C. Healthcare research in oncology: growing importance and increasing influence on freedom of therapy. *Der Onkologe*. 2011;17(7):634-637.

Damm K, Barth I, Greiner W, Kreienberg R, Maass N, Riederer C. The health services research in oncology against the background of the AMNOG—125 Congress of the German Society for Gynecology and Obstetrics. *Gesundheitsökonomie & Qualitätsmanagement*. 2011;16(4):194-195.

Damm K, Müller-Riemenschneider F, Vauth C, Willich SN, Greiner W. Non-drug secondary prevention of coronary heart disease. *Prävention und Gesundheitsförderung*. 2011;6(4):255-261.

Drees A, Langkau T, Leppert F, Peters C, Soltani N, Greiner W. Use of process reference models to measure and increase the productivity of services. *Controlling*. 2011;23(10):516-522.

Eidt-Koch D, Greiner W. Quality of life results of balloon kyphoplasty versus non surgical management for osteoporotic vertebral fractures in Germany. *Health Econ Rev*. 2011;1(1):7.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and

vomiting in patients with lung cancer receiving multi-day chemotherapy. *SpringerLink—Supportive Care in Cancer, Online First*. 2011 Mar 29;19(3),1-9.

Feinberg BA, Gilmore A, Lunacsek O, Haislip S, Yu E, Yim Y, Gilmore JW. Patient (Pt)-reported symptoms of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer (MCR) in a US community-based oncology practice network. *J Clin Oncol*. 2011;29(suppl 4; abstr 575).

Fonseca V, Sharma PP, Shah M, Deedwania P. Original article: risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. *Curr Med Res Opin*. 2011;27(4):799-807.

Greiner W. Away with old pigtailed—the German health care system suffers not from underregulation, but from lack of competition direct contracts between health insurance companies and hospitals could solve many abuses. *Wirtschaftswoche*. 2011;6:36.

Greiner W. Base rate; Diagnosis related groups; Uniform assessment scale; Fallpauschale; Fixed amounts; Fee schedule doctors; Complex package; Care kit; Special consideration; Optional services; Optional plans; Co-payments. In: Burchert H, ed. *Lexikon Gesundheitsmanagement*. Herne: NWB Verlag. 2011: 29, 64, 74, 92, 8, 100, 57, 211, 39, 68, 77.

Greiner W. Health economics: on the rational allocation of scarce resources in everyday care. In: T S, C H, eds. *Die Gesellschaft und ihre Gesundheit, 20 Jahre Public Health in Deutschland: Bilanz und Ausblick einer Wissenschaft*. Wiesbaden: VS Verlag für Sozialwissenschaften. 2011:329-343.

Greiner W. Is there a solidary competition in health care? Zukunft der GKV solidarität bewahren—durch mehr Wettbewerb. *AOK im Dialog*. 2011;26:6-1744-1754.

Greiner W, Damm O, eds. *Health economic evaluation of vaccines. Nationales Innovationsforum Medizin: Prävention und Behandlung von Infektionskrankheiten*. 2011.

Greiner W, Knittel M. Economic potential of individualized medicine. In: V S, B V, eds. *Medizin nach Maß*. Freiburg: Verlag Herder; 2011:367-387.

Greiner W, Knittel M. Economic potentials of individualized medicine. *Pharmaco Economics German Research Articles*. 2011;9(1):45-54.

Greiner W, Scholz S. Basic care rate. In: Is cognitive behavioral therapy cost-effective? *Gesundheitsökonomie & Qualitätsmanagement*. 2011;16(3):151.

Greiner W, Scholz S. Cost and benefit assessment from EVITA to ICER—what is really relevant? In: T E, KJ P, R T, eds. *Handbuch Market-Access*. Düsseldorf: Fachverlag der Verlagsgruppe Handelsblatt. 2011:79-90.

Greiner W, Scholz S. Disability—encyclopedia of health economics. *Gesundheitsökonomie & Qualitätsmanagement*. 2011;16(2):78.

Gutierrez DV, Mark MD, Maseck O, Maejima T, Kuckelsberg D, Hyde RA, Krause M, Kruse W, Herlitze S. Optogenetic control of motor coordination by Gi/o protein-coupled vertebrate rhodopsin in cerebellar Purkinje cells. *J Biol Chem*. 2011;286(29):25848-25858.

Hodek JM, Scholz S, Vieten B, Greiner W. Activity analysis in the medical and nursing service—comparison of the PsychPV guidelines with the daily work routine at a stationary psychiatric facility. *Der Nervenarzt*. 2011;83(3):351-359.

Hodek JM, von der Schulenburg JM, Mittendorf T. Measuring economic consequences of preterm birth—methodological recommendations for the evaluation of personal burden on children and their caregivers. *Health Econ Rev*. 2011;1(1):6.

Italia N, Rehfues EA. Is the Global Solar UV Index an effective instrument for promoting sun protection? A systematic review. *Health Educ Res*. 2011;27(2):200-213.

Jackson J, Kohn-Parrott K, Parker C, Levins N, Dyer S, Hedalen E, Frank E, Bramer S, Brandt D, Doyle J. Blood pressure success zone: you auto know—a worksite-based program to improve blood pressure control among auto workers. *Popul Health Manag.* 2011 Oct;14(5):257-263.

Jacob C, Mittendorf T, Schulenburg JM. Medical expenses and health-related quality of life (HRQoL) in community-acquired pneumonia (CAP)—a systematic review. *Pneumologie.* 2011;65:498-502.

Kirchhoff T, Ruof J, Mittendorf T, Rihl M, Bernateck M, Mau W, Zeidler H, Schmidt RE, Merkesdal S. Cost of illness in rheumatoid arthritis in Germany in 1997–98 and 2002: cost drivers and cost savings. *Rheumatology (Oxford).* 2011;50(4):756-761.

Kruep EJ, Hogue S, Eaddy M, Chandra M. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. *P T.* 2011 Aug;36(8):493-507.

Lamerato L, Kruep E, Hogue S, Chaudhari S, Eaddy M. Outcomes with early versus delayed 5ARIs for benign prostatic hyperplasia. *Am J Pharm Benefits.* 2011 Nov/Dec;3(6):e127-e134.

Lenoir-Wijnkoop I, Dapoigny M, Dubois D, van Ganse E, Gutierrez-Ibarluzea I, Hutton J, Jones P, Mittendorf T, Poley MJ, Salminen S, Nuijten MJ. Nutrition economics—characterising the economic and health impact of nutrition. *Br J Nutr.* 2011;105(1):157-166.

Madison T. Regional variations. *Int Clin Trials.* 2011 Nov:88-94.

Mark MD, Maejima T, Kuckelsberg D, Yoo JW, Hyde RA, Shah V, Gutierrez D, Moreno RL, Kruse W, Noebels JL, Herlitze S. Delayed postnatal loss of P/Q-type calcium channels recapitulates the absence epilepsy, dyskinesia, and ataxia phenotypes of genomic *Cacna1a* mutations. *J Neurosci.* 2011;31(11): 4311-4326.

Mauceri E, Bienkowski C, Hanson K, Doyle JJ, Jackson J, Bramer S. A health outcome assessment of the cardio metabolic mission health program at Novartis. *J Occup Environ Med.* 2011 Jun;53(6):647-652.

May D, Shields S. Healthcare reform brings opportunities and risks: learn what the Affordable Care Act means to you and your practice. *Optometric Management.* October 2011.

Naslund M, Eaddy M, Hogue SL, Kruep EJ, Shah M. The economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia. *Am Health Drug Benefits.* 2011 May/Jun;4(3):155-162.

Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. *Eur J Health Econ.* 2011;12(3):231-241.

O'Day K, Meyer K, Miller R, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. *J Med Econ.* 2011;14(5):617-627.

Pettaway C, Lamerato L, Eaddy M, Edwards J, Hogue S, Crane M. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. *BJU Int.* 2011 Oct;108(8):1302-1308.

Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. *Health Econ Rev.* 2011;1(1):1.

Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. *Eur J Health Econ.* 2011;12(3):273-283.

Prenzler A, Mittendorf T, Schulenburg JM, Theidel U, Montag T, Müller-Busch MC. Aspects of outpatient palliative care in Germany—a survey among office-based physicians. *J Public Health.* 2011;19(2):155-160.

Prenzler A, Yen L, Mittendorf T, von der Schulenburg JM. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. *BMC Health Serv Res.* 2011;11:157.

Pundt J, Drees L. Asymmetries in the health professions: male or female domain? *Public Health Forum*. 2011;19(71):15.e1-.e4.

Raval K, Lofland JH, Waters H, Piech CT. Disease and treatment burden of psoriasis: examining the impact of biologics. *J Drugs Dermatol*. 2011;10(2):189-196.

Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. *J Clin Oncol*. 2011 Nov 20;29(33):4436-4441.

Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. *Clin Ther*. 2011;33(10):1413-32.
doi:10.1016/j.clinthera.2011.09.009

Schulenburg JM, Zuchandke A. Exercises on insurance economics. Berlin: Springer- Lehrbuch; 2011.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT₃ RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Aug;11(4):481-488.

Schwartzberg L, Szabo S, Gilmore J, Haislip S, Jackson J, Gagan J, Balu S, Buchner D. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC). *Curr Med Res Opin*. 2011;27(4):837-845.

Shenolikar R, Bruno A, Eaddy M, Cantrell C. Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature. *Am Health Drug Benefits*. 2011;4(7):465-474.

Sroczyński G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U. Cost-effectiveness of primary HPV screening for cervical cancer in Germany—a decision analysis. *Eur J Cancer*. 2011;47(11):1633-1646.

Stokes M, Ye X, Shah M, Mercaldi K, Reynolds M, Rupnow M, Hammond J. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. *BMC Health Serv Res*. 2011;11:135.

Thiem U, Hinrichs T, Müller CA, et al. Anforderungen an ein neues Versorgungsmodell für ältere Menschen mit Multimorbidität. [Requirements for a new care model for older people with multimorbidity.] *Gerontologie + Geriatrie [Gerontology and Geriatrics]*. 2011;44(2):101-112.

Vauth C, Greiner W. Costs in pain therapy. *Gesundheitsökonomie & Qualitätsmanagement*. 2011;16(1):3-9.

Waters H, Vanderpoel J, Nejadnik B, Lunacsek O, Lennert B, Goff J, Augustyn D, McKenzie S. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. *J Med Econ*. 2011;15(1):45-52.

Yeung W, Burns III H, Loiacono D. Are ACOs the answer to high-value healthcare? *Am Health Drug Benefits*. 2011;4(7):441-450.

2010

[Return to Publications](#)

Akhrass F, Skinner N, Boswell K, Travis LB. Evolving trends in insulin delivery: in pursuit of improvements in diabetes management. *Am Health Drug Benefits*. 2010 Mar/Apr;3(2):117-122.

Birnbaum DS, Braun S. Evaluation of disease management programs—evaluation of the methodology and the first results from a health economics perspective. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*. 2010;104(2):85-91.

- Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT 3rd, Reilly J, Gajra A, Vokes EE, Green MR. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. *J Clin Oncol*. 2010 Jan 10;28(2):202-206.
- Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. *J Opioid Manag*. 2010;6(4):269-289. doi:10.5055/jom.2010.0025
- Bramley TJ. Evidence-based medicine and comparative effectiveness research: toward appropriate utilization of biopharmaceuticals in multiple sclerosis. *Am Health Drug Benefits*. 2010 Jan/Feb;3(1)4:S54-S58.
- Brandes I, Kleine-Budde K, Mittendorf T. Medical expenses in endometriosis. *Geburtshilfe und Frauenheilkunde*. 2010;69(10):925-930.
- Braun S, Greiner W. Gesundheitsökonomische evaluation der integrierten versorgung „OPTI-MuM“. [Health economic evaluation of the integrated care “OPTI-MuM.”] *Das Gesundheitswesen [Healthcare]*. 2010;72(12):71-77.
- Braun S, Kreimeier S, Greiner W. Messung der patientenzufriedenheit in integrierten gesundheitsprojekten—Eine pilotstudie mit einem modifizierten ZAP-fragebogen. [Measuring patient satisfaction in integrated care—a pilot study using the modified ZAP questionnaire.] *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. [Journal of Evidence, Education and Quality in Health Care]*. 2010;104(2):106-112.
- Braun S, Zeidler J, Mittendorf T, Schulenburg JM. Cost effectiveness of quetiapine and haloperidol in patients with partially refractory schizophrenia. *PharmacoEconomics—German Research Articles*. 2010;8(1):21-29.
- Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. *J Clin Oncol*. 2010 Jan 1;28(1):29-34.
- Carlton RI, Bramley TJ, Nightengale B, Conner TM, Zacker C. Review of outcomes associated with formulary restrictions: focus on step therapy. *Am J Pharm Benefits*. 2010;2(1):50-58.
- Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. *Prostate Cancer Prostatic Dis*. 2010 Jun;13(2):162-167.
- D'Souza A, Meissner BL, Tang B, McKenzie RS, Piech CT. Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. *Am Health Drug Benefits*. 2010;3(4):266-273.
- D'Souza AO, Rahnema R, Regan TS, Common B, Burch S. H-E-B's value-based health management program: impact on asthma medication adherence and healthcare cost. *Am Health Drug Benefits*. 2010;3(6):394-402.
- Dalal A, Shah M, D'Souza AO, Rane P. Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. *J Med Econ*. 2010;13(4):591-598.
- Eaddy M, Seal B, Tangirala M, Davies E, O'Day K. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. *Am J Health-Syst Pharm*. 2010;67:2110-2114.
- Eidt-Koch D, Wagner T, Mittendorf T, Reimann A, von der Schulenburg JM. Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany. *Pediatr Pulmonol*. 2010;46(3):278-285.
- Eidt-Koch D, Wagner TOF, Mittendorf T, Schulenburg JM. Outpatient medication costs of patients with cystic fibrosis in Germany. *Appl Health Econ Health Policy*. 2010;8(2):111-118.
- Foster T, Edwards D, Lumpkin M, Hubbard W, Cayetano M, Fernandez-Lopez S. Models and mechanisms for assisting the underinsured. *Oncol Bus Rev*. 2010 May;3:1-5.

- Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR. Prognostic significance of mucin and P53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALG 9633. *J Thorac Oncol*. 2010;5:810-817.
- Greiner W. Evidence-based public health from a health economic perspective. In: A G, ed. Evidence-Based Public Health. Bern: Huber Verlag; 2010:83-92.
- Greiner W. Financial management in medical practices and medical networks. In: R B, J S, C G, eds. Management im Gesundheitswesen. Heidelberg: Springer-Verlag; 2010:248-258.
- Greiner W. Trace elements of a reform—still outweighs the Dirigismus. *ifo Schnelldienst*. 2010;63(16):12-15.
- Greiner W, Kuhlmann A, Schwarzbach C. Economic assessment of the efficiency boundary concept—in economic evaluation of IQWiG's efficient frontier. *Gesundheitsökonomie & Qualitätsmanagement*. 2010;10(5):241-250.
- Greiner W, Schulenburg JM. HTA in Germany: very special and specific. *Eur J Health Econ*. 2010;11(1):1-3.
- Hodek JM, Greiner W. Correlation of health-related quality of life and multimorbidity. *Public Health Forum*. 2010;18(1):8.e1-8.e3.
- Hodek JM, Ruhe AK, Greiner W. Health-related quality of life in multimorbidity. *Gesundheitswesen*. 2010;72(8):455-465.
- Icks A, Chernyak N, Bestehorn K, et al. Methoden der gesundheitsökonomischen Evaluation für die Versorgungsforschung. [Methods of health economic evaluation in health services research.] *Gesundheitswesen [Healthcare]*. 2010;72(12):917-933.
- Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Stewart M, Tyler T, Vose JM, Weinstein S, Li EC, DeMartino J. NCCN oncology risk evaluation and mitigation strategies white paper: recommendations for stakeholders. *JNCCN*. 2010;8(Suppl 7):S7-S27.
- Kresimon J, Theidel U, Runge C, Rychlik R, Krueger W. Treatment cost of secondary peritonitis in Germany—a comparative study of medical cost incurred for tigecycline therapy and standard regimens. *Crit Care*. 2010;14(1):P54.
- Kuhne F, Mittendorf T, Germing U, Tesch H, Weinberg R, Grabenhorst U, Mohr A, Lipp R, von der Schulenburg JM. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective. *Ann Hematol*. 2010;89(12):1239-1247.
- Kulp W. Health Technology Assessment of Medicines and Medical Devices. Göttingen: Cuvillier; 2010.
- Langley PC, Patkar AD, Boswell KA, Benson CJ, Schein JR. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. *Curr Med Res Opin*. 2010;26:239-251.
- Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. *P T*. 2010;35(12):680-689.
- Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. *Cancer Invest*. 2010;28(3):312-322.
- McLaughlin T, Buxton M, Mittendorf T, Redekop W, Mucha L, Darba J, Jonsson L, Lacey L, Leibman C. Assessment of potential measures in models of progression in Alzheimer disease. *Neurology*. 2010;75(14):1256-1262.

Min JK, Gilmore A, O'Day K, Budoff MJ. The cost-effectiveness of coronary computed tomography Angiography versus Myocardial perfusion SPECT imaging for the evaluation of patients with chest pain and no known coronary artery disease. *Radiology*. 2010 Mar;254(3):801-808.

Mittendorf T. Ambulatory health care structures for rheumatology in Germany. *Zeitschrift Fur Rheumatologie*. 2010;69(9):830-835.

Müller-Riemenschneider F, Meinhard C, Damm K, Vauth C, Bockelbrink A, Greiner W, Willich SN. Effectiveness of nonpharmacological secondary prevention of coronary heart disease. *Eur J Cardiovasc Prev Rehabil*. 2010;17(6):688-700.

Neutel JM, Eaddy M, Lunacsek OE, Roberts C, Chen L, Kean AJ, Jackson JH. Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. *J Clin Hypertens (Greenwich)*. 2010 Jun;12(6):396-406. doi:10.1111/j.1751-7176.2010.00290.x

Nocon M, Roll S, Mittendorf T, Schulenburg JM, Willich SN. Human papillomavirus (HPV) tests in cervical carcinoma early detection. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*. 2010;104(2):138-142.

Nuijten M, Mittendorf T. A health economic evaluation of disease modifying drugs (DMD) for treatment of relapse-remitting multiple sclerosis from the German societal perspective. *Clin Ther*. 2010;32(4):717-728.

Nuijten M, Mittendorf T, Persson U. A few practical issues for the conduction of a budget impact analysis (BIA). *ISPOR Connections*. 2010.

Ose D, Grande G, Greiner W. Patient-oriented quality reporting—approaches and perspectives. In: W K, M M, R R, eds. *Aspekte der Prävention*. Stuttgart: Thieme. 2010:148-157.

Park J, Jackson J, Skinner E, Ranghell K, Saiers J. Impact of an adherence intervention program of medication adherence barriers, asthma control, and productivity/daily activities in patients with asthma. *J Asthma*. 2010 Dec;47(10):1072-1077.

Plagemann T, Braun S, Schulenburg JM. Eigeneinrichtungen within the GKV—an evaluation from an economic point of view. *Gesundheits- und Sozialpolitik*. 2010;64(5):22-28.

Prenzler A, Bokemeyer B, Mittendorf T, Graf von der Schulenburg JM. Kosten der colitis ulcerosa—eine kalkulation aus der perspektive der gesetzlichen krankenversicherung. [Cost of ulcerative colitis within the Germany Statutory Health Insurance.] *Deutsche Medizinische Wochenschrift [German Weekly Medical Magazine]*. 2010;135(7):281-286.

Prenzler A, Müller-Busch MC, Mittendorf T, Theidel U, von der Schulenburg JM, Montag T. Care situation of palliative care patients and assessment of the workload of the carers—a survey among ambulatory nurses in Germany. *Pflegezeitschrift*. 2010;63(5):300-304.

Prenzler A, Reddemann S, Schulenburg JM. The choice of perspective in health economic evaluations—an interdisciplinary analysis. *Gesundheits- und Sozialpolitik*. 2010;64(2):30-38.

Prenzler A, Schulenburg JM, Zeidler J. *Exercises on Public Health and Health Economics*. Berline: Springer-Verlag; 2010.

Prenzler A, Zeidler J, Braun S, von der Schulenburg JM. Evaluation of resources in health care from the perspective of German social security. *Pharmacoeconomics German Research Articles*. 2010;8(1):47-66.

Rasch A, Klose K, Greiner WTH. Behavioral smoking cessation in statutory health insurance—analysis of the supply and reimbursement situation. *Prävention und Gesundheitsförderung*. 2010;5(2):151-158.

Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Gusi N, Herdman M, Jelsma J, Kind P, Olivares PR, Scalone L, Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. *Qual Life Res.* 2010;19(6):887-897.

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. *J Thorac Oncol.* 2010 Sep;5(9):1382-1390.

Reddemann S, Basse T, Schulenburg JM. The impact of the financial crisis on the dividend policy of the European insurance industry. *Geneva Papers for Risk and Insurance.* 2010;35(1):53-62.

Rieckmann N, Nocon M, Roll S, Schwarzbach C, Vauth C, Greiner W, Willich SN. Nursing care concepts in patients with dementia—a systematic review. *Gerontol Geriatr.* 2010;43(3):183-189.

Schulenburg JM, Greiner W. EJHE has an official impact factor of 1.337. *Eur J Health Econ.* 2010;11(5):435.

Schulenburg JM, Greiner W, Dierks C. Methods for determining cost-benefit ratios for medicinal products in Germany. *Gesundheitsökonomie und Qualitätsmanagement.* 2010;15:S1-S28.

Schulenburg JM, Hodek JM. Benefits and costs of the current regulation of the pharmacy market in Germany. *Gesundheits- und Sozialpolitik.* 2010;64(1):19-30.

Schulenburg JM, Prenzler A, Schurer W. Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer. *Eur J Health Econ.* 2010;10(1):21-26.

Soper AM, Reeder CE, Brown LM, Stojanovska A, Lennert BJ. The national oncology working group (now) initiative: payer and provider collaborations in oncology benefits management. *Am J Manag Care.* 2010;16(4):e94-e97.

Sroczyński G, Schnell-Inderst P, Muehlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf J, Jutta E, Peters H, Karl-Ulrich P, Alexander K. Decision analytic model to evaluate long-term effectiveness and cost-effectiveness of the introduction of HPV testing in cervical cancer screening in Germany. *MS Health Technol Assess.* 2010;92:6:Doc05.

Thiem U, Theile G, Junius-Walker U, Holt S, Thürmann P, Hinrichs T, Platen P, Diederichs C, Berger K, Hodek JM, Greiner W, Berkemeyer S, Pientka L, Trampisch HJ. Prerequisites for a new health care model for elderly people with multi-morbidity—the PRISCUS research consortium. *Gerontol Geriatr.* 2010;44(2):115-120.

Tinnemann P, Stöber Y, Roll S, Vauth C, Willich SN, Greiner W. Dental indications for standardized methods of instrumental functional analysis, taking into account health economic aspects. Information DAfMDu, ed. Köln: DIMDI; 2010.

Ueberle M, Greiner W. Estimation of economic costs and benefits of occupational health management in the hospital. In: W H, ed. *Handbuch der Integrierten Versorgung: Strategien, Konzepte, Praxis.* Heidelberg: Springer-Verlag; 2010:248-258.

Ueberle M, Greiner W. Kennzahlenentwicklung. In: Badura B WU, Hehlmann T, ed. *Occupational health policy: the way to healthy organization.* Heidelberg: Springer-Verlag; 2010:254-261.

Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. *Qual Life Res.* 2010;19(6):875-886.

Zellner MA, Prenzler A, Kasch C, Mittendorf T, Mittelmeier W, Schulenburg JM. Therapy advice in the light of daily practice using the example of osteoporosis. *Gesundheitsökonomie und Qualitätsmanagement.* 2010;15(1):20-26.

Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for hemophilia patients with inhibitors undergoing major orthopedic surgeries. *Haemophilia*. 2009 Sep;15(5):1083-1089.

Brandes I, Kleine-Budde K, Mittendorf T. Cost of illness in endometriosis. *Geburtshilfe Frauenheilkd*. 2009;69(10):925-930.

Braun S, Mittendorf T, Greiner W, Menschik T, Schulenburg JM. Cost-effectiveness of exemestane vs. tamoxifen in post-menopausal women with early breast cancer in Germany. *Breast Care*. 2009;4(6):389-396.

Braun S, Prenzler A, Mittendorf T, Schulenburg JM. Assessment of resource consumption in the German healthcare system from the point of view of the statutory health insurance. *Das Gesundheitswesen*. 2009;71(1):19-23.

Claes C, Mittendorf T, Schulenburg JM. Health economic modeling of allergen-specific immunotherapy for seasonal allergic rhinitis from the perspective of the payers. *Allergo J*. 2009;18(1):60-70.

Claes C, Mittendorf T, Schulenburg JM. Persistenz und verordnungshäufigkeit der von der gesetzlichen Krankenversicherung verordneten subkutanen allergenspezifischen Immuntherapie (SCIT). [Persistence and frequency of prescriptions in the field of subcutaneous allergen-specific immunotherapy (SCIT) in GKV patients in Germany.] *Medizinische Klinik [Medical Clinic]*. 2009;104(7):536-542.

Claes C, Mittendorf T, Stoll M. Care for HIV patients in the future: challenges for the future. *Spektrum Virologie*. 2009;3(1):3-11.

Claes C, Mittendorf T, Stoll M. Recent developments in the provision of health care services for HIV. *Gesundh ökon Qual Manag*. 2009;14:227-229.

Claes C, Reinert RR, Schulenburg JM. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. *Eur J Health Econ*. 2009;10(1):25-38.

Damm K, Scheunemann B, Vauth C, Schulenburg JM. Five years of case-related fixed fees in the inpatient sector—effects on in-house structures and processes of hospitals. *Betriebswirtschaftliche Forschung und Praxis*. 2009;61(3):271-282.

Damm O, Hodek JM, Greiner W. Methodische standards von krankheitskostenstudien am beispiel von brust-, prostata- und darmkrebs. [Methodological standards of disease cost studies using the example of breast, prostate and colorectal cancer.] *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen [Journal of Evidence, Education and Quality in Health Care]*. 2009;103(6):305-316.

Damm O, Nocon M, Roll S, Vauth C, Willich SN, Greiner W. Human papillomavirus (HPV) vaccine for the prevention of HPV 16/18 induced cervical carcinomas and their precursors. Information DAfMDu, ed. Köln: DIMDI; 2009.

Eidt D, Frank M, Reimann A, Wagner T, Mittendorf T, Von der Schulenburg JM. Measures to enhance health care for rare diseases. Berlin: Federal Ministry of Health—Referat Öffentlichkeitsarbeit. 2009.

Eidt D, Mittendorf T, Wagner TOF, Reimann A, Schulenburg JM. Kostenanalyse zur ambulanten Behandlung von Mukoviszidose-Patienten in Deutschland. Übersicht der prospektiven Studienergebnisse. [Cost analysis for ambulatory treatment of cystic fibrosis in Germany. Overview of the prospective study results]. *Medizinische Klinik [Medical Clinic]*. 2009;104(7):529-535.

Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. *BMC Pediatrics*. 2009;9(1):55-62.

- Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek O, Happe L. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. *Curr Med Res Opin.* 2009;25(5):1081-1087.
- Feinberg B, Gilmore J, Gondesen T, Jackson J, Saleh M. Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. *Community Oncol.* 2009 Jun;6(6):257-261.
- Fernandez-Lopez S, Lennert B. Quality improvement initiatives: the missed opportunity for health plans. *Am Health Drugs Benefits.* 2009 Nov/Dec;2(7):297-304.
- Garnett WR, St Louis EK, Henry TR, Bramley T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. *Curr Neuropharmacol.* 2009 Jun;7(2):83-95.
- Garris C, Shah M, D'Souza A, Stanford R. Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms, retrospective cohort analysis of pharmacy claims data. *Clin Drug Invest.* 2009;29(8):515-526.
- Green MR, West H, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, Iovino L. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. *J Thorac Oncol.* 2009 Aug;4(8):983-987.
- Greiner W. Chancen und grenzen einer standardisierung bei der bewertung von kostenanalysen (Kommentar). [Opportunities and limits of standardizing the evaluation in cost analysis (commentary).] *Gesundheitswesen [Healthcare].* 2009;71(1):26-27.
- Happe L, Lunacsek O, Kruzikas D, Marshall G. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. *Pediatr Infect Dis J.* 2009;28(2):98-101.
- Hodek JM, Gramsch A, Greiner W. Branding in the hospital sector. *Betriebswirtschaftliche Forschung und Praxis.* 2009;61(3):254-270.
- Hodek JM, Ruhe AK, Greiner W. Multimorbidität und gesundheitsbezogene lebensqualität bei älteren menschen. [Multimorbidity and health-related quality of life among elderly persons.] *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz [Federal Health Gazette - Health Research - Health Protection].* 2009;52(12):1188-1201.
- Howell P, Reeder G, Regan TS. Payer perspectives on healthcare reform. *Am Health Drug Benefits.* 2009;2(4):181-183.
- Jackson J, Gutierrez B, Lunacsek O, Ramachandran S. Better asthma management with advanced technology: creation of an asthma utilization Rx analyzer (AURA) tool. *P T.* 2009 Feb;34(2):80-85.
- Krummacker S, Mittendorf T, Stürmann H, Schulenburg JM. Developments in the statutory health insurance market in Germany: results of an empirical survey. *Gesundheits- und Sozialpolitik.* 2009;62(6):28-39.
- Lennert B. Care management for TIA and stroke patients: riding the quality improvement wave. *Am Health Drugs Benefits.* 2009 Sep/Oct;2(6)8Suppl:S24-S27.
- Meissner B, Nelson W, Hicks R, Sikirica V, Gagne J, Schein J. The rate and costs attributable to intravenous patient-controlled analgesia errors. *Hospital Pharmacy.* 2009 Apr;44(4):312-314.
- Mittendorf T. Health technology assessment in Germany—are we heading for new shores in health economic research ignited by the new methods from the IQWiG? *Euro Observer.* 2009;11(1):6-7.
- Mittendorf T. Outpatient rheumatological care—business aspects. *Rheuma Manag.* 2009;2:8-10.

- Mittendorf T, Bevan S, Barham L. Should health technology assessments value labour market participation as a clinical outcome? The case for early intervention and management of musculoskeletal disorders (MSD) in the EU. *Ann Acad Med Singapore*. 2009;11.
- Mittendorf T, Briggs A, Lopez Bastida J, Nuijten M, Persson U. Do health politicians really listen to health economists? Observations from Europe. *ISPOR Connections*. 2009;15(6):15-16.
- Mittendorf T, Greiner W, von der Schulenburg JM. Methods of economic evaluation for the German statutory healthcare system. *Pharmacoeconomics*. 2009;27(3):265.
- Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide versus insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. *Diabetes Obes Metab*. 2009;11(11):1068-1079.
- Müller-Riemenscheider F, Bockelbrink A, Ernst I, Schwarzbach C, Vauth C, Schulenburg JM, Vauth C. Stereotactic radiosurgery for the treatment of brain metastases. *Radiother Oncol*. 2009;91(1):67-74.
- Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. *Curr Med Res Opin*. 2009;25(11):2663-2669.
- O'Day K, Salamanca-Brosig L, Regan T, Boswell K, Seal B, Reeder G. Asthma disease burden and formulary decision making: MCO and employer perspectives. *Drug Benefit Trends*. 2009;21(2):43-49.
- Prenzler A, Mittendorf T, Conrad S, Schulenburg JM, Bokemeyer B. The direct cost of care for patients with Crohn's disease from the perspective of statutory health insurance. *Zeitschrift für Gastroenterologie*. 2009;47(7):659-666.
- Rasch A, Greiner W. Effectiveness and cost-effectiveness of smoking cessation courses in statutory health insurance: a literature review. *Das Gesundheitswesen*. 2009;71(11):732-738.
- Rasch A, Greiner W. Health economic model of smoking cessation with varenicline. *Suchtmedizin in Forschung und Praxis*. 2009;11(2):47-55.
- Rasch A, Greiner W. Smoking and health-related quality of life: a systematic review. *SUCHT*. 2009;55(6):328-338.
- Rasch A, Hodek JM, Runge C, Greiner W. Determinants of willingness to pay for a new therapy in a sample of menopausal-aged women. *Pharmacoeconomics*. 2009;27(8):693-704.
- Reeder C, Divers C, Deem D, Cherney B, Fortner G, Probst L. Employer-based health initiative: impact on employees' cardiovascular outcomes. *Am Health Drug Benefits*. 2009 Feb/Mar;2(2):80-85.
- Riepe MW, Mittendorf T, Forstl H, Frolich L, Haupt M, Leidl R, Vauth C, von der Schulenburg MG. Quality of life as an outcome in Alzheimer's disease and other dementias—obstacles and goals. *BMC Neurol*. 2009;9:47.
- Ruof J, Hülsemann JL, Mittendorf T, Schulenburg JM, Zeidler H, Merkesdal S. Conceptual and methodical basis of health cost surveys in rheumatology. *J Rheumatol*. 2009;63(5):372-379.
- Sarnes M. Impact of market trends on drug pipelines: the need for value-based R&D. *Am Health Drug Benefits*. 2009 Jan;2(1)Suppl:S55-S60.
- Saverno K, Seal B, Goodman MJ, Meyer K. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis. *Am Health Drug Benefits*. 2009 Nov/Dec;2(7):309-316.
- Schulenburg JM. Schuster stick to your last: the IQWiG and the health economy. *Monitor Versorgungsforschung*. 2009;2(2):35-37.

- Schulenburg JM, Mittendorf T, Kulp W, Greiner W. Health technology assessment (HTA) in the field of medical devices—same game with the same rules? *Gesundheitsökonomie und Qualitätsmanagement*. 2009;14(3):144-155.
- Schulenburg JM, Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. *Eur J Health Econ*. 2009;8(1):5-31.
- Schumacher HK, Gewaltig M, Busse T, Greiner W. Discount agreements—stocktaking 2009: ratio of selective contractual constellations in the reimbursement system of the GKV. *Die Krankenversicherung*. 2009;61(6):137-141.
- Schumacher HK, Greiner W. Alternative methods for estimating the effect comparability using the example of the fixed-dose group of ACE inhibitors. *Gesundheits- und Sozialpolitik*. 2009;63(5):28-37.
- Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in europe—the HEALTH Model. *Value Health*. 2009;12(6):857-871.
- Schwarzbach C, Kuhlmann A, Vauth C, Schulenburg JM. The efficiency limit of the IQWiG: a successful adaptation of the models of Markowitz and Koopmanns? *Sozialer Fortschritt*. 2009;58(7):137-146.
- Smith BJ, St Louis EK, Stern JM, Green C, Bramley T. Concerns with AED conversion: comparison of patient and physician perspectives. *Curr Neuropharmacol*. 2009 Jun;7(2):120-124.
- St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. *Curr Neuropharmacol*. 2009 Jun;7(2):77-82.
- Stoll M, Claes C, Mittendorf T, Schulenburg JM. Pharmacoeconomic evaluation of darunavir for the treatment of treatment-experienced HIV patients. *Fortschritte der Medizin*. 2009;151(1):97-103.
- Stoll M, Schulte E, Claes C, Schulenburg JM, Schmidt RE. The HIV-infected patient and his costs: burdened by the healthcare system or burden on the budget? *Fortschritte der Medizin*. 2009;151(1):72-77.
- Vauth C, Greiner W. Aspekte der gesundheitsökonomie bei der behandlung von schmerzen und schlafmangel. [Aspects of health economic in treatment of pain and sleep deficit.] *Deutsche Medizinische Wochenschrift*. 2009;134(Suppl 4):S144-147.
- Wall B, Chiao E, Plauschinat C, Miner P, Jackson J, Humphrey B. Trends from the field: provider organization performance assessment utilizing diabetes physician recognition program. *Am J Manag Care*. 2009 Feb 14;15(2).

2008

[Return to Publications](#)

- Assmann C, Hodek JM, Greiner W. Practical guide: IGeL without sting. *Deutsches Ärzteblatt*. 2008;105(46):12-17.
- Bockelbrink A, Roll S, Ruether K, Rasch A, Greiner W, Willich SN. Cataract surgery and the development or progression of age-related macular degeneration: a systematic review. *Surv Ophthalmol*. 2008;53(4): 359-367.
- Bokemeyer B, Hüppe D, Hartmann P, Düffelmeyer M, Klugmann T, Weismüller J, Mittendorf T, Raspe. Clinical status, psychosocial impairments, provided health care services and cost of medication for inflammatory bowel disease (IBD) in Germany: an online IBD-registry. *J Crohns Colitis*. 2013;7(5):355-368.
- Bramley T, Peebles P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in Medicare beneficiaries with glaucoma. *Arch Ophthalmol*. 2008 Jun;126(6):849-856.

- Braun S, Greiner W. The assumption of budget responsibility by integrated supply providers. *Gesundheits - und Sozialpolitik*. 2008;62(5):49-53.
- Braun S, Greiner W, Schulenburg JM. The avoidance of care costs in Alzheimer's disease caused by galatamine. *Prävention und Gesundheitsförderung*. 2008;3(3):145-150.
- Claes C, Mittendorf T, Grond M, Von der Schulenburg JM. Incremental cost-effectiveness of dipyridamole vs. Ass in secondary prevention of ischemic stroke. *Med Klin*. 2008;103:778.
- Comp P, Happe LE, Sarnes MW, Farrelly E. Clinically detected venous thromboembolism following hip fracture surgery with prophylaxis in a clinical practice setting. *Am J Orthop*. 2008;37(9):470-475.
- D'Souza A, Smith M, Miller L, Doyle J, Ariely R. Persistence, adherence and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. *J Manag Care Pharm*. 2008;14(3):291-301.
- Dickson M, Bramley TJ, Kozma C, Doshi D, Rupnow MF. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. *Am J Health Syst Pharm*. 2008 Sep 15;65(18):1720-1726.
- Eaddy M, Shah M, Lunacsek O, Stanford R. The burden of illness of hypertension and comorbid diabetes. *Curr Med Res Opin*. 2008;24(9):2501-2507.
- Fang E, Law S, Walt J, Chiang T, Williams E. The prevalence of glaucomatous risk factors in patients from a managed care setting: a pilot evaluation. *Am J Manag Care*. 2008;14:S28-S36.
- Fenter T, Davis EA, Shah M, Lin P. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged 65 years. *Am J Manag Care*. 2008;14(5):S154-S159.
- Friedrich M, Müller-Riemenschneider F, Roll S, Kulp W, Vauth C, Greiner W, Willich S, von der Schulenburg JM. Health technology assessment of laparoscopic compared to conventional surgery with and with-out mesh for incisional hernia repair regarding safety, efficacy and cost-effectiveness. *GMS Health Technol Assess*. 2008;67(4).
- Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. *Am Health Drug Benefits*. 2008;1(8):26-34.
- Greiner W, Bestehorn K. Effects of the introduction of fixed prices for statins on lipid levels in Germany. *J Public Health*. 2008;16(3):215-219.
- Greiner W, Eikötter T. Instruments for measuring quality of care in integrated care. *Gesundheitsökonomie & Qualitätsmanagement*. 2008;13(1):25-31.
- Greiner W, Mittendorf T. Reflections on 'Sicko' by Michael Moore from a European point of view. *ISPOR Connections*. 2008;14(1):13-14.
- Greiner W, Ose D, Grande G, Badura B. Patient information for evaluation of health facilities. *Prävention und Gesundheitsförderung*. 2008;3(3):152-162.
- Greiner W, Rasch A. Prevention of smoking from a health economic point of view. *Gesundheitsökonomie & Qualitätsmanagement*. 2008;13:127-129.
- Greiner W, Roll S, Muller-Nordhorn J, Keil T, Scholz H, Eidt D, Greiner W, Willich SN. Dacron vs. PTFE as bypass materials in peripheral vascular surgery—systematic review and meta-analysis. *BMC Surgery*. 2008;8(22):1-8.

- Greiner W, Rose MA, Raab-Pless S, Schmitter S, Hutt H. Rotavirus disease—annoying evil or heavy burden on family and health care system? *Prävention und Gesundheitsförderung*. 2008;3(4):266-372.
- Greiner W, Scherenberg V. Bonus programs—between competition and prevention—an inventory of the design of preventative bonus programs. *Gesundheits- und Sozialpolitik*. 2008;62(3):19-25.
- Hanker T, Vauth C, Mittendorf T, Schulenburg JM. Provision of health information by health insurances. An empirical analysis. *Gesundheits- und Sozialpolitik*. 2008;62(5):21-28.
- Happe L, Farrelly E, Stanford R, Sarnes M. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopedic surgeries. *J Thromb Thrombolysis*. 2008 Oct;26(2):125-131. doi:10.1007/s11239-007-0170-1
- Hartmann K, Hodek JM, Greiner W, Flöttmann A. Mystery shopping in the statutory health insurance—use of test buyers for quality assurance. *Zeitschrift für die gesamte Versicherungswissenschaft*. 2008;97(2):124-143.
- Hass B, Arns W, Kuchenbecker U, Juergensen JS. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany. *Value Health*. 2008;11(3):A302.
- Hicks RW, Sikirica V, Nelson W, Schein JR, Cousins DD. Medication errors involving patient-controlled analgesia. *Am J Health-Syst Pharm*. 2008;65(5):429-440.
- Hines JL, Danciu SC, Shah M, Borg MJ, Biga C. Use of multidetector computed tomography after mildly abnormal myocardial perfusion stress testing in a large single-specialty cardiology practice. *J Cardiovasc Computed Tomography*. 2008 Oct 10;2(6):372-378.
- Hodek JM, Mittendorf T, Schulenburg JM. Fields of application and significance of health economic evaluation in orthopedic technology. *Orthopädie-Technik*. 2008;12:934-939.
- Howell P. Cutting through the politics: presidential candidates' healthcare platforms and impact on health benefits. *Am Health Drug Benefits*. 2008;1(8):8-14.
- Issa M, Lin P, Eaddy M, Shah M, Davis EA. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. *Am J Manag Care*. 2008;14(5):S160-S166.
- Jackson J, Sobolski J, Krienke R, Wong K, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7 Guidelines). *J Am Board Fam Med*. 2008;2(1):512-521.
- Kulp W, Von der Schulenburg JM. Institutions of the Fourth Hurdle. In: Schöffski O, Von der Schulenburg JM, eds. *Gesundheitsökonomische Evaluationen*. Hannover: Springer; 2008.
- Kwong LM, Happe LE, Horblyuk R, Farrelly E. Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery. *J Arthroplasty*. 2008;23(6 Suppl 1):25-30.
- Levin L, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. *Am J Manag Care*. 2008;14:S11-S14.
- Liu J, Mittendorf T, Chang J, Von der Schulenburg JM. A structured review of studies on health-related quality of life in kidney cancer, hepatocellular carcinoma and leukemia. *Value Health*. 2008;11(6):A484.
- Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. *Eur J Health Econ*. 2008;9(1):7-15.

- McKinnon S, Goldberg L, Peeples P, Walt J, Bramley T. Current management of glaucoma and the need for complete therapy. *Am J Manag Care*. 2008;14:S20-S27.
- Mittendorf T. Gesundheitsgüter und deren Besonderheiten. In: Greiner W, Von der Schulenburg JM, Vauth C, eds. *Healthcare management—management of healthcare companies*. Bern: Hans Huber. 2008:15-27.
- Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, Schulenburg JM. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. *Rheumatology*. 2008;47(2):188-193.
- Mittendorf T, Werner I, Von der Schulenburg JM. The awarding of the 3rd North German BKK Science Award honors two junior researchers for topics to increase efficiency in the hospital sector. *Gesundh ökon Qual manag*. 2008;13:56-58.
- Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. *Int J Technol Assess Health Care*. 2008;24(2):184-192.
- Müller-Riemenschneider F, Bockelbrink A, Reinhold T, Rasch A, Greiner W, Willich SN. Long-term effectiveness of behavioural interventions to prevent smoking among children and youth. *Tobacco Control*. 2008;17(5):301-302.
- Müller-Riemenschneider F, Rasch A, Bockelbrink A, Vauth C, Willich SN, Greiner W. Effectiveness and cost-effectiveness of behavioral measures to prevent cigarette smoking. Information DAfMDu, ed. Köln: DIMDI; 2008.
- Naslund M, Eaddy M, Kruep E, Hogue S. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. *Am J Manag Care*. 2008;14(5):S167-S172.
- Naslund M, Regan T, Ong C, Hogue S. 5-alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. *Am J Manag Care*. 2008;14(5):S148-S153.
- Nuijten MJ, Mittendorf T, Jäcker A, Osowski U. Cost-effectiveness analysis of Rebif in first-line relapsing remitting multiple sclerosis in Germany. *Value Health*. 2008;11(6):A602.
- Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, Franklin M. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery. *Ann Pharmacother*. 2008;42(9):1216-1221.
- Prenzler A, Mittendorf T, Conrad S, von der Schulenburg JM, Bokemeyer B. Costs of Crohn's disease within the German statutory health insurance. *Value Health*. 2008;11(6):A522.
- Rasch A, Greiner W. Cost-effectiveness of smoking prevention measures in adolescents. *J Public Health*. 2008;16(1):3-11.
- Rasch A, Hodek JM, Runge C, Greiner W. Influencing factors on the willingness to pay for the example of a novel therapy in menopausal women. *Gesundheitsökonomie & Qualitätsmanagement*. 2008;13(5):288-297.
- Rasch A, Müller-Riemenschneider F, Vauth C, Willich SN, Greiner W. Federal structures and measures for the primary prevention of smoking in Germany. Information DAfMDu, ed. Köln: DIMDI; 2008.
- Reeder C, Franklin M, Bramley T. Managed care and the impact of glaucoma. *Am J Manag Care*. 2008;14:S5-S10.
- Scharf F, Mittendorf T, Schulenburg JM. Fraud in the German pharmaceutical sector. *Gesundheits - und Sozialpolitik*. 2008;62(2):47-57.

Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. *Value Health*. 2008;11(4):539-544.

Schulenburg JM, Mittendorf T, Vauth C, Greiner W. Scientific guidelines and their implementation in health policy. *Value Health*. 2008;11(4):547-548.

Schumacher HK, Greiner W. Fixed amounts as an instrument of expenditure control in statutory health insurance, system of calculation and resulting effects. *Gesundheits- und Sozialpolitik*. 2008;62(1):53-64.

Shabsigh R, Shah M, Sand M. Erectile dysfunction and men's health: developing a comorbidity risk calculator. *J Sex Med*. 2008;5:1237-1243.

Sheehan D, Keene M, Eaddy M, Krulewicz S, Kraus JE, Carpenter D. Differences in medication adherence and healthcare resource utilization patterns; older versus newer antidepressant agents in patients with depression and/or anxiety disorders. *CNS Drugs*. 2008;22(11):963-973.

Shorr AF, Nutescu EA, Farrelly E, Horblyuk R, Happe LE, Franklin M. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. *Ann Pharmacother*. 2008;42(9):1222-1228.

Stanford E, Chen A, Wan G, Lunacsek O, Sand P. Treatment modalities, health care resource utilization, and costs in patients diagnosed with interstitial cystitis. *Am J Obstet Gynecol*. 2008;199(1):71.e1-10.

Varma R, Peeples P, Walt J, Bramley T. Disease progression and the need for neuroprotection in glaucoma management. *Am J Manag Care*. 2008;14:S15-S19.

Vauth C, Greiner W. Chronic pain diseases in Germany—a stepchild of health economics? *Gesundheitsökonomie & Qualitätsmanagement*. 2008;13(1):5-10.

Zeidler J, Mittendorf T, Vahldiek G, Schulenburg JM. Cost comparison analysis of outpatient and inpatient cardiological rehabilitation. *Herz*. 2008;33(6):440-447.

Zeidler J, Mittendorf T, Vahldiek G, Zeidler H, Merkesdal S. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany. *J Rheumatol*. 2008;47(10):1527-1534.

2007

[Return to Publications](#)

Black L, Runken MC, Eaddy M, Shah M. Chronic disease prevalence and burden in elderly men: an analysis of Medicare medical claims data. *J Health Care Finance*. 2007 Summer;33(4):68-78.

Bramley T, Franklin M, Mitrzyk B. Management and treatment of insomnia and its impact on today's managed care. *Am J Manag Care*. 2007;13(5):S110-S111.

Evans C, Schein J, Nelson W, Crespi S, Gargiulo K, Horowicz-Mehler N, Panchal S. Improving patient and nurse outcomes: a task and time associated with two patient-controlled analgesia modalities using Delphi panels. *Pain Manag Nurs*. 2007;8(2):86-95.

Fenter T, Runken C, Black L, Eaddy M. Finasteride versus dutasteride: a real-world economic evaluation. *Am J Manag Care*. 2007;13(1 Suppl):S23-S27.

Goldstein J, Matuszweski K, Delaney C, Senagore A, Chiao E, Shah M, Meyer K, Bramley T. Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. *P T*. 2007;32(2):82-90.

- Green M R, Dowlati A, Yellamraju L, Daniels L, Willey J, Andrews M, Leff R. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000–2006. *J Thoracic Oncol*. 2007 Oct;2(10):953-956.
- Happe L, Lunacsek O, Marshall G, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. *Am J Manag Care*. 2007;13:506-512.
- Harding G, Vallow S, Leidy N, Olson W, Hewitt DJ, Polomano R, Nelson WW, Schein JR. Ease of care with patient controlled analgesia system: questionnaire development and validation. *J Adv Nurs*. 2007;59(5):530-541.
- Hensle T, Grogg A, Hyun Grace, Eaddy M, Elder J, Shah M, Batiste L, Koyle M, Caldamone A. Challenges surrounding vesicoureteral reflux: fuel for a paradigm shift in treatment. *Curr Med Res Opin*. 2007;23(4):S1-21.
- Hymes J, Bickimer T, Jackson J, Bookhart B, Mody S, Piech C. Dosing patterns, drug costs and hematologic outcomes in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. *Curr Med Res Opin*. 2007;23(8):1931-1937.
- Issa M, Regan T. Medical therapy for benign prostatic hyperplasia—present and future impact. *Am J Manag Care*. 2007;13(1 Suppl):S4-S9.
- Issa M, Runken C, Grogg A, Shah M. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. *Am J Manag Care*. 2007;13(1 Suppl):S10-S16.
- Marshall G, Happe L, Lunacsek O, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. *Pediatr Infect Dis J*. 2007;26:496-500.
- Naslund M, Black L, Eaddy M, Batiste L. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5ARIs. *Am J Manag Care*. 2007;13(1 Suppl):S17-S22.
- Navarro R, Mitrzyk BM, Bramley TJ. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations. *Am J Manag Care*. 2007;13(5 Suppl):S121-124.
- Poston S, Dickson M, Johnsrud M, Rupnow MF, Gdovin JM, Bramley TJ, Armstrong RB. Topiramate prescribing patterns among Medicaid patients: diagnosis, comorbidities, and dosing. *Clin Ther*. 2007 Mar; 29(3):504-518.
- Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? *Ann Pharmacother*. 2007;41:193-200.
- Reeder C, Franklin M, Bramley T. Current landscape of insomnia in managed care. *Am J Manag Care*. 2007;13(5):S112-S116.
- Richardson G, Mitrzyk B, Bramley T. Circadian rhythmicity and the pharmacologic management of insomnia. *Am J Manag Care*. 2007;13(5):S125-S128.
- Rolnick SJ, Jackson J, Nelson WW, Butani A, Herrinton LJ, Hornbrook M, Neslund-Dudas C, Bachman DJ, Coughlin SS. Pain management in the last six months of life among women who died of ovarian cancer. *J Pain Symptom Manage*. 2007;33(1):24-31.
- Roth T, Franklin M, Bramley TJ. The state of insomnia and emerging trends. *Am J Manag Care*. 2007;13(5 Suppl):S117-S120.
- Shabsigh R, Duval S, Shah M, Regan T, Juhasz M, Veltry L. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: meta-analysis of clinical trial data. *Curr Med Res Opin*. 2007;23(10):2453-2460.

Shah M, Butler M, Bramley T, Curtice T, Fine S. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. *Curr Med Res Opin.* 2007;23(2):417-426.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. *Thromb Res.* 2007;121(1):17-24.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. *Am J Health-Syst Pharm.* 2007 Nov;64:2349-2355.

St Louis EK, Gidal BE, Henry TR, Kaydanova Y, Krumholz A, McCabe PH, Montouris GD, Rosenfeld WE, Smith BJ, Stern JM, Waterhouse EJ, Schulz RM, Garnett WR, Bramley T. Conversions between monotherapies in epilepsy: expert consensus. *Epilepsy Behav.* 2007 Sep;11(2):222-234.

Vargo JJ, Bramley T, Meyer K, Nightengale B. Practice efficiency and economics: the case for rapid recovery sedation agents for colonoscopy in a screening population. *J Clin Gastroenterol.* 2007;41(6):591-598.

2006

[Return to Publications](#)

Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. *J Manag Care Pharm.* 2006;12(3):239-245.

Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating adherence of antidepressant therapy: a real-world comparison of adherence and economic outcomes. *Med Care.* 2006;44(4):300-303.

Dornbusch D, Allegra C, Willey J, Andrews M, Leff R, Epstein J, Jones J, Lokey L, Green M R. How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599. *The Oncologist.* 2006 Jan;11(1):31-38.

Fenter TC, Naslund MJ, Shah MB, Eaddy MT, Black L. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. *Am J Manag Care.* 2006;12(4 Suppl):S90-S98.

Gdovin JM, Moya F, Vishalpuria T, Grogg A. A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome. *J Pediatr Pharmacol Ther.* 2006;11(1):43-54.

Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. *Am J Manag Care.* 2006;12(4 Suppl):S83-S89.

Jackson J, Fernandes A, Nelson W. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: a retrospective data analysis. *Clin Ther.* 2006;28(9):1462-1471.

Meissner B, Dickson M, Shinogle J. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. *J Manag Care Pharm.* 2006;12(4):331-340.

Meissner B, Harrison D, Carter J, Borrego M. Predicting the impact of Medicare Part D implementation on the pharmacy workforce. *Res Social Adm Pharm.* 2006;2(3):315-328.

Naslund MJ, Chiao E, Black L, Eaddy MT. The hidden condition: status, challenges, and opportunities in the management of enlarged prostate for managed care. *Am J Manag Care.* 2006;12(4 Suppl):S76-S82.

Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L. Clinical and economic outcomes in patients treated for enlarged prostate. *Am J Manag Care*. 2006;12(4 Suppl):S111-S116.

Patric K, Stickles J, Turpin R, Simmons JB, Jackson J, Bridges E, Shah M. Diabetes disease management in Medicaid managed care: a program evaluation. *Dis Manag*. 2006;9(3):144-156.

Raebel MA, Carroll NM, Andrade SE, Chester EA, Lafata JE, Feldstein A, Gunter MJ, Nelson WW, Simon SR, Chan KA, Davis RL, Platt R. Monitoring of drugs with a narrow therapeutic range in ambulatory care. *Am J Manag Care*. 2006;12:268-274.

Raebel MA, Carroll NM, Simon SR, Andrade SE, Feldstein AC, Lafata JE, Nelson WW, Chan KA, Gunter MJ, Tolsma D, Platt R. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. *J Manag Care Pharm*. 2006;12:656-664.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. *Ann Pharmacother*. 2006;40:386-391.

Solberg LI, Enstad CJ, Boyle RG, Nelson WW. Physician-patient interaction for smoking cessation medications: a dance of mutual accommodation? *J Am Board Fam Med*. 2006;19:251-257.

Stein M, Cantrell R, Sokol M, Eaddy MT, Shah MB. The national anxiety managed care database: a focus on antidepressant utilization, patient adherence, and resource utilization. *Psychiatr Serv*. 2006;57(5):673-680.

2005

[Return to Publications](#)

Andrade SE, Graham DJ, Staffa JA, Schech SD, Shatin D, La Grenade L, Goodman MJ, Platt R, Gurwitz JH, Chan KA. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. *J Clin Epidemiol*. 2005;58(2):171-174.

Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT. Active surveillance of vaccine safety: a system to detect early signs of adverse events. *Epidemiology*. 2005;16(3):336-341.

DeVane CL, Chiao E, Franklin M, Kruep E. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. *Am J Manag Care*. 2005;11(Suppl):S344-S353.

Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE. Relationship of total health care charges to SSRI utilization patterns including the length of antidepressant therapy. *J Manag Care Pharm*. 2005;11(2):145-150.

Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. *Clin Ther*. 2005;27(2):263-272.

Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes MW. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis. *Manag Care Interface*. 2005;18(1):55-63.

Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. *Am J Manag Care*. 2005;11(4):206-210.

Green M, Andrews M, Leff R, Willey J, Allegra C, Denes A, Epstein J, Jones J, Lokey L. Adjuvant therapy choices in patients with resected non-small-cell lung cancer: correlation of doctors' treatment plans and relevant phase III trial data. *J Oncol Pract*. 2005;1(2):37-42.

Hurley JS, Roberts M, Solberg LI, Gunter MJ, Nelson WW, Young L, Frost FJ. Laboratory safety monitoring of chronic medications in ambulatory care settings. *J Gen Intern Med*. 2005;20(4):331-333.

Johnsrud M, Crismon MI, Thompson A, Grogg A. An economic comparison of risperidone and olanzapine use within an integrated managed mental health program. *Adm Policy Men Health*. 2005;20:1-7.

Kaliner M, Amin A, Gehling R, Crivera C, Chiao E, Vishalpura T, Bramley T. Impact of inhaled corticosteroid-induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi panel. *Pharm Ther Dig*. 2005;30(10):573-601.

Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. *Arch Intern Med*. 2005;165:2497-2503.

Keene MS, Eaddy MT, Mauch RP, Regan TS, Shah M, Chiao E. Differences in compliance patterns across the SSRIs. *Curr Med Res Opin*. 2005;21:1651-1658.

Keene M, Eaddy M, Nelson WW, Sarnes MW. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. *Am J Manag Care*. 2005;11(Suppl):S362-S369.

Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. *Am J Health Syst Pharm*. 2005;62(24):2597-2603.

Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. *Am J Manag Care*. 2005;11(Suppl):S370-S379.

Sheehan D, Chiao E, Eaddy M, Shah M, Sarnes M. Differences in patterns of therapy change across the SSRIs for treatment of depression and anxiety. *Drug Benefit Trends*. 2005;17:403-410.

Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. *Am J Manag Care*. 2005;11(Suppl):S354-S361.

Simon SR, Andrade SE, Ellis JL, Nelson WW, Gurwitz JH, Lafata JE, Davis RL, Feldstein A, Raebel MA. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. *J Am Geriatr Soc*. 2005;53(12):2165-2169.

Yost RD. New economics of the pharmaceutical supply chain. *Am J Health Syst Pharm*. 2005;62(5):525-526. doi:10.1093/ajhp/62.5.525

2004

[Return to Publications](#)

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA*. 2004;292(21):2585-2590.

Jackson J, Frech F, Ronen R, Mullany L, Lennert B, Jhaveri V. Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension. *J Manag Care Pharm*. 2004;10(6):513-520.

Kennedy DT, Paulson DM, Eddy TD, Patel PC, Patkar AD, Holdford DA, Genina VY, Griffin EN. A smoking-cessation program consisting of extensive counseling, pharmacotherapy, and office spirometry: results of a pilot project in a Veterans Administration medical center. *Pharmacotherapy*. 2004;24(10):1400-1407.

Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. *Am J Manag Care*. 2004;10(6):383-391.

McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. *Clin Ther*. 2004;26(1):115-124.

Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Non-sedating antihistamine utilization impact following an increase in prescription co-payment. *J Manag Care Pharm.* 2004;10(3):226-233.

Mlads DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. *Curr Med Res Opin.* 2004;20(12):1883-1893.

Nelson WW, Sybilrud LE, Porter DR, et al. Erroneous manufacturer-assigned thromboplastin reagent ISI value. *Lab Med.* 2004;35(6):327-328.

Sarnes MW, Frankum (Happe) LE. Pharmacoeconomic evaluation of antidepressant therapies. *Manag Care.* 2004;13(Suppl 6):34-41.

Saver BG, Ritzwoller DP, Maciosek M, Goodman MJ, Conrad DA, Finkelstein E, Haase M, Barrett P, Cain KC. Does payment drive procedures? Payment for specialty services and procedure rate variations in 3 HMOs. *Am J Manag Care.* 2004;10(3):229-237.

Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation. *J Clin Psychopharmacol.* 2004;24:544-548.

Solberg LI, Hurley JS, Roberts MH, Nelson WW, Frost FJ, Crain AL, Gunter MJ, Young LR. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. *Am J Manag Care.* 2004;10(11 Pt 1):753-759.

Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov Model. *Value Health.* 2004;7(5):569-584.

Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. *Psychiatr Serv.* 2004;55:886-891.

2003

[Return to Publications](#)

Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. *Arch Intern Med.* 2003;163(17):2052-2057.

Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuance: a comparison of controlled-release paroxetine and immediate-release SSRIs. *Manag Care Interface.* 2003;16(12):22-27.

Fendrick AM, Monto AS, Sarnes MW, Nightengale BS. The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch Intern Med.* 2003;163:487-494.

Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. *Pharmacotherapy.* 2003;23(8):1037-1043.

Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. *Clin Ther.* 2003;25(4):1150-1171.

Godley P, Nguyen A, Yokoyama K, Rohack J, Woodward B, Chiang T. Improving hypertension care in a large group-model MCO. *Am J Health Syst Pharm.* 2003;60(6):554-564.

Holdford D, Patkar A. Identification of the service quality dimensions of pharmaceutical education. *Am J Pharm Educ.* 2003;67(4):article 108.

Maue SK, Jackson JH, Weiss BA, Rivo ML, Jhaveri V, Lennert B. The hypertension management program: identifying opportunities for improvement. *J Clin Hypertens*. 2003;3(Suppl 2):33-40.

Monto AS, Bramley TJ, Sarnes M. Development of a predictive index for picornavirus infections. *Clin Infect Dis*. 2003;36:253-258.

Offman JJ, Segal R, Russell WL, Cook DJ, Sandhu M, Maue SK, Lowenstein EH, Pourfarzib R, Blanchette E, Ellrodt G, Weingarten SR. A randomized trial of an acid-peptic disease management program in a managed care environment. *Am J Manag Care*. 2003;9(6):425-433.

Sapienza S, Sacco P, Floyd (Flemister) K, DiCesare J, Doan QD. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. *Clin Ther*. 2003;25(6):1872-1887.

2002

[Return to Publications](#)

Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, Buist DS, Goodman M, LaCroix AZ, Levin TR, Platt R. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. *J Clin Epidemiol*. 2002;55(3):310-313.

Bramley TJ, Lerner D, Sarnes M. Productivity losses related to the common cold. *J Occup Environ Med*. 2002;44:822-829.

Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DS, Carey VJ, Chandler JM, Chase GA, Ettinger B, Fishman P, Goodman M, Guess HA, Gurwitz JH, LaCroix AZ, Levin TR, Platt R. Gastric and duodenal safety of daily alendronate. *Arch Intern Med*. 2002;162(8):936-942.

Fischer LR, Defor TA, Cooper S, Scott LM, Boonstra DM, Eelkema MA, Goodman MJ. Pharmaceutical care and health care utilization in an HMO. *Eff Clin Pract*. 2002;5(2):49-57.

Gianfrancesco F, Grogg AL, Mahmoud R, Wang R, Nasrallah H. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type II diabetes: findings from a large health plan database. *J Clin Psychiatry*. 2002;63:920-930.

Girts TK, Crawford AG, Goldfarb NI, Bachleda M, Grogg A. Predicting high utilization of emergency department services among patients with a diagnosis of psychosis in a Medicaid managed care organization. *Dis Manag*. 2002;5(4):189-196.

Jackson JH, Bramley TJ, Chiang TS, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in an African-American hypertensive population. *Ethn Dis*. 2002;12(4 Suppl 3):53-57.

Mahmoud R, Kozma C, Reeder CE, Grogg AL, Meissner B. The role of pharmaceuticals in mental health care outcomes. In: *Neuropsychopharmacology—5th Generation of Progress*. Nashville, TN: American College of Neuropsychopharmacology; 2002.

Maue SK, Rivo ML, Weiss B, Farrelly EW, Brower-Stenger S. Effect of a primary care physician-focused, population-based approach to blood pressure control. *Fam Med*. 2002;34(7):508-513.

Offman J, Shaw M, Sadik K, Grogg A, Emery K, Lee J, Reyes E, Fullerton S. Identifying patients with gastroesophageal reflux disease—validation of a practical screening tool. *Dig Dis Sci*. 2002;47(8):1863-1869.

Putnam KG, Buist DS, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Arnold Chan K. Chronic disease score as a predictor of hospitalization. *Epidemiology*. 2002;13(3):340-346.

2001

[Return to Publications](#)

Godley P, Pham H, Woodward B, Rohack J, Maue SK. Opportunities for quality improvement in hypertension care in a managed care setting. *Am J Health Syst Pharm.* 2001;58(18):1728-1733.

Mauch R, Goldstein W, Lutes M, et al. Pharmaceutical industry and payer partnerships: program overview, legal updates and panel discussion proceedings. *Manag Care.* 2001;10(9 Suppl):5-6.

Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: a review of clinical outcomes. *Clin Ther.* 2001;23(10):1615-1627.

Ofman J, Ryu S, Borenstein J, Kania S, Lee J, Grogg A, Farup C, Weingarten S. Identifying patients with gastroesophageal reflux disease in a managed care organization. *Am J Health Syst Pharm.* 2001;58(17):1607-1613.

Phillips C, Polakoff D, Mauch RP, Maue SK. Assessment of constipation management in long-term care patients. *J Am Med Dir Assoc.* 2001;2(4):149-154.

Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, Soumerai S, Ross-Degnan D, Andrade S, Goodman MJ, Martinson B, Raebel MA, Smith D, Ulcickas-Yood M, Chan KA. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for education and research on therapeutics. *Pharmacoepidemiol Drug Saf.* 2001;10(5):373-377.

2000

[Return to Publications](#)

Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme a reductase and risk of fracture among older women. *Lancet.* 2000;355(9222):2185-2188.

Floyd (Flemister) KM, Maue SK, Aqui W, Augello F. The prevalence and treatment patterns of constipation in the long-term care setting: a multicenter cross-sectional study. *Consultant Pharmacist.* 2000.

Hawkins D, Jackson J. Application of pharmacoeconomics in cardiovascular disease: economic evaluation of lipid-lowering therapies. Introduction to Applied Pharmacoeconomics. Chapter 9: 179-196.

Maue SK, Segal R. Application of pharmacoeconomics and decision analysis in gastrointestinal disorders in the context of disease management. Introduction to Applied Pharmacoeconomics. Chapter 8: 144-178.

Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease patients converted from omeprazole to lansoprazole. *Arch Intern Med.* 2000;160(16):2491-2496.

Polakoff D, Tuell KT, Collette A, Wolfe M, Floyd (Flemister) KM. Collaborative partnership for optimizing heart failure outcomes in the long-term care environment: a disease management experience. *J Am Med Dir Assoc.* 2000;1(5):217-222.

Sarnes MW, Doan Q. Impact of drug interactions and adverse reactions on therapeutics. In: *Pharmacotherapeutics for Advanced Practice*, 1st edition. Arcangelo V, Peterson A, eds. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.

Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. *JAMA.* 2000;284(23):3036-3039.

1999

[Return to Publications](#)

Lee J, Lawrence BJ, Sullivan SD, Johnson NE, Barriere SL, Lake KD, Stevenson JG. Guidelines for pharmaco-economic research fellowships. *Pharmacotherapy*. 1999;19(9):1105-1109.

Meenan RT, O'Keeffe-Rosetti C, Hornbrook MC, Bachman DJ, Goodman MJ, Fishman PA, Hurtado AV. The sensitivity and specificity of forecasting high-cost users of medical care. *Med Care*. 1999;37(8):815-823.

Nelson WW, Frear RS. Physician attitudes toward human growth hormone products. *Am J Health Syst Pharm*. 1999;56(1):51-56.

Willey VJ, Sarnes MW, Cziraky MJ. Counseling the patient with hyperlipidemia. *Pharm Times*. June 1999.

1998

[Return to Publications](#)

Donahue JG, Andrade SE, Cain EM, Defor TA, Goodman MJ, Gurwitz J, Platt R. Lamotrigine and severe skin eruptions. *Pharmacoepidemiol Drug Saf*. 1998;7(6):415-417.

Gourley DR, Gourley GA, Solomon DK, Portner TS, Bass GE, Holt JM, Braden RL, Rawls N, Wicke WR, Ogden J, Lawrence B. Development, implementation and evaluation of a multicenter pharmaceutical care outcomes study. *J Am Pharm Assoc (Wash)*. 1998;38(5):567-573.

Maine LL, Regan TS. Integrated pharmacy services: cornerstone of a new model of care at Celebration Health. *J Am Pharm Assoc*. 1998;38(2):131-136.

Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents versus risperidone. *Psychopharmacol Bull*. 1998;34:373-382.

Nightengale BS, Garrett MS, Waugh S, Lawrence BJ, Andrus J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. *Am J Manag Care*. 1998;4:400-407.

Nightengale BS, Mauch RP. Granisetron in the treatment of chemotherapy-induced nausea and vomiting: a pharmaco-economic review. *P T*. 1998;23:119-132.

Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM, Wicke WR, Braden RL, Eberle TN, Self TH, Lawrence BL. Part 2: Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. *J Am Pharm Assoc*. 1998;38(5):574-585.

1997

[Return to Publications](#)

Kernodle (Maue) SJ. Improving health care with clinical practice guidelines and critical pathways: implications for pharmacists in ambulatory practice. *Pharm Pract Manag Q*. 1997;17(3):76-89.

Lim D, Farup C, Lawrence BJ, Sorrell L. Gastrointestinal illness in managed care: healthcare utilization and costs. *Am J Manag Care*. 1997;3(12):1859-1872.

Splinter MY, Sagraves R, Nightengale BS, Rayburn WF. Prenatal use of medications by women giving birth at a university hospital. *South Med J*. 1997;90(5):498-502.

Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of health-care resources. *Psychiatr Serv*. 1997;48(9):1153-1159.

1996

[Return to Publications](#)

Abbott TA, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. *Clin Ther.* 1996;18(1):127-149.

Mauch RP, Lawrence BJ, Nissenbaum R, Dallman J. Clinical and economic impact of fluvastatin on a managed care formulary. *Manag Care Med.* 1996;3(3):28-35.

Nightengale BS, Savage G. Oxygen transport, delivery and tuberculosis protection in the perianesthesia care unit (PACU): a cost study. *J Perianesth Nurs.* 1996;11:1-8.

Payne K, Kozma CM, Lawrence BJ. Comparing DHE and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. *Pharmacoeconomics.* 1996;10(1):59-71.

Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists' perceptions of a common interaction classification scheme. *Ann Pharmacother.* 1996;30:926-934.

1995

[Return to Publications](#)

Kozma CM, Motheral B, Lawrence BJ. Outcomes research and pharmacoeconomics for practicing pharmacists. Sandoz Continuing Education Series. 1995;8(1):1-15.

Nightengale BS. Cost-effectiveness of Tl-201 and Tc-99m sestamibi. *J Nucl Med Technol.* 1995;23:36-41.

Nightengale BS, Brune MB, Blizzard SP, Ashley-Johnson M, Slan S. Strontium-89 chloride for the palliative treatment of metastatic bone disease. *Am J Health Syst Pharm.* 1995;52:2189-2195.

O'chi H, Kuwayama T, Tanaka N, Hess GP, Kozma CM, Grogg AL. Japanese pharmacoeconomic survey. Institute for Health Economics and Policy, Tokyo, Japan. 1995.

1994

[Return to Publications](#)

Grogg AL, Pittman D. Beta-blockers in congestive heart failure (CE article). *Georgia J Hospital Pharm.* 1994;8(1):8-12.

Kozma CM, Mauch RP, Reeder CE, Lawrence BJ. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. *Clin Ther.* 1994;16(6):137-152.

Pakulski L, Grogg AL. Steroid pretreatment for ionic contrast media. *P T.* 1994;19(6):648.

1993

[Return to Publications](#)

Hawkins D, Jackson J. Application of pharmacoeconomics in cardiovascular disease: economic evaluation of lipid-lowering therapies. Introduction to Applied Pharmacoeconomics. Chapter 9: 179-196.

Reeder CE, Lingle EW, Schulz RM, Mauch RP Jr, Nightengale BS, Pedersen CA, Watrous ML, Zetzi SE. Economic impact of cost-containment strategies in third party programmes in the US (part I). *Pharmacoeconomics.* 1993;(2):92-103.

POSTERS

[Return to Publications](#)

Poster links by year:									
2020		2021		2022		2023		2024	
2010	2011	2012	2013	2014	2015	2016	2017	2018	Return to Posters Return to Publications
1997	1999	2000	2001	2002	2003	2004	2005	2008	
									2019
									2009

*Xcenda provided medical writing and editorial assistance for posters marked with an asterisk.

2024

[Return to Publications](#)

Baker L, Szydowski N, Loo V, Westrich K. Better late than never? Payer appetite and vision for a national value assessment body. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Brisibe T, Ng J, Hydery T, Abdel-Sattar M, Dean B, Sporck M, Schroader B. US payer perceptions on formulary evaluation and management of cell and gene therapies. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Brisibe T, Nguyen L, Penley B, Haileselassie H, Westrich K. A preliminary assessment of ICER's new HTA methods that support health equity. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Dittrich K, Klusmeier N, Kubinski M, Löpmeier-Röh JF, Kossow S, Kulp W. Do orphan drugs lack evidence in health technology assessments compared to non-orphan drugs? Poster presented at: ISPOR EU 2024; November 17-20, 2024; Barcelona, Spain.

Frank T, Pearson A, Riggs K, Hilton P, Noonan K. Changes in US payer biosimilar coverage policies of granulocyte colony stimulating factor products. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Gill M, Ng J, Szydowski N, Fusco N, Ruiz K. Artificial intelligence for targeted literature review screening within the Rayyan platform. Poster presented at: ISPOR 2024 Annual Meeting; May 5-8, 2024; Atlanta, GA.

Hikmat Z, Le D, Schroader B, Abdel-Sattar M, Sporck M, Hanna D. Impact of route of administration on access and reimbursement of cell and gene therapies: a survey of US payers. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Howard N, Nguyen L, Ha J, Westrich K. Sourcing value: understanding payer perceptions of value assessment information for formulary decision-making. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Le D, Ng J, Nielsen M, Berns C, McCart M, Ruban C, Abdel-Sattar M. Evaluation of healthcare decision-maker perspectives on artificial intelligence workflow implementation in healthcare and its utilization in the formulary decision-making process. Poster presented at: Academy of Managed Care Pharmacy Nexus 2024; October 14-17, 2024; Las Vegas, NV.

Ng J, Szydowski N, Gill M, Fusco N, Ruiz K. An evaluation of the Rayyan artificial intelligence tool for systematic literature review screening. Poster presented at: ISPOR 2024 Annual Meeting; May 5-8, 2024; Atlanta, GA.

Noonan K, Baker L, Schroader BK, Dale H, Abdel-Sattar M, Dale J. Payer perspectives of cell therapy and gene therapy treatment paradigms for an inherited retinal disorder. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Penley B, Brisibe T, Dragovich CM. How does pre-approval information exchange (PIE) affect formulary decision-making? Poster presented at: Academy of Managed Care Pharmacy Nexus 2024; October 14-17, 2024; Las Vegas, NV.

Penley B, Downen S, Ha J, Zheng C, Westrich K. Payer willingness to pay for novel value attributes. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Penley B, Hyder T, Dragovich CM. Optimizing the timing of pre-approval information exchange (PIE) engagement for oncology products, products for rare diseases, and cell and gene therapies (CGTs). Poster presented at: Academy of Managed Care Pharmacy Nexus 2024; October 14-17, 2024; Las Vegas, NV.

Piaskowski N, Downen S, Necas K, Westrich K. Navigating uncertainty: trends in ICER's evidence ratings. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Piaskowski N, Le D, Hyder T, Westrich K. Beyond value assessment reports: a review of payer perspectives on ICER's initiatives and tools. Poster presented at: Academy of Managed Care Pharmacy 2024 Annual Meeting; April 15-18, 2024; New Orleans, LA.

Schroader B, Gundlach A, Abresch L, Ruiz K, Szydowski N, Nguyen L. Prevalence of plain-language summaries (PLS) in open access patient-reported outcome (PRO) publications. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Washington J, Singh L, Howard N, Necas K, Shields S, Ford C. Lessons from history: gauging Part D plan access restrictions of protected class drugs as a harbinger for coverage of negotiating drugs. Poster presented at: ISPOR 2024; May 5-8, 2024; Atlanta, GA.

Yoshida S, Hsu L, Sugarman R, Chiang T. The role of patient experience data in payer decision-making. Poster presented at: Academy of Managed Care Pharmacy Nexus 2024; October 14-17, 2024; Las Vegas, NV.

2023

[Return to Posters](#)

[Return to Publications](#)

Bannister B, Washington J, Gorey C, Gaiser A, Merritt J, McCart M. The utilization of natural language processing (NLP) to gauge healthcare decision-maker perceptions of cell and gene therapies (CGTs). Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Buelt L, Sauvageau G, Huang D, Westrich K. Beyond value assessment: payer perceptions of ICER's policy initiatives. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Chaplin S, van Stiphout J, Chen A, Li E. Budget impact analysis of including biosimilar adalimumab on formulary: a United States payer perspective. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Dhamane A. COVID-19 and nonvalvular atrial fibrillation: anticoagulation treatment patterns, thromboembolic events, and mortality. Poster presented at: International Society on Thrombosis and Haemostasis; June 25, 2023; Montréal, Québec, Canada.

Chaplin S, Depalma S, Chen A, Mehl A, Rose L. Timely use of biosimilars in rheumatoid arthritis: a cost-effectiveness model from the US payer perspective. Poster presented at: Academy of Managed Care Pharmacy NEXUS; October 16-19, 2023; Orlando, FL.

Dodda S, Himat Z, Sugarman R, Zheng C, Stuchiner A, Sporck M, Schroader B. US payer perceptions of innovative contracts with cell and gene therapies. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Gatwood J, Gomez-Espinosa E, Fusco N, Stempiewicz N, Singer D. Value and real-world utilization of preventive services for the management of older adults in the United States. Poster presented at: Academy of Managed Care Pharmacy 2023 Nexus; October 16-19, 2023; Orlando, FL.

Gomez-Espinosa E, Koufopoulou M. Carers' health-related quality of life in economic appraisals for mental health, behavioural and neurodevelopmental conditions in England and Wales. Poster presented at: Society for Medical Decision Making 18th Biennial European Conference; May 21-23, 2023; Berlin, Germany.

Farahbakhshian S, Arnold A, Liu E, Dragovich C, Yoshida S, Chiang T, Duhig A. Understanding payer perceptions of preapproval information exchange in rare disease. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

*Frühwein M, Schelling J, Wahle K, Beier D, Kwetkat A, Schwarz TF. Weiterentwickelte zielgruppenorientierte influenzazimpfstoffe: neue evidenz zeigt höhere effektivität in älteren erwachsenen [Enhanced targeted influenza vaccines: new evidence shows higher effectiveness in older adults]. Presented at 129. Kongress der Deutschen Gesellschaft für Innere Medizin; April 22-25, 2023.

Ha J, Piaskowski N, Devendorf A, Westrich K. Making the cut: an assessment of ICER's acceptance of evidence in unsupported price increase reports. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Hydery T, Piaskowski N, Kralick B, Hayward D, Siciliano C. Preliminary evaluation of perceptions surrounding biosimilar landscape, uptake, and adoption among pediatric hospitals and health systems in the United States. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Loo V, Noonan K, Hydery T, Westrich K. Trends in payer uptake and perceptions of the Institute for Clinical and Economic Review value assessment framework from 2016 to 2022. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Lorenzi M, Ali SN, Makhija D, Ebohon S, Olodapo T, Diaby V, Mathur M, Fernandes AW. The association between surrogate kidney endpoints and hard clinical outcomes in IgA nephropathy: a systematic literature review. Poster presented at: National Kidney Foundation Spring Clinical Meetings; April 11-15, 2023; Austin, TX.

Mannino D, Roberts M, Mapel D, Zhang Q, Lunacsek O, Grabich S, van Stiphout J, Meadors B, Feigler N, Pollack M. National and state-specific burden of chronic obstructive pulmonary disease and estimated healthcare expenditures in the United States. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Mody R, Meyer K, Ward J, O'Day K. Cost per patient achieving treatment targets and the number needed to treat with tirzepatide versus semaglutide 1 mg in patients with type 2 diabetes in the United States. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Ng J, Knight J, Hydery T, Fazio L. A landscape assessment of digital engagement with healthcare decision-makers. Poster presented at: National Association of Specialty Pharmacy Annual Convention; September 18-21, 2023; Grapevine, TX.

Ng J, Knight J, Hyderey T, Fazio L, Lee H. Assessing the evolving landscape of digital engagement between healthcare decision makers and biopharma companies. Poster presented at: Academy of Managed Care Pharmacy 2023 Nexus; October 16-19; Orlando, FL.

Noonan K, Hikmat Z, Kilgore A, Snow J, Shields S. Analysis of pharmacy benefit manager formulary exclusions in oncology. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX. *Bronze Medal Winner*.

Noonan K, Loo V, Hyderey T, Westrich K. Deconstructing ICER value assessments: which components do payers value most? Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Ogbonnaya A, Flynn C, Farrelly E, Gaiazov S, Mullen W. Utilization of medication for opioid use disorder in opioid treatment programs. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Penley B, Ng J, Haileselassie H, Westrich K. An assessment of the evolving methods and role of health equity factors in ICER's Final Evidence Reports. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Perez-Rodriguez M, Stull DE, Dhanda R, Bron M, Dunayevich E, Correll CU. Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment. Poster presented at: International Congress of Parkinson's Disease and Movement Disorders 2023; August 27-31, 2023; Copenhagen, Denmark.

Sauvageau G, Noonan K, Devendorf A, Schroader B, Zheng C, Penzner B. Payer perceptions on incentives and barriers to innovative partnerships between biopharmaceutical manufacturers and payer organizations. Poster presented at: Academy of Managed Care Pharmacy 2023 Annual Meeting; March 21-24, 2023; San Antonio, TX.

Su J, Kistler K, Schwartz J. Immunosuppression therapy in retinal pigmented epithelial cell transplantation: a targeted literature review. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

*Tapper E, Fishman J, Mospan AR, Morris HL, Munoz B, Newsome P, Loomba R, on behalf of TARGET-NASH Investigators. NASH progression rates based on fibrosis and inflammation (NAS): a paired biopsy analysis from a natural history cohort in the US. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Westrich K, Buelt L, Asukai Y. Examining ICER's inclusion of novel value factors: do they move the needle on value appraisals? Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

Zhang C, Ha J, Hyderey T, Westrich K. Impact of ICER assessments on payer decision making in the United States. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA.

2022

[Return to Posters](#)

[Return to Publications](#)

Abogunrin S, Lorenzi M, Cadarette S, Belleli R, Polito L, Wissinger E. Disease-free survival as a potential surrogate endpoint for overall survival in patients with early-stage non-small cell lung cancer: a systematic literature review and meta-analyses. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Benson C, Patel C, Grabich S, Morrison L, Pilon D. Development of a visual tool to evaluate the burden of schizophrenia in the United States: the schizophrenia ecosystem tool. Poster presented at: American Psychiatric Association Meeting; May 21-25, 2022; New Orleans, LA.

Barten M, Sax B, Schopka S, Epailly E, Maccherini M, Amarelli C, Altevers J, Borchert K, Behlke S, Ingram A, Zuckermann A. Real-world use of extracorporeal photopheresis after heart transplantation—clinical outcomes from a seven centre European study. Poster presented at: International Society for Heart and Lung Transplantation; April 27-30, 2022; Boston, MA.

Beckert U, Borchert K, Seudel K, Harrow B, Pars M, Bauer S. Pilot study to assess the prevalence of advanced gastrointestinal stromal tumor identified using German claims data. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Buesch K, Watts-James J, Konstanski M, Zhang R, Martel MJ. Systematic literature review of the humanistic and economic impact of Angelman syndrome. Poster presented at: ISPOR Meeting; May 15-18, 2022; Washington, DC.

Chakinala M, Morland K, Steinbis S, Wu B, Grabich S, Chopra D, Thenappan T. Incidence and predictors of catheter-related adverse events among Medicare adult patients with pulmonary arterial hypertension using intravenous prostacyclin therapy. Poster presented at: American Thoracic Society Meeting; May 13-18, 2022; San Francisco, CA.

*Chepke C, Bron M, Jen E, Benning B, Giraldo E, Cicero S. Healthcare provider perspective of benztropine use in drug-induced movement disorders, including tardive dyskinesia, a 2021–2022 real-world survey. Poster presented at: Psych Congress; September 17-20, 2022; New Orleans, LA.

*Chepke C, Cicero S, Giraldo E, Hull M, Coyle K, Yeaw J, Jen E, Bron M. Real-world treatment patterns and healthcare resource utilization in patients prescribed benztropine: a claims analysis from 2017–2020. Poster presented at: NEI Congress; November 3-6, 2022; Colorado Springs, CO and virtual.

*Cho S, Bekaii-Saab T, Kavati A, Badajanyan S, Hocum B, Barzi A. Value of third-line therapies in colorectal cancer in the United States. Poster presented at: Academy of Managed Care Pharmacy; March 29–April 1, 2022; Chicago, IL.

Faraci D, Ha J, Ijioma S, Wissinger E, Tan R. The current impact of ICER assessments on payer decision making. Poster presented at: ISPOR Meeting; May 15-18, 2022; Washington, DC.

Ferries E, Chitnis A, Vera T, Suthoff E. Targeted literature review of caregiver burden and generational burden in depression. Poster presented at: ISPOR Europe 2022; November 6-9 2022; Vienna, Austria.

Hallock C, Gorey C, Lee H, Knight J, McCart M, Penley B, Kusdono H, Mody L. Real-world effect of pre-approval information exchange on formulary placement decisions. Poster presented at: Academy of Managed Care Pharmacy Meeting; March 29–April 1, 2022; Chicago, IL.

Koufopoulou M, Teng Y, Gomez-Espinosa E. Patients' perspective on barriers related to delayed diagnosis of endometriosis: a systematic review of qualitative studies. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Krinke K-S, Röhrkaste J, Braun S. Evidence generation of digital health applications in Germany—an overview of the status quo. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Loo V, Bannister B, Cook S, Hyderey T, Tan R. Payer perceptions of ICER's impact on rare disease assessment. Poster presented at: ISPOR Meeting; May 15-18, 2022; Washington, DC.

May DM, Shaw A, Baird J, Ford C, Quillen A, Czora AR, Morin S, Kwarta D. TAME: an observational study to assess the frequency of psychosis-related events in long-term care facilities and the time associated with the management of these events by facility caregivers. Poster presented at: American Society of Consultant Pharmacists Annual Meeting; November 3-6, 2022; San Antonio, TX.

Oniangue-Ndza C, Tao C, Dhamane A. Major ischemic or hemorrhagic events and associated costs among anticoagulated patients with non-valvular atrial fibrillation in Switzerland. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Pan X, Jiao X, Ruiz K, Stewart F, Kistler K, Patel R, Zong J, Bernard-Gauthier V. Clinical outcomes of patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusion cancer treated with non-tropomyosin receptor

kinase inhibitors: a systematic literature review. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Penley B, Ha J, Sarnes E. Health disparities in health technology assessment: an opportunity for improvement. Poster presented at: ISPOR Meeting; May 15-18, 2022; Washington, DC.

Phelps H, Lin D, Huang D, Cheng CY, Benson C. Budget impact of introducing once-every-6-months paliperidone palmitate for the management of schizophrenia among Medicaid beneficiaries in Georgia. Poster presented at: American Psychiatric Association Meeting; May 21-25, 2022; New Orleans, LA.

Qi C, Huang D, Carlton R, Phillips G. Budget impact of efgartigimod in anti-AChR antibody-positive generalized myasthenia gravis. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 11-14, 2022; National Harbor, MD.

Scarlet Haas J, Meise D, Braun S. The rise of real-world evidence (RWE) in EU marketing authorization decisions—past, present, and future. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Schley K, von Eiff C, Borchert K, Seidel K, Jacob C, Laurenz M. Mögliche Auswirkung einer unterschiedlicher Pneumokokken-Impfempfehlungen bei frühgeborenen (3+1) und reifgeborenen (2+1) Säuglingen auf die Impftrate von Frühgeborenen. Poster presented at: Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI); May 19-21, 2022; Aachen, Germany.

Schley K, von Eiff C, Borchert K, Seidel K, Jacob C, Laurenz M. Potential impact of two different recommendations for pneumococcal vaccination in preterm (3+1) and term (2+1) infants—a claims data analysis in Germany. Poster presented at: European Society for Paediatric Infectious Diseases; May 9-13, 2022; Athens, Greece.

Schley K, von Eiff C, Borchert K, Seidel K, Jacob C, Laurenz M. Was the change of the recommendation for pneumococcal vaccination from a 3+1 to a 2+1 schedule in term infants accompanied by an increased vaccination acceptance? Poster presented at: European Society for Paediatric Infectious Diseases; May 9-13, 2022; Athens, Greece.

Schnaidt S, Seidel K, Viering T, Löpmeier J-F, Borchert K, Jacob C. Methods used for trend estimation of epidemiological figures in the German benefit assessment (AMNOG) process. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Schnaidt S, Silies H, Jacob C. Treatment landscape for patients with advanced systemic mastocytosis in Germany in 2015 to 2020 based on claims data analysis. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Seidel K, Schnaidt S, Viering T, Löpmeier J-F, Borchert K, Jacob C. 10 years of AMNOG: importance of real-world evidence studies in the German benefit assessment process. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

Sporck M, Dodda S, Sugarman R, Stuchiner A. Innovative contracts between healthcare payers and pharmaceutical manufacturers: a survey of US payers. Poster presented at: Academy of Managed Care Pharmacy Meeting; March 29–April 1, 2022; Chicago, IL.

Tillotson G, Le J, Lodise TP, Bochan M, Ng S, Poole C, Guo A, Feuerstadt P. Twelve-month inpatient mortality and economic burden of *Clostridioides difficile* infections in the US: 2016–2019. Poster presented at: ISPOR Meeting; May 15-18, 2022; Washington, DC.

Viering T, Theil J, Jacob C. Rise of the machines—analysis of robotic-assisted surgery from 2005 to 2020 based on German hospital data. Poster presented at: ISPOR Europe; November 6-9, 2022; Vienna, Austria.

2021

- Abdel-Sattar M, Cook S, Wheeler A, Mullen W, Maiese BA, Heidbreder C, Santoro W. Impact of COVID-19 on OUD management and MOUD access in the US. Poster presented at: American Society of Addiction Medicine Meeting; April 22-24, 2021; virtual meeting.
- Abdel-Sattar M, Cook S, Wheeler A, Mullen W, Maiese BA, Heidbreder C, Santoro W. Impact of COVID-19 on OUD management and MOUD access in the US. Poster presented at: National Commission on Correctional Health Care Correctional Mental Health Conference; July 17-18, 2021; Washington, DC.
- Buesch K, Solanke O, Williams K, Skrobanski H, Zhang R, Acaster S, Martel MJ. Economic burden of informal care and productivity loss due to caring for individuals with aromatic L-amino acid decarboxylase (AADC) deficiency—an analysis for the US. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.
- Carlton R, Coppolecchia R, Lennert B, Yan A. An update on the budget impact of appropriate low-dose aspirin utilization for primary and secondary cardiovascular event prevention in the managed care setting. Poster presented at: Academy of Managed Care Pharmacy Meeting; April 12-16, 2021; virtual meeting.
- Chamberlain CX, Zagadailov E, Kistler K, Colby JA, Ruiz K. Global thalassemia epidemiology: a systematic literature review. Poster presented at: 26th Annual Congress of the European Hematology Association; June 9-17, 2021; virtual meeting.
- Choate A, Yan A, Tan R, Tennant L. Current utilization and perceptions of value assessment frameworks among United States payers. Poster presented at: ISPOR; May 2021; Montreal, Canada.
- Choi M, Hyderey T, Tan R, Tennant L. Trends in the uptake and impact of the Institute for Clinical and Economic Review value assessment framework in payer coverage decisions from 2016 to 2020. Poster presented at: Academy of Managed Care Pharmacy Meeting; April 12-16, 2021; virtual meeting.
- Classi P, Morland K, Wu B, DeRuiter A, Lee H, Stafkey-Mailey D, Dean B. Health outcomes and costs associated with oral Trepstinil and selexipag one year into treatment: a United States claims database analysis in patients with pulmonary arterial hypertension. Poster presented at: CHEST Annual Meeting; October 2021; Orlando, FL.
- Cook S, Loos AM, Tan R, Tennant L. The evolution of payer perceptions of ICER. Poster presented at: ISPOR; May 2021; Montreal, Canada.
- Csomor P, Schneider K, Stremel T, Kaiser E, Meise D. Burden of secondary hyperparathyroidism: a matched comparison using administrative claims data from Germany. Poster presented at: ASN Kidney Week 2021; November 4-7, 2021; virtual conference.
- Dall'Era M, Hermes T, Eaddy M, Ogbonnaya A, Farrelly E, Mina-Osorio P. Real-world economic implications of achieving low disease activity in lupus nephritis. Poster presented at: European Congress of Rheumatology (European Alliance of Associations for Rheumatology) Meeting; June 2-5, 2021; virtual meeting.
- De Courville C, Cadarette S, Wissinger E, Alvarez F. The economic burden of influenza among adults aged 18–64: a systematic literature review. Oral presentation at: European Scientific Working Group on Influenza 8th Annual Conference; December 4-7, 2021; virtual meeting.
- de Lepper M, Wölle R, Luzak A, Wang W, Jacob C, Schneider K, Buxmann H, Goelz R, Hamprecht K, Kummer P, Modrow S, Greiner W, Reuschenbach M, Stephan A. Zusätzliche belastung durch folgeschäden im ersten lebensjahr bei säuglingen und kleinkindern mit kongenitaler zytomegalie (cCMV) in Deutschland: eine retrospektive analyse von daten der gesetzlichen krankenkversicherung. [Additional burden from consequential damage in the first year of life in infants and young children with congenital cytomegaly (cCMV) in Germany: a

retrospective analysis of data from statutory health insurance.] Poster presented at: Nationale Konferenz zu Seltenen Erkrankungen [National Conference on Rare Diseases]; September 23-24, 2021; virtual meeting.

Epailly E, Amarelli C, Maccherini M, Sax B, Schopka S, Zuckermann A, Altevers J, Borchert K, Behlke S, Ingram A, Barten M. Real world use and clinical impact of extracorporeal photopheresis in heart transplant patients—results from a European multicenter study. Poster presented at: European Society for Organ Transplantation Congress; August 29–September 1, 2021; Milan, Italy.

Fiehn C, Zinke S, Haas J, Prasad V, Gurrath M, Orzechowski H. Real-world treatment persistence among rheumatoid arthritis (RA) patients initiating disease-modifying anti-rheumatic drugs (DMARDs) in Germany—a claims data analysis. Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); September 15-18, 2021; virtual.

Gaiser A, Knight J, Hughes J, Gorey C, Jackson J. Manufacturer perceptions and practices regarding healthcare economic information. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 18-21, 2021; Denver, CO.

Gärtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, Schwarz TF. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective—a systematic review of recently published literature on real-world data. Poster presented at: Virtual EWSI Influenza Conference; December 4-7, 2021.

HAMPL M, Stephan A, Wölle R, Saxena K, Jacob C, Schneider K, Schneider A, Greiner W, Prabhu V, Reuschenbach M. CIN2+ diagnoses between 2013 and 2018 in women 18 to 45 years old—an analysis of German statutory health insurance claims data. Poster presented at: EUROGIN 2021 (International Multidisciplinary HPV Congress); May 30–June 1, 2021; virtual meeting.

Heresi GA, Castillo H, Lee H, Classi P, Stafkey-Mailey D, Morland KD, Sketch MR, Kantorovich A, Wu B, Dean BB. Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis using US claims data. Poster presented at: CHEST Annual Meeting; October 2021; Orlando, FL.

Hohmann C, Lutz M, Vignali S, Seidel K, Baldus S, Näbauer M. Comparative analysis of clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study. Poster presented at: 87th Annual Meeting of the German Society for Cardiology—Heart and Circulatory Research; April 7-10, 2021; Mannheim, Germany.

Koptelova N, Mehl A, Chaplin S, Maiese B. Cost-effectiveness of granulocyte colony stimulating factors (G-CSFs) for the prevention of febrile neutropenia in breast cancer patients. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

Kulp W, Agashe V, Couybes N, Ward J. Patient-relevance of endpoints other than overall survival (non-OS endpoints) in oncology health technology assessments by the Federal Joint Committee (G-BA) in Germany. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

McCann WA, Nowak-Wegrzyn A, Hass SL, Huang D, McLaughlin TP, Donelson S. Factors associated with health-related quality of life in adolescents with peanut allergy: a multivariate analysis. Poster presented at: American College of Allergy, Asthma, and Immunology 2021 Annual Scientific Meeting; November 4-8, 2021; New Orleans, LA.

McLaughlin T, Mullen W, Lunacsek O, Wheeler A, Heidbreder C, Amick B. Impact of changes in utilization management programs (UMPs) on the use of medications for opioid use disorder (MOUD) and outcomes in opioid use disorder (OUD) patients served by a state Medicaid program. Poster presented at: Academy of Managed Care Pharmacy Meeting; April 12-16, 2021; virtual meeting.

Meise D, Schneider KM, Stremel T, Kaiser EA, Soro M. Economic burden of secondary hyperparathyroidism in Germany: a matched comparison using administrative claims data. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

Okhuoya P, Altevers J, Arnoux JB, Bouée S, Charrière S, Jacob C, Jha A, Maillot F, Schneider KM. Health economic impact of phenylketonuria—a retrospective claims database study in France. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

Reuschenbach M, Mihm S, Wölle R, Wähner C, Schneider KM, Jacob C, Greiner W, Hampf M, Goodman E. Healthcare utilization and costs of human papillomavirus (HPV) associated anogenital diseases in young women—an analysis of statutory health insurance claims data from Germany. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

Saxena K, Stephan A, Reuschenbach M, Wähner C, Prabhu V, Wölle R, Jacob C, Schneider K, Schneider A, Hampf M, Greiner W. Healthcare related costs during 24 months follow-up of patients undergoing cervical conization—a retrospective study of German statutory health insurance claims data. Poster presented at: EUROGIN 2021 (International Multidisciplinary HPV Congress); May 30–June 1, 2021; virtual meeting.

Schley K, von Eiff C, Borchert K, Braun S, Jacob C, Laurenz M. Mögliche auswirkung unterschiedlicher pneumokokken-impfempfehlungen bei frühgeborenen (3+1) und reifgeborenen (2+1) säuglingen auf die impfrate—zwischenanalyse der geburtskohorte 2018 nach 9 monaten. [Possible impact of different pneumococcal vaccination recommendations for premature (3+1) and full term (2+1) infants on the vaccination rate—interim analysis of the 2018 birth cohort after 9 months.] Poster presented at: Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin 2021 [Society for Neonatology and Pediatric Intensive Care Medicine 2021 Meeting]; June 16-19, 2021; virtual meeting.

Schley K, von Eiff C, Borchert K, Braun S, Jacob C, Laurenz M. Pneumococcal vaccination rates in term infants after change of recommendation from a 3+1 to a 2+1 schedule in Germany—birth cohort 2018. Poster presented at: 39th Annual Meeting of the European Society for Paediatric Infectious Disease; May 24-28, 2021; Geneva, Switzerland; hybrid virtual meeting.

Schley K, von Eiff C, Borchert K, Braun S, Jacob C, Laurenz M. Potential effect of two different recommendations for pneumococcal vaccination in preterm (3+1) and term (2+1) infants in Germany. Poster presented at: 39th Annual Meeting of the European Society for Paediatric Infectious Disease; May 24-28, 2021; Geneva, Switzerland; hybrid virtual meeting.

Singh R, Wissinger E, Dobie C, Yuxian D. A systematic literature review of treatment patterns, safety profiles, and long-term disease progression in patients with chronic kidney disease and type 2 diabetes mellitus. Poster presented at: American Society of Nephrology Kidney Week; November 2-7, 2021; San Diego, CA.

Solanke O, Martel MJ, Buesch K. Economic burden of aromatic L-amino acid decarboxylase (AADC) deficiency in Europe, from the caregivers' perspective. Poster presented at: Virtual ISPOR Europe; November 30–December 3, 2021; virtual meeting.

Stephan A, Reuschenbach M, Prabhu V, Wölle R, Saxena K, Jacob C, Schneider K, Schneider A, Greiner W, Hampf M. Cervical conization between 2013 and 2018 in women 18 to 45 years old—results from a German statutory health insurance claims data analysis. Poster presented at: EUROGIN 2021 (International Multidisciplinary HPV Congress); May 30–June 1, 2021; virtual meeting.

2020

[Return to Posters](#)

[Return to Publications](#)

Altevers J, Seidel K, Stolskij A, Stross L. Major and life-threatening bleeds on anticoagulation therapy—patient numbers and outcomes in Germany in 2017. Poster presented at: ISPOR European Annual Meeting; November 16-19, 2020; virtual meeting.

Borchert K, Seidel K, Löpmeier J, Braun S, Jacob C. Trends in the relevance of real world evidence studies in the German Benefit Assessment (AMNOG) Process 2011–2019. Poster presented at: ISPOR European Annual Meeting; November 16-19, 2020; virtual meeting.

Brown D, Farrell J, Vera-Llonch M, Voss P, O'Day K, Carlton R. Budget impact of Tegsedi (inotersen) for patients with hereditary amyloid transthyretin amyloidosis. Poster presented at: Academy of Managed Care Pharmacy Nexus; week of October 19, 2020; virtual meeting.

Chang A, Maiese B, Mody L, Cheadle A, Brown B. Impact of early disease-modifying therapy (DMT) treatment initiation and use of high-efficacy therapy (HET) on clinical and health outcomes in patients with multiple sclerosis (MS). Poster presented at: ISPOR European Annual Meeting; November 16-19, 2020; virtual meeting.

Clark J, Hughes J, Gorey C, Duhig A, Jackson J. Trends in manufacturer perceptions and practices regarding pre-approval information. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 19, 2020; virtual meeting.

Donelson SM, Tilles S, Hass SL, Robison D, Norrett K, Cameron A, Etschmaier M, Duhig A, McCann WA. Peanut allergy burden survey: comparison of responses from adolescents and caregivers of adolescents. Poster presented at: 2020 American Academy of Allergy, Asthma, and Immunology Annual Meeting; March 13-16, 2020; Philadelphia, PA.

Dornstauder E, Jacob C, Maas C, Sidelnikov E, Pinto L, Leidl R, Ahrens I. Healthcare resource utilization and costs of myocardial infarction in patients with atherosclerotic cardiovascular disease in Germany: results of a claims database study. Poster presented at: ISPOR European Annual Meeting; November 16-19, 2020; virtual meeting.

Feindt W, Sauer AK, Eckert N, Löpmeier JF, Kulp W. Introduction to the AMNOG benefit assessment in Germany and analysis of its outcomes from 2011 to 2019. Poster presented at: ISPOR European Annual Meeting; November 16-19, 2020; virtual meeting.

Feng X, Farej R, Xia F, et al. Demographic and clinical characteristics of chronic kidney disease patients with and without type 2 diabetes by regional CKD prevalence. Poster presented at: American Academy of Family Physicians 2020 Family Medicine Experience; October 13-17, 2020; virtual meeting.

Feng X, Farej R, Xia F, et al. Regional variations in chronic kidney disease prevalence among patients with or without type 2 diabetes (RADAR) in the US. Poster presented at: American Diabetes Association's 80th Scientific Sessions; June 12-16, 2020; virtual meeting.

Förster-Ruhrmann U, Seidel K, Jacob C, Kießlich A, Bergmann K. Schweres asthma und nasenpolypen: orales steroid summiert sich aus verschreibungen verschiedener Facharztgruppen—besteht Optimierungsbedarf in der Versorgung? [Severe asthma and nasal polyps: oral steroid adds up from prescriptions from various specialist groups—is there a need to optimize care?] Poster presented at: 15. Deutscher Allergiekongress [15th Annual German Allergy Congress]; September 24-26, 2020; Wiesbaden, Germany.

Freedland SJ, Schultz NM, Coutinho AD, et al. Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA). Poster presented at: 2020 Genitourinary Cancers Symposium; February 13-15, 2020; San Francisco, CA.

HAMPL M, Stephan A, Wölle R, et al. CIN2+ diagnosen bei Frauen im Alter von 18 bis 45 Jahren in Deutschland—Ergebnisse einer Analyse mit GKV-abrechnungsdaten von 2013 bis 2018. [CIN2 + diagnoses in women aged 18 to 45 in Germany—results of an analysis with statutory health insurance billing data from 2013 to 2018.] Poster presented at: Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe eV [Congress of the German Society for Gynecology and Obstetrics]; October 7-9, 2020; Munich, Germany.

Huttner H, Gerner S, Connolly S, et al. Andexanet alfa versus usual care in patients with DOAC associated intracerebral hemorrhage: a propensity-score based historical comparison of patients from ANNEXA4 and RETRACEII. Poster presented at: ESO-WSO 2020; November 7-9, 2020; virtual meeting.

Kanaskar A, Tennant L, Olson BM, Gladman J, Mak E, Migliaccio-Walle K. Access and utilization of the Institute for Clinical and Economic Review (ICER) value assessment framework (VAF) reports in healthcare decision making. Poster presented at: ISPOR 24th Annual International Meeting; May 14-June 30, 2020; Orlando, FL.

Laurenz M, von Eiff C, Borchert K, Braun S, Jacob C, Schley K. Pneumokokken-konjugatimpfung: impfraten und impfzeitpunkte bei reifgeborenen kindern vor und nach umstellung auf das 2+1 schema. [Pneumococcal conjugate vaccination: vaccination rates and times of vaccination in full-term children before and after switching to the 2+1 scheme.] Poster presented at: Deutsche Gesellschaft für Kinder- und Jugendmedizin [German Society for Child and Adolescent Medicine]; September 17-29, 2020; Berlin, Germany.

Laurenz M, von Eiff C, Borchert K, Braun S, Jacob C, Schley K. Unterschiedliche pneumokokken-impfempfehlungen bei frühgeborenen (3+1) und reifgeborenen (2+1) säuglingen—auswirkung auf die impfrate bei frühgeborenen der geburtskohorte 2016. [Different pneumococcal vaccination recommendations for premature infants (3+1) and full term (2+1) infants—effect on the vaccination rate in premature infants of the 2016 birth cohort.] Poster presented at: Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin [Society for Neonatology and Pediatric Intensive Care Medicine]; 2020 Annual Meeting; October 29-30, 2020; virtual meeting.

Laurenz M, von Eiff C, Borchert K, Braun S, Jacob C, Schley K, Schiffner-Rohe J. Pneumococcal vaccination rates in term infants after change of recommendation from 3+1 to a 2+1 schedule in Germany. Poster presented at: European Society for Paediatric Infectious Diseases; October 26-29, 2020; Rotterdam, Netherlands.

Loos A, Tan R, Gladman J, Mak E, Migliaccio-Walle K. ICER's influence on healthcare delivery: how managed care organizations use ICER reports in decision making. Poster presentation for: Academy of Managed Care Pharmacy 2020 Conference; April 21-24, 2020; Houston, TX. (AMCP 2020 was canceled due to the pandemic.)

Mahtani R, Lalla D, Oestreicher N, Ogbonnaya A, Saundankar V, Willey J, Coutinho A, McCann K. Healthcare costs for metastatic breast cancer patients treated with human epidermal growth factor receptor 2 targeted agents. Poster presented at: San Antonio Breast Cancer Symposium; December 8-12, 2020; virtual meeting.

Maiese BA, Colby JA, Pareja K, Laplante A, Wang X, McCormick L, Nourbaksh A, Wang T, Sanon M. Global real-world evidence of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). Poster presented at: American Society of Nephrology Kidney Week 2020; October 20-25, 2020; virtual meeting.

Nowak-Wegrzyn A, Hass SL, Tilles S, Donelson SM, Robison D, Norrett K, Cameron A, Etschmaier M, Duhig A, McCann WA. Peanut allergy burden survey: impact of peanut allergy on global quality of life in adolescent patients. Poster presented at: 2020 American Academy of Allergy, Asthma, and Immunology Annual Meeting; March 13-16, 2020; Philadelphia, PA.

Reuschenbach M, Prabhu V, Wölle R, Tanniru S, Jacob C, Schneider K, Schneider A, Greiner W, Hampf M, Stephan A. Konisation der cervix uteri bei frauen im alter von 18 bis 45 jahren in Deutschland—ergebnisse einer analyse mit GKV-Abrechnungsdaten von 2013 bis 2018. [Conization of the uterine cervix in women aged 18 to 45 in Germany—results of an analysis with statutory health insurance billing data from 2013 to 2018.] Poster presented at: Konferenz der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e V 2020 [Conference of the German Society for Gynecology and Obstetrics 2020 Annual Meeting]; October 7-9, 2020; Munich, Germany.

Seal B, Lunacsek O, Yong C, Willey J, Dean B, Coutinho A, Boron M, Cotalra I, Ganti A. Treatment patterns and overall survival in patients with extensive stage small cell lung cancer from US community-based oncology practices. Abstract included in: Academy of Managed Care Pharmacy Annual Meeting abstract book and JMCP supplement (meeting canceled due to COVID-19).

Seidel K, Jacob C, Braun S, Borchert K. The new quality requirements for claims data analyses in the German AMNOG HTA process. Poster presented at: ISPOR Annual Meeting; May 18-20, 2020; virtual meeting.

Sewerin P, Borchert K, Meise D, Mahlich J. Real-world treatment persistence with biologic disease modifying antirheumatic drugs among German patients with psoriatic arthritis. Poster presented at: European Alliance of Associations for Rheumatology Annual Meeting; EULAR E-Congress from June 3, 2020; virtual meeting.

Silvestri N, Maiese BA, Colby JA, Leighton T, Guglietta A, Beauchamp J, Locklear J. The economic and quality-of-life burden that myasthenia gravis has on patients: a US-targeted literature review. Poster presented at: ISPOR Annual Meeting; May 18-20, 2020; virtual meeting.

Silvestri N, Maiese BA, Colby JA, Leighton T, Guglietta A, Beauchamp J, Locklear J. Current view of the epidemiology and treatment options for myasthenia gravis: results from a United States-targeted literature review. Poster presented at: American Association of Neuromuscular and Electrodiagnostic Medicine; October 7-9, 2020; virtual meeting.

Silvestri N, Maiese BA, Colby JA, Leighton T, Guglietta A, Beauchamp J, Locklear J. Direct costs associated with myasthenia gravis: results from a targeted United States literature review. Poster presented at: American Association of Neuromuscular and Electrodiagnostic Medicine; October 7-9, 2020; virtual meeting.

Stephan A, Prabhu V, Wölle R, Tanniru S, Jacob C, Schneider K, Schneider A, Greiner W, Reuschenbach M, Hampf M. CIN2+ diagnoses between 2013 and 2018 in women 18 to 45 years old—results from a German statutory health insurance claims data analysis. Poster presented at: International Papillomavirus Conference 2020; July 2020; virtual conference.

Tilles S, Hass SL, Donelson SM, Robison D, Norrett K, Cameron A, Etschmaier M, Duhig A, McCann WA. Peanut allergy burden survey: correlates of food allergy quality of life questionnaire—teen form scores. Poster presented at: 2020 American Academy of Allergy, Asthma, and Immunology Annual Meeting; March 13-16, 2020; Philadelphia, PA.

Williamson T, Lennert B, Carlton R, McCart M, Brown D, Moradi A. Economic analysis of inpatient adverse event-related expenditures in metastatic solid tumor patients exposed to larotrectinib or entrectinib. Poster presented at: ISPOR Annual Meeting; May 18-20, 2020; virtual meeting.

Wissinger E, Gaiser A, Ruiz K, Rametta M, Singh S. A systematic literature review of health-related quality of life in patients with chronic kidney disease and type 2 diabetes mellitus. Poster presented at: American College of Osteopathic Internists Annual Convention and Scientific Sessions; October 21-24, 2020; virtual meeting.

Yong C, Seal B, Coutinho A, Hamilton L, Dean B, Wiley J, Branman J, Boron M, Ganti A. Treatment patterns, healthcare resource utilization, and costs of care in patients with extensive stage small cell lung cancer. Abstract included in: Academy of Managed Care Pharmacy Annual Meeting abstract book and JMCP supplement (meeting canceled due to COVID-19).

Ziemssen T, Kurzeja A, Haas J, Alexander J, Driessen M. Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy. Poster presented at: 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis/European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS) meeting; September 11-13, 2020; virtual meeting; and: 28th Annual European Charcot Foundation Meeting; November 15-19, 2020; virtual meeting.

2019

[Return to Posters](#)

[Return to Publications](#)

Altevers J, Eisenmenger N, Jacob C. Increase of salpingectomies in Germany since 2005. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Anguiano R, Stafkey-Mailey D, Saundankar V, Dean B, Classi P, Gordon K, Nails A, Nelsen A. Early versus late initiation of treatment with prostacyclin-class therapy in patients with pulmonary arterial hypertension (PAH). Poster presented at: International Conference of the American Thoracic Society; May 17-22, 2019; Dallas, TX.

Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K. Number needed to treat analysis of the SAGE-217 phase 2 clinical study results in major depressive disorder. Poster presented at: Psych Congress 2019; October 3-6, 2019; San Diego, CA.

Ballew NG, Wissinger E, Ruiz K. Multivariate network meta-analysis models that incorporate multiple outcomes can produce more accurate comparative effectiveness estimates than standard univariate models. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Banaschewski T, Wiescholleck V, Spalding W, et al. Retrospective healthcare claims database study evaluating characteristics and treatment patterns of patients with attention-deficit/hyperactivity disorder in Germany. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Bell JA, Dalal M, Farrelly E, Blazer M, Ogbonnaya A, Raju A, Fram R, Faller DV. Characteristics of untreated patients with higher-risk myelodysplastic syndrome identified in a United States electronic medical record database. Poster presented at: 15th International Symposium on Myelodysplastic Syndromes; May 8-11, 2019; Copenhagen, Denmark.

Benitez B, Duhig A, Jackson J. Are medical directors' and pharmacy directors' attitudes different toward proactive healthcare economic information (HCEI) and preapproval information exchange (PIE)? Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Benitez B, Duhig A, Jackson J. Comparing payer and manufacturer experiences with HCEI and PIE after passage of the 21st Century Cures Act. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Billig S, Bigger A, Claes AK, Freese L, Kulp W. Key factors for the consideration of quality of life data in AMNOG benefit assessments. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Birchwood C, Hass SL, Robison DR, Treanor K, Norrett KE, Cameron A, Etschmaier M, Duhig AM, McCann WA. Real-world experience and management of peanut allergy: a quantitative study of adolescents with peanut allergy in the United States. Poster presented at: European Academy of Allergy and Clinical Immunology; June 1-5, 2019; Lisbon, Portugal.

Birchwood C, Hass SL, Robison DR, Treanor K, Norrett KE, Cameron A, Etschmaier M, Duhig AM, McCann WA. Real-world experience of peanut-allergic adolescents in the United States: health-related concerns and resource utilization for peanut allergy. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Blazer M, Ogbonnaya A, Farrelly E, Raju A, Saundankar V, Eaddy M, Romanus D. Approaches to pragmatic methodology in oncology retrospective studies. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Bloudek L, Zhao Y, Ogundele A, Brown D, Carlton R. Budget impact of cyclosporine ophthalmic solution 0.09% for the treatment of dry eye disease in the US. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

Borchert K, Altevers J, Wetzell N, Jänicke M, Eggers E, Sauer A, Marschner N, Jacob C, Mittendorf T, Braun S, Greiner W. Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry—results from a Tobit regression. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Borchert K, Krinke K, Rancea M, Sager U, Haeger M, Greiner W, Braun S. Die epidemiologie von B-Thalassämie in Deutschland: Ergebnisse einer krankenkassendatenanalyse. [The epidemiology of B-thalassemia in Germany: results from a health insurance data analysis.] Poster presented at: Deutsche Gesellschaft für Hämatologie und medizinische Onkologie; October 11-15, 2019; Berlin, Germany.

Borchert K, Krinke K, Wächter S, Gavata-Steiger S, Haas J, Braun S. A comparative healthcare cost analysis of patients with non-dialysis chronic kidney disease and iron deficiency/anemia treated with oral or intravenous iron

using a German claims database. Poster presented at: ERA EDTA—56th Congress of the European Renal Association and European Dialysis and Transplant Association; June 13-16, 2019; Budapest, Hungary.

Borchert K, Löpmeier J, Braun S, Jacob C. The relevance of real-world evidence studies in the German benefit assessment (AMNOG) process. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Campbell D, Gittings K, Kanaskar A, Riggs K, Meyer K. Recent health technology assessment (HTA) decisions across the globe: a focus on prostate cancer—results, rationale, and trends. Poster presented at: ISPOR Europe Annual Meeting; November 2-6, 2019; Copenhagen, Denmark.

Canbay A, Kachru N, Meise D, Haas J, Ozbay A. Annual healthcare costs double for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients who progress to advanced liver disease—a multivariable analysis of German real-world data. Poster presented at: International Liver Congress 2019 (EASL 2019); April 10-14, 2019; Vienna, Austria, and the 2nd International Conference on Fatty Liver; June 27-29, 2019; Berlin, Germany.

Canbay A, Kachru N, Meise D, Haas J, Ozbay A. Increasing risk of disease progression and mortality in nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients with advanced liver disease: a German real-world analysis. Poster presented at: the 2nd International Conference on Fatty Liver; June 27-29, 2019; Berlin, Germany, and the International Liver Congress 2019 (EASL 2019); April 10-14, 2019; Vienna, Austria.

Casilli G, Lidonnici D, Isernia M, Morichi M, Konstanski M, Kuchenbecker U, Mittendorf T, and Lanati EP. Price analysis of new medicinal products reimbursed in Italy and Germany. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Claes AK, Sauer AK, Freese L, Löpmeier JF, Erwes KL, Kulp W. AMNOG benefit assessment in Germany and its impact on price negotiations. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Clark J, Psychojos M, Benitez B, Mody L, Jackson J. Trends in payer experiences, attitudes, and perceptions of pre-approval information exchange. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

Classi P, Dean B, Broderick M, Nelsen A. Real-world dosing for oral tadalafil and selexipag using administrative claims data. Poster presented at: Association of Managed Care Pharmacy Nexus 2019; October 29–November 1, 2019; National Harbor, MD.

Douyon L, Kang I, Colby JA, Mody L, Sarnes E. Targeted literature review evaluating the efficacy and safety of Sativex® (nabiximols) for pain treatment. Poster presented at: Pain Therapeutics Summit; September 23-24, 2019; Washington, DC.

Gaiser A, Gittings K, Burgess SM. Competitor review of patient-reported outcome measures in clinical trials for gastrointestinal disorders. Poster presented at: ISPOR Europe Annual Meeting; November 2-6, 2019; Copenhagen, Denmark.

Gaiser A, Gittings K, Burgess SM, Nelson K, Duhig A, McCart M. Payer perceptions of patient-reported outcomes and other clinical outcome assessments in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Gaiser A, Louie D, Wilkins TL, Skelton JB, Chiang TH. Multiple stakeholder evaluation of issues, barriers, and needs for substance use disorder treatment in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Gaiser A, Tennant L, Duhig A, Walters T, Popelar B, Lu Y. A review of the use of work productivity endpoints in clinical trials. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

Gerbası M, Crawford S, Malakhova V, Eldar-Lissai A, Meise D, Haas J, Braun S, Greiner W, Park S. Assessing the rate of postpartum depression in Germany—a large claims database study. Poster presented at: Kongress der Deutschen Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde [Congress of the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neurology]; November 27-30, 2019; Berlin, Germany.

Gingrich A, Baigger A, Scharrenbroich J, Erwes KL, Kulp W, C T. Surrogate validation in German AMNOG benefit assessments. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Gittings K, Gaiser A, Burgess SM. A comparison of European Medicines Agency and US Food and Drug Administration patient-reported outcome guidances for gastrointestinal disorders. Poster presented at: ISPOR Europe Annual Meeting; November 2-6, 2019; Copenhagen, Denmark.

Gittings K, Kang I, Lee H, Gaiser A, Louie D, Burgess SM. A comparison of European Medicines Agency and US Food and Drug Administration patient-reported outcome guidances for chronic obstructive pulmonary disease. Poster presented at: ISPOR Europe Annual Meeting; November 2-6, 2019; Copenhagen, Denmark.

Gittings K, Riggs K, Campbell D, Kanaskar A, Meyer K. Health technology assessment decisions for pain therapies: results, rationales, and trends. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Heymann R, Potthoff D, Maas C, Kleine-Vossbeck U, Jacob C. Claims data analysis of patients with newly diagnosed multiple myeloma—analysis of epidemiological aspects and untreated patients. Poster presented at: 64 Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie eV [64th Annual Meeting of the German Society for Medical Informatics, Biometry and Epidemiology]; September 8-11, 2019; Dortmund, Germany.

Hilton P, Popelar B, Psychojos M, Eichenbrenner P, Schneider P. Forces driving change in healthcare: payer insights on key trends. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Italia N, Claes AK, Löpmeier JF, Kulp W. Fast changing appropriate comparators in German AMNOG benefit assessments in multiple myeloma. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Jacob C, Braun S, Zvolanek M, Groettrup-Wolfers E, Kunze ZM, Wichmann K, Deten A. Real world evidence on current treatment of women with uterine fibroids in Germany—an analysis of statutory health insurance claims data from 2011 to 2016. Poster presented at: 5th Society of Endometriosis of Uterine Disorders Congress; May 15-18, 2019; Montreal, Canada.

Jang SR, Danavar A, Choi M, Kaufman S, McCart M. Payer perceptions on access to breastfeeding support in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Kanaskar A, Campbell A, Campbell C, Riggs K, Meyer K. Recent health technology assessment (HTA) decisions across the globe: a focus on non-small cell lung cancer. Poster presented at: ISPOR Europe Annual Meeting; November 2-6, 2019; Copenhagen, Denmark.

Kanaskar A, Choi M, Migliaccio-Walle K, Tennant L, Snow J. Evaluation of the Institute for Clinical and Economic Review (ICER) public engagement process: stakeholder comment analysis. Poster presented at: ISPOR 24th Annual International Meeting; May 18–22, 2019; New Orleans, LA.

Kanaskar A, Tennant L, Migliaccio-Walle K, Campbell C. Current utilization and perceptions of value assessment frameworks by pharmacy and therapeutics committees in the United States. Poster presented at: ISPOR 24th Annual International Meeting; May 18–22, 2019; New Orleans, LA.

Kang I, Ren SP, Mody LB, Boswell KA, Benitez B, Clark J, Kaufman S. Has there been a change in the payer perspective on the Academy of Managed Care Pharmacy (AMCP) format version 4.0 (v4.0) pre-approval dossier? Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

König C, Altevers J, Maas C, Meise D, Bierbaum M, Riederer C, Wobbe-Ribinski S, Greiner W, Braune S, Pöhlau D, Bergmann A, Braun S. Burden of multiple sclerosis in Germany—a matched cohort study using a large claims database. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

König C, Altevers J, Maas C, Meise D, Bierbaum M, Riederer C, Wobbe-Ribinski S, Greiner W, Braune S, Pöhlau D, Bergmann A, Braun S. Versorgungsrealität von multiple sklerose-patienten in Deutschland—Ergebnisse einer retrospektiven Krankenkassendatenanalyse. [Reality of care for multiple sclerosis patients in Germany—results from a retrospective health insurance data analysis.] Poster presented at: 18 Deutscher Kongress für Versorgungsforschung [18th Annual German Congress for Health Services Research]; September 30–October 2, 2019; Berlin, Germany.

Krinke K, König C, Jacob C, Mittendorf T, Braun S. Preference elicitation for cancer treatment in Europe: a systematic literature review of discrete choice experiments. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Kuchenbecker U, Konstanski M, Mittendorf T. Reference price groups (RPG) defined from 2008 to 2018 in Germany—a detailed overview and discussion. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Kudrow D, Sagar M, Bensimon L, Lokhandwala T, Yue B, Silberstein S. Comorbidity, treatment patterns, and economic burden of primary headache disorders: an administrative claims data analysis. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Laurenz M, von Eiff C, Borchert K, et al. Implementation of two different recommendations regarding pneumococcal vaccination for preterm (3+1) and term (2+1) infants in Germany (birth cohort 2016). Poster presented at: European Society for Paediatric Infectious Diseases; May 6-11, 2019; Ljubljana, Slovenia.

Laurenz M, von Eiff C, Borchert K, Braun S, Jacob C, Schiffner-Rohe J, Schley K. Impfzeiten und Impfzeitpunkte der Pneumokokken-Konjugatimpfung bei Reifgeborenen Säuglingen vor und nach Umstellung auf das 2+1 Schema. [Vaccination rates and timing of pneumococcal conjugate vaccination in full-term infants before and after switching to the 2+1 scheme.] Deutsche Gesellschaft für Kinder- und Jugendmedizin [German Society for Child and Adolescent Medicine]; September 11-14, 2019; Munich, Germany.

Laurenz M, von Eiff C, Borchert K, Braun S, Kohlscheen K, Jacob C, Schley K, Schiffner-Rohe J. Umsetzung der unterschiedlichen Pneumokokken-Impfempfehlungen bei frühgeborenen (3+1) und reifgeborenen (2+1) Säuglingen der Geburtskohorte 2016 (Zwischenanalyse nach 9 Lebensmonaten). [Implementation of the different pneumococcal vaccination recommendations for premature (3+1) and full-term (2+1) infants in the 2016

birth cohort (interim analysis after 9 months of life).] Poster presented at: Deutsche Gesellschaft für Pädiatrische Infektiologie German Society for Pediatric Infectious Diseases]; May 23-25, 2019; Leipzig, Germany.

Lokhandwala T, Lee A, Yue B, Thach A, Navia B. Correlation between PDQ-39 and MDS-UPDRS scores in a phase 3 randomized controlled trial of patients with Parkinson's disease. Poster presented at: 2019 International Congress of the International Parkinson and Movement Disorder Society; September 22-26, 2019; Nice, France.

Lokhandwala T, Yue B, Coutinho A, Bell C. Within-trial cost analysis of flares from a phase 3 clinical trial evaluating subcutaneous belimumab for the treatment of systemic lupus erythematosus. Poster presented at: 2019 American College of Rheumatology/ Association of Rheumatology Professionals Annual Meeting; November 8-13, 2019; Atlanta, GA.

Laurenz M, von Eiff C, Borchert K, Braun S, Kohlscheen KM, Jacob C, Schiffner-Rohe KSJ. Implementation of different pneumococcal vaccination recommendations in premature (3 + 1) and full-term (2 + 1) infants of the birth cohort 2016 (interim analysis after 9 months of life). Poster presented at: Deutsche Gesellschaft für Pädiatrische Infektiologie; May 23-25, 2019; Leipzig, Germany.

Laurenz M, von Eiff C, Borchert K, Braun S, Kohlscheen KM, Jacob C, Schiffner-Rohe KSJ. Implementation of two different recommendations regarding pneumococcal vaccination for preterm (3+1) and term (2+1) infants in Germany (birth cohort 2016). Poster presented at: European Society for Paediatric Infectious Diseases; May 6-11, 2019; Ljubljana, Slovenia.

Louie D, Gittings K, Burgess SM. A landscape assessment of standalone patient-reported outcome (PRO) measures used in clinical trials for rheumatoid arthritis (RA). Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Maas C, Meise D, Jacob C, Keßel S, Piehl C, Siggelkow H. The burden of severe hypoparathyroidism in Germany—a claims database analysis. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Mayer W, Kontekakis A, Maas C, Kuchenbecker U, Caesar M, Schennach H. Retrospective data analysis related to the use of multistep and integrated extracorporeal photopheresis systems. Poster presented at: American Society for Apheresis 40th Annual Meeting; May 14-18, 2019; Portland, Oregon.

Mezzio D, Moradi A, Kaufman S, Spargo A, O'Day K. Influencing factors and formulary consequences of budget impact thresholds as perceived by payers. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Mihm S, Reuschenbach M, Wölle R, Schneider KM, Jacob C, Braun S, Greiner W, Hampf M. Burden of HPV related anogenital diseases in young women in Germany—an analysis of German statutory health insurance claims data. Poster presented at: EUROGIN (International Multidisciplinary HPV Congress); December 4-7, 2019; Monaco.

Moradi A, Spargo A, Mezzio D, Kaufman S. A discrete choice experiment and cost-minimization analysis of payer preferences for innovative payment schemes aimed at financing high-cost, potentially curative therapies. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Pollack M, Schroader B, Kang I, Tuten A, Hennenfent K, Mody L, Sarnes E, Shields K. Market access strategies for novel oncology products: evaluating new pathways to minimize hurdles to patient access. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

Raju AD, Pimple P, Stafkey-Mailey D, Farrelly EM, Shetty S. A real-world claims analysis of costs among patients with type 2 diabetes mellitus and cardiovascular disease receiving empagliflozin or other antihyperglycemic agents. Poster presented at: American Heart Association Quality of Care and Outcomes Research 2019 Scientific Sessions; April 5-6, 2019; Arlington, VA.

Reuschenbach M, Mihm S, Wölle R, Kohlscheen KM, Tharmarajah T, Jacob C, Braun S, Greiner W, Hampf M. Krankheitslast von HPV-assoziierten anogenitalen Erkrankungen bei jungen Frauen in Deutschland - Eine Analyse von GKV Abrechnungsdaten von 2012–2017. [Disease burden of HPV-associated anogenital diseases in young women in Germany—an analysis of statutory health insurance payroll data from 2012–2017.] Poster presented at: 6 Nationale Impfkonzferenz [6th National Vaccination Conference]; May 23-24, 2019; Hamburg, Germany.

Rizzo M, Pollack M, Ballew NG, Kulp W, Wissinger E. Evaluation of the evolving treatment landscape in early-stage/locally-advanced non-small cell lung cancer (Es/La-Nscl): a forward-looking network meta-analysis (NMA) feasibility study. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Ruban C, Tennant L, Burgess SM. A landscape assessment of patient-reported outcome (PRO) and observer-reported outcome (ObsRO) measures used in clinical trials for atopic dermatitis (AD). Poster presented at: ISPOR 24th Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Schneider K, Seidel K, Röhrkaste J, Braun S. Data sources used to determine the target population size for orphan drugs—a review of German AMNOG benefit assessments. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Seidel K, Borchert K, Jacob C, Braun S, Mittendorf T. Status quo of claims data analyses in the German AMNOG HTA process—did quality improve? Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Shah SN, Wissinger E, Ballew N, Hepp Z. A systematic literature review (SLR) to support network meta-analyses (NMA) in the treatment of locally advanced or metastatic urothelial carcinoma (LA/MUC) following PD-1/L1 inhibitors. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Stafkey-Mailey D, Saundankar V, Dean B, Classi P, Gordon K, Nails A, Nelsen A, Anguiano R. A real-world health insurance claims analysis of oral prostacyclin class therapy utilization and outcomes. Poster presented at: International Conference of the American Thoracic Society; May 17-22, 2019; Dallas, TX.

Sugarman R, Ruban C, Duhig A, Kaufman S, Jackson J. Value-based contracting: do perspectives differ by payer type? Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Tennant L, Kanaskar A, Gittings K, Migliaccio-Walle K. Trends in the uptake and impact of the Institute for Clinical and Economic Review (ICER) value assessment framework (VAF) in coverage decisions. Poster presented at: ISPOR 24th Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Tennant L, Kanaskar A, Migliaccio-Walle K, Campbell C. Are payers using value assessment frameworks in the United States? Poster presented at: Academy of Managed Care Pharmacy Nexus; October 29–November 1, 2019; National Harbor, MD.

Templin C, Thamm K, Rinker F, Kulp W. Added benefit assessment of ATMPs in Germany: does the data basis meet HTA requirements? Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Tetzlaff J, Cadarette SM, Oblenis P, Ruiz K. Pragmatic intelligence-based reference screening in systematic reviews. Poster presented at: ISPOR Annual International Meeting; May 18-22, 2019; New Orleans, LA.

Ulrich S, Damen D, Templin C, Kulp W. German benefit assessment in the field of oncology: factors influencing the benefit rating in addition to complying with the appropriate comparator. Poster presented at: ISPOR 22nd Annual European Congress; November 2-6, 2019; Copenhagen, Denmark.

Yong C, Seal B, Coutinho AD, Lunacsek O, Dean B, Willey J, Eaddy M, Cotarla I, Mehra R. Changing treatment patterns in patient with stage IV non-small cell lung cancer (NSCLC) from US community-based oncology

practices. American Society of Clinical Oncology Quality of Care Symposium 2019; September 6-7, 2019; San Diego, CA.

2018

[Return to Posters](#)

[Return to Publications](#)

Abdel-Sattar M, Gittings K, Nguyen V, Shamseddine N, Donne L, Bramley T, Long-Boyle J, Maltepe E. The Initiative for Pediatric Drug and Device Development (iPD3): a promising new model to address the unmet needs in pediatric research in the United States. White paper presented at: Precision Medicine World Conference (PMWC); January 2018; Mountain View, CA.

Agashe VR, Arvin-Berod C, Martel M, Sarnes M. Market access for companion diagnostics in oncology in the EU5 and Asia-Pacific region. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Ananthasubramaniam K, Saval M, Malas H, Van Harn M, Mueller C, Kitt TM, Kristy RM, Spalding JR. Real-world experience with regadenoson SPECT myocardial perfusion imaging: patient characteristics, safety, and impact of results on clinical management. Poster presented at: Annual Scientific Session of the American Society of Nuclear Cardiology; September 6-9, 2018; San Francisco, CA.

Bloudek L, Brokars J, Campbell D, Makenbaeva D. Realized and projected cost savings from the introduction of generic imatinib, with minimal additional savings to payers through formulary management. Poster presented at: 60th American Society of Hematology Annual Meeting and Exposition; December 1-4, 2018; San Diego, CA.

Borchert K, Krinke K, Paramore C, et al. The burden of disease of B-thalassemia in Germany—current results from a claims database analysis. Poster presented at: European Conference on Rare Diseases and Orphan Products; May 10-12, 2018; Vienna, Austria.

Borchert K, Krinke K-S, Paramore C, Sager U, Haeger M, Greiner W, Braun S. Feasibility of evaluating the burden of β -thalassemia with German claims data. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Borchert K, Löpmeier J, Braun S, Mittendorf T, Jacob C. Die bedeutung von beweis aus der realen welt im verfahren der nutzenbewertung nach § 35a SGB V. [The importance of real world evidence studies in the process of benefit assessment according to §35a SGB V.] Poster presented at: 17 Deutscher Kongress für Versorgungsforschung [17th Annual German Congress for Health Services Research]; October 10-12, 2018; Berlin, Germany.

Bozkaya D. Projected savings in direct and indirect costs due to reduced diabetes prevalence with vegetarian diets. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Bozkaya D, Bloudek LM, O'Hara K, Kirby SL, Shah S. Rifaximin and eluxadoline utilization for irritable bowel syndrome with diarrhea (IBS-D) in the United States and budget impact analysis of switching from eluxadoline to rifaximin. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Cadarette SM, Douyon L, Ranganathan P, Ballew NG, Colby JA, Maiese BA, Slaff S, Wissinger E, Ruiz K. Systematic literature review evaluating quality assessment tools. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Cameron A, Macomson B, Kaufman S, Behl A, Agarwal N. Willingness to pay (WTP) to avoid treatment-related fatigue in patients with metastatic castrate-resistant prostate cancer (mCRPC). Poster presented at: National Comprehensive Cancer Network 23rd Annual Conference; March 22-23, 2018; Orlando, FL.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA[®] (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018, Baltimore, MD.

Chari A, Romanus D, Farrelly E, Huang H, Blazer M, Raju A, Noga S, Skacel T, Richardson P. Randomized clinical trial (RCT) representativeness and outcomes in relapsed/refractory multiple myeloma (RRMM) real-world patients: comparison of ASPIRE, TOURMALINE-MM1, POLLUX, and ELOQUENT-2 RCTs. Poster presented at: European Hematology Association 23rd Congress; June 14-17, 2018; Stockholm, Sweden.

Chari A, Romanus D, Farrelly E, Huang H, Blazer M, Raju A, Noga S, Skacel T, Richardson P. Randomized clinical trial (RCT) representativeness and outcomes in relapsed/refractory multiple myeloma (RRMM) real-world patients: comparison of ASPIRE, TOURMALINE-MM1, POLLUX, and ELOQUENT-2 RCTs. Poster presented at: Society of Hematologic Oncology 6th Annual Meeting; September 12-15, 2018; Houston, TX.

Claes AK, Kossow S, Italia N, Stückemann V, Kulp W. Diversity in safety data analysis in German AMNOG benefit assessments for multiple myeloma. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Clark RS, Gittings K, Campbell CM, Meyer KL. 2018 update of health technology assessment decisions across the globe: a focus on oncology. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Clark RS, Meyer KL, Campbell DJ. 2018 update of health technology assessment decisions for novel psoriasis and psoriatic arthritis agents: results, rationale, and trends. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Clark RS, Meyer KL, Campbell DJ. Health technology assessment decisions for novel asthma therapies: results, rationale, and trends. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Damen D, Templin C, Ulrich S, Kulp W. Implications of the fast-evolving therapeutic landscape on appropriate comparators in oncological AMNOG benefit assessments. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Farahbakhshian S, Flechsig S, Meise D, Borchert K, Greiner W, Braun S. Retrospective healthcare claims data analysis for children/adolescents with attention-deficit/hyperactivity disorder receiving second-line pharmacotherapy in Germany, evaluating patient characteristics and healthcare costs. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Flechsig S, Meise D, Borchert K, Farahbakhshian S, Greiner W, Braun S. Merkmale und gesundheitskosten von kindern / jugendlichen mit aufmerksamkeitsdefizit-hyperaktivitätsstörung (ADHS) mit medikamentöser zweitlinientherapie: eine retrospektive analyse von krankenkassendaten in Deutschland. [Characteristics and health costs of children / adolescents with attention deficit hyperactivity disorder (ADHD) with second-line drug therapy: a retrospective analysis of health insurance data in Germany.] Poster presented at: Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde Kongress [German Society for Psychiatry and Psychotherapy, Psychosomatics and Neurology Congress]; November 28–December 1, 2018; Berlin, Germany.

Gaiser A, Abdel-Sattar M, Shamseddine N, Shields S. Payer evaluation of organizational management approaches to limit opioid abuse and overdose deaths in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Gillard KK, Bloudek LM. Epidemiology of hyperhidrosis in the United States: a systematic literature review. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Gillard KK, Moradi A, Bloudek L. Budget impact analysis of glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis (PAHH). Poster presented at: Academy of Managed Care Nexus; October 22-25, 2018; Orlando, FL.

Gittings K, Moradi A, Begovic E, Sarnes E, Mody L. A systematic literature review of health outcomes associated with plant-based diets. Poster presented at: Academy of Managed Care Nexus; October 22-25, 2018; Orlando, FL.

Haas J, Borchert K, Krinke K-S, Gavata-Steiger S, Greiner W, Braun S. The treatment of iron deficiency/anaemia in patients with non-dialysis chronic kidney disease in Germany—a claims database analysis. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Italia N, Kossow S, Claes AK, Templin C, Kulp W. Appropriate comparator in German AMNOG benefit assessments in melanoma—a dynamic situation. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Kuchenbecker U, Massanari M, Mittendorf T, Werner I. Budget impact of using FeNO in the management of asthma patients in Germany. Poster presented at: European Academy of Allergy and Clinical Immunology Congress; May 26-30, 2018; Munich, Germany.

Kohlscheen K, Jacob C, Braun S, Mittendorf T. Pharmaceutical treatment of mild Alzheimer's disease in Germany—results from a Delphi panel. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

König C, Borchert K, Meise D, Braun S, Meier F, Tian H, Boehm K, von Hinuber U. Estimating the prevalence, and describing the medical history and treatment patterns of patients with non-radiographic axial spondyloarthritis in Germany—an approach using a claims database. Poster presented at: ISPOR 21st Annual European Congress; November 10-14; 2018; Barcelona, Spain.

König C, Krinke K-S, Haas J, McLeod K, Braun S. Landscape assessment of prospective real-world evidence studies in Europe. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Krinke K-S, Borchert K, Paramore C, et al. Die prävalenz der β -thalassämie in Deutschland—Ergebnisse einer krankenkassen-datenanalyse. [The prevalence of β -thalassemia in Germany—results of a health insurance data analysis.] Poster presented at: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie [Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology]; September 28–October 2, 2018; Vienna, Austria.

Lamerato L, Harris YT, Bissoonauth AA, Patel C, Durkin M, McLeod K, Quillen A, Turner B. Characterization of patient activation, clinical assessments, and patient-reported outcomes in patients with type 2 diabetes mellitus. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Landsman-Blumberg P, Lokhandwala T, Le Lay A, Dean B, Stafkey-Mailey D. Standard propensity score weighting did not result in balanced cohorts, now what? Poster presented at: 34th International Conference on Pharmacoepidemiology; August 22-26, 2018; Prague, Czech Republic.

Laurenz M, von Eiff C, Borchert K, et al. Pneumokokken-konjugat-impfung—vergleich von impfraten und impfbeginn bei säuglingen, die vor und nach umstellung auf das 2+1-schema geboren wurden (zwischenanalyse nach 9 Monaten). [Pneumococcal conjugate vaccination—comparison of vaccination rates and time of onset in infants born before and after switching to the 2 + 1 scheme (interim analysis after 9 months of age).] Poster presented at: 26 Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie [26th Annual Meeting of the German Society for Pediatric Infectious Diseases]; June 22-23, 2018; Cologne, Germany.

Laurenz M, von Eiff C, Borchert K, et al. Vergleich der impfraten und impftermine der pneumokokken-konjugat-impfung bei frühgeborenen vor und nach umstellung auf das 1+2-schema (zwischenanalyse nach 9 monaten). [Comparison of immunization rates and vaccination dates of pneumococcal conjugate vaccination in premature infants before and after switching to the 1 + 2 scheme (interim analysis after 9 months of age).] Poster presented at: Kongress für Kinder- und Jugendmedizin [Congress for Pediatric and Adolescent Medicine]; September 12-15, 2018; Leipzig, Germany.

Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, O'Brien G, McCart M, Eaddy M. Mortality rates and predictors of in-hospital mortality among intubated and mechanically ventilated adult patients with gram-negative pneumonia. Poster presented at: 2018 American Thoracic Society International Conference; May 18-23, 2018; San Diego, CA.

Lodise TP, Law A, Spilsbury-Cantalupo M, Liao L, O'Brien G, McCart M, Eaddy M. Predictors of 30-day readmission among intubated and mechanically ventilated adult patients with gram-negative pneumonia. Poster presented at: 2018 American Thoracic Society International Conference; May 18-23, 2018; San Diego, CA.

Lopes S, O'Day K, Stiphout JV, Punekar Y, Radford M, Haas JS. Prescription patterns of comedication and potential for drug-drug interactions with antiretroviral therapy (ART) in human immunodeficiency virus (HIV) patients in a retrospective claims database in Germany: implications for adequate HIV treatment selection. Poster presented at: HIV Drug Therapy Glasgow; October 28-31, 2018; Glasgow, UK.

Maas C, Krinke K-S, Haas J, Barck I, Hardt T, Braun S. The burden of hyperkalemia in Germany—a claims database analysis. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Mallick R, Carlton R. Economic and budget impact model of maintenance treatment of CIDP with IgPro20 in the US. Poster presented at: Peripheral Nerve Society Annual Meeting; July 21-25, 2018; Baltimore, MD.

Mezzio D, Brown D. Assessing drug price changes over 1 year and their influence on budget impact. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Mody LB, Boswell KA, Ren SP, Kaufman S, Hughes J, Sarnes EF. Payer perspective on the Academy of Managed Care Pharmacy (AMCP) Format Version 4.0 (v4.0) pre-approval dossier in a managed care network. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Moradi A, Simmons D, Yun SA, Regan TS, Eaddy M. Comparing the ability of comorbidity and polypharmacy measures to predict payer healthcare expenditures: a literature review. Poster presented at: Academy of Managed Care Nexus; October 22-25, 2018; Orlando, FL.

Nguyen V, Kanaskar A, Migliaccio-Walle K, Shields K. Utilization and impact of value assessment frameworks on payer decisions regarding chimeric antigen receptor T-cell therapies. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

O'Day K, Mezzio D. Taming the tornado chart: simplifying one-way sensitivity analyses for large-scale multi-parameter models. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.

Parcher B, Gabriel S, Ruiz K, Ariely R, Mosnaim G. Digital technology interventions and their outcomes in moderate to severe asthmatic patients: a targeted literature review. Poster presented at: AAAAI/WAO Joint Congress; March 2-5, 2018; Orlando, FL.

Rametta M, LaRose A, Farej R, McLeod K, Quillen A. Impact of BETACONNECT™ auto-injector on Betaseron® (interferon beta-1b) therapy adherence and patient satisfaction. Poster presented at: 2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 30–June 2, 2018; Nashville, TN.

Ruban C, Burgess SM. Atopic dermatitis: development of a literature-based conceptual model and review of patient-, observer-, and clinician-reported outcome measures. Poster presented at: International Society for Quality of Life Research 25th Annual Conference; October 24-27, 2018; Dublin, Ireland.

Ruban C, Burgess SM. Development of a conceptual model and review of patient and observer-reported outcome measures in atopic dermatitis. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Rutsch F, Muntau A, Alvarez I, et al. Health economic burden of illness in adult patients with phenylketonuria—a retrospective database study in Germany. Poster presented at: Annual Clinical Genetics Meeting 2018; April 10-14, 2018; Charlotte, NC.

Rutsch F, Muntau A, Alvarez I, Lane P, Altevers J, Kohlscheen K, Jacob C, Jain M, Schroeder C, Jha A, Trefz F. Burden of illness in adult patients with phenylketonuria and associated comorbidities—a retrospective database study in Germany. Poster presented at: Annual Clinical Genetics Meeting 2018; April 10-14, 2018; Charlotte, NC.

Schiffner-Rohe J, Borchert K, Braun S, Haas J, Kohlscheen K, Jacob C, Laurenz M, von Eiff C. Does a change in vaccination scheme affect pneumococcal conjugate vaccination adherence? Comparison of quotas and adherence in mature born infants in Germany. Poster presented at: ISPOR 21st Annual European Congress; November 10-14, 2018; Barcelona, Spain.

Senagore A, Oderd G, Morland K, Iqbal S, Kugel M, Liu S, Habib A. Prevalence and burden of opioid-induced respiratory depression and postoperative nausea/vomiting associated with the treatment of acute postoperative pain following general/colorectal surgery. Poster presented at: American Society of Colon and Rectal Surgeons; May 19-23, 2018; Nashville, TN.

Shih HC, Forsy A, Le J, Kugel M, Roberto P. Medicare Part D spending trends among enrollees in employer group waiver plans compared to non-low-income subsidy enrollees. Poster presented at: Annual Research Meeting (AcademyHealth); June 24-26, 2018; Seattle, WA.

Stafkey-Mailey D, Lokhandwala T, Said Q, Bhor M, Graves A. Comparison of adherence, persistence, and bleed-related event rates in patients diagnosed with immune thrombocytopenia and treated with thrombopoietin receptor agonists. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Taylor A, Wissinger E, Cadarette S, Ruiz K, Akbari M. Adverse event (AE) profile of treatments used in steroid-refractory acute graft vs host disease (SR-aGvHD) in comparison to autoimmune disease indications: a literature review. Poster presented at: Blood and Marrow Transplant Tandem Meeting; February 21-25, 2018; Salt Lake City, UT.

Valderrama A, Duchesneau E, Zichlin M, Bhak R, Yaldo A, Appukkuttan S, Sun L, Gharibo M, Babajanyan S, Duh MS. Budget impact model of ALIQOPA® (copanlisib): introduction in relapsed follicular lymphoma treatment. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Williamson T, LaRose A, Cameron J, Lott J, Eaddy M, Hopson S, Shih HC. Rosacea treatment satisfaction surveys: matching adjusted indirect treatment comparison analysis of concerns and side effects of treatment with metronidazole gel or cream vs azelaic acid foam. Poster presented at: DERM2018 NP/PA CME Conference; July 19-22, 2018; Las Vegas, NV.

Wilson S, Frank T, Hilton P, Snow J, Shields S, Campbell C. Payer familiarity and perceptions with state legislative measures to control drug cost in the US. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 22-25, 2018; Orlando, FL.

2017

[Return to Posters](#)

[Return to Publications](#)

Agashe V, Duhig A, Floyd J, Maiese B, Slaff S. Quality of life (QoL), functional status (FS), and survival in triple negative breast cancer (TNBC): discordance of definitions between a targeted literature review and stakeholder interviews. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Altevers J, Jacob C, Maas C, Barck I, Hardt T. Retrospective health insurance data analysis to determine differences between heart failure patients with and without iron deficiency or iron deficiency anemia. Poster presented at: DGGÖ Jahrestagung 2017; March 9-10, 2017; Basel, Switzerland.

Altevers J, Jacob C, Maas C, Krinke K, Barck I, Hardt T, Braun S. Survival differences in heart failure patients with and without iron deficiency/anemia and by oral and intravenous iron treatment. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Beckert U, Vorwerk H, Löpmeier J, Kulp W. Non-quantifiable benefit within the German AMNOG system: factors contributing to time limits set for benefit resolutions and potential implications on price discounts. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Bell J, Galaznik A, Farrelly E, Blazer M, Che Shih H, Ogbonnaya A, Eaddy M, Dezube B. Treatment patterns among patients with higher-risk myelodysplastic syndromes in a real-world setting: electronic medical record-based data. Poster presented at: American Society of Clinical Oncology 2017 Quality Care Symposium; March 3-4, 2017; Orlando, FL.

Bell J, Galaznik A, Farrelly E, Blazer M, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Survival outcomes after first-line therapy in higher-risk myelodysplastic syndromes (HR-MDS) using a US electronic medical record (EMR)-based cohort. Poster presented at: 14th International Symposium for Myelodysplastic Syndromes; May 3-6, 2017; Valencia, Spain.

Bell J, Galaznik A, Farrelly E, Blazer M, Seal B, Ogbannaya A, Eaddy M, Fram RJ, Faller DV. Beyond hypomethylating agents: treatment of patients with higher-risk myelodysplastic syndromes after first-line therapy using a United States electronic medical record. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Bell J, Galaznik A, Farrelly E, Blazer M, Shih H-C, Raju A, Ogbannaya A, Eaddy M, Fram RJ, Faller DV. Economic impact and healthcare utilization in patients with higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States (US): claims database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Bell J, Galaznik A, Farrelly E, Blazer M, Shih H-C, Raju A, Ogbannaya A, Eaddy M, Fram RJ, Faller DV. Survival outcomes in patients with higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States (US): a claims database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Bell J, Galaznik A, Farrelly E, Blazer M, Shih H-C, Raju A, Ogbannaya A, Eaddy M, Fram RJ, Faller DV. Treatment patterns in patients with higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States (US): a claims database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Bell JA, Galaznik A, Farrelly E, Pollack M, Raju A, Ogbonnaya A, Eaddy M, Fram R, Faller DV. Treatment patterns in elderly patients (pts) with acute myeloid leukemia (AML) in routine clinical care in the United States (US). Poster presented at: 42nd European Society for Medical Oncology Congress; September 8-12, 2017; Madrid, Spain. Bell JA, Galaznik A, Murty S, Pollack M, Ogbonnaya A, Eaddy MT, Fram RJ, Faller DV, Kota V. Healthcare costs in elderly patients with acute myeloid leukemia (AML) in routine clinical care in the United States (US). Poster presented at: 59th Annual Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA.

Bloudek L, O'Day K. Assessment of economic model stability by repeated one-way sensitivity analysis. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Borchert K, Hardt T, Haas J, Ong S, Lechat E, Nip K, Foerster D, Braun S, Stein J. Comparative analysis of oral versus intravenous iron in patients with inflammatory bowel disease and iron deficiency/anaemia—impact on hospitalisation in Germany. Poster presented at: 12th Congress of European Crohn's and Colitis Organisation; February 15-18, 2017; Barcelona, Spain.

Borchert K, Jacob C, Wetzel N, Jaenicke M, Eggert E, Sauer A, Marschner N, Meise D, Altevers J, Mittendorf T, Braun S, Greiner W. Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry. Poster presented: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Brown D, Bozkaya D. The economic impact of switching to Herceptin (trastuzumab) biosimilar for the treatment of metastatic breast cancer from a UK payer perspective. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Brown D, Campbell C, Migliaccio-Walle K, Jackson J, Meyer K. Recent trends in provider perceptions and use of value frameworks in the United States (US). Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Campbell C, Migliaccio-Walle K, O'Day K, Byars C, Jackson J. Recent trends in payer perception and use of value frameworks in the United States (US). Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO. *Silver Medal Winner*.

Campbell D, Clark R, Meyer K. Trends in oncology appraisal decisions: a comparison between the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC). Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Carlton R, Eaddy M. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis and ascites requiring large volume paracentesis. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Chari A, Romanus D, Luptakova K, Raju A, Farrelly E, Cain LE, Blazer M, Skacel T, Hari P. Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib, and ixazomib combinations with lenalidomide/dexamethasone (VRd, KRd, IRd) in patients with relapsed/refractory multiple myeloma (RRMM): early clinical practice experience in the United States vs clinical trial experience. Poster presented at: 59th Annual Meeting and Exposition of the American Society of Hematology; December 9-12, 2017; Atlanta, GA.

Chiang T, Poplar B, Hilton P, Kaufman S, Hughes J, Jackson J, Sarnes M. Cell and gene therapy evaluation and coverage challenges. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX.

Clark R, Campbell C, Meyer K. 2017 update of recent trends in multiple sclerosis-related health technology assessment decisions: an assessment of five countries. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Clark R, Campbell CM, Meyer KL. Results, rationales, and trends in health technology assessments for novel diabetes agents. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Duhig A, Jackson J, Sarnes M, Kaufman S, Popelar B. The exchange of healthcare economic information in the US: payer and manufacturer experiences with FDAMA 114 and future directions. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Farrelly E, Blazer M, Ogonnaya A, Eaddy M. Beyond hypomethylating agents (HMA): treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS) after first-line therapy (1LT) using a United States (US) electronic medical record (EMR). Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Farsani SF, Brodovicz KG, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis in adults with type 1 diabetes: a systematic literature review. Poster presented at: American Diabetes Association 77th Scientific Sessions Conference; June 9-13, 2017; San Diego, CA.

Galaznik A, Bell J, Hamilton L, Ogonnaya A, Hennenfent K, Eaddy M, Shou Y. Economic impact and healthcare utilization in patients with diffuse large B-cell lymphoma in routine clinical care in the United States—

a claims database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Galaznik A, Bell JA, Hamilton L, Ogonnaya A, Hennenfent K, Eaddy MT, Shou Y. Healthcare burden of patients with follicular lymphoma (FL) in routine clinical care in the United States. Poster presented at: 59th Annual Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA.

Galaznik A, Bell J, Hamilton L, Ogonnaya A, Hennenfent K, Eaddy M, Shou Y. Treatment patterns and treatment response in patients with follicular lymphoma in routine clinical care—a United States electronic medical record database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Galaznik A, Bell J, Hamilton L, Ogonnaya A, Hennenfent K, Eaddy M, Shou Y. Treatment patterns and treatment response in patients with diffuse large B-cell lymphoma in routine clinical care in the United States—a claims database study. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Galaznik A, Bell JA, Hamilton L, Ogonnaya A, Hennenfent K, Eaddy MT, Shou Y. Treatment patterns in newly treated and relapse/refractory patients with follicular lymphoma in routine clinical care—a United States electronic medical record database study. Poster presented at: 59th Annual Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, GA.

Galaznik A, Bell J, Hamilton L, Ogonnaya A, Raju A, Hennenfent K, Eaddy M, Shou Y. Survival outcomes after first-line therapy in diffuse large B-cell lymphoma (DLBCL) using a United States (US) electronic medical record (EMR)-based cohort. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Galaznik A, Bell J, Hamilton L, Ogonnaya A, Raju A, Hennenfent K, Eaddy M, Shou Y. Survival outcomes after first-line therapy in follicular lymphoma using a United States electronic medical record-based cohort. Poster presented at: European Hematology Association 22nd Congress; June 22-25, 2017; Madrid, Spain.

Germeno R, Liao L, Blazer M, Ogonnaya A. Treatment patterns in non-cystic fibrosis bronchiectasis (NCFB): a 2-year assessment post-exacerbation. Poster presented at: 2017 American Thoracic Society International Conference; May 19-24, 2017; Washington, DC.

Germeno R, Rametta M, McLeod K, McCart M, Quillen A. An interim analysis of the impact of BETACONNECT™ auto-injector on patient adherence to Betaseron® (interferon beta-1b) therapy. Poster presented at: 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 24–27, 2017; New Orleans, LA.

Haas J, Borchert K, Löpmeier J, Braun S, Mittendorf T. Relevance of real world data in German AMNOG submissions in oncology. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Haas JS, Meise D, Ogonnaya A, Braun S, Eaddy M, Daeßler K, Sandner R, Binninger A, Jaenicke M, Chiabudini M, Marschner N. Clinical comparison of first-line platinum chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Hennenfent KL, Girvan AC, Chaudhry A, Abada P, Sheffield K, Herren CK, Raju A, Farrelly E, Bowman L, Landsman-Blumberg P. Overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): a real-world retrospective study. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL.

Jacob C, Guenther J, Borchert K, Krinke K, Braun S. Overcoming the limitations of claims data: linkage of claims data with secondary data sources in Germany. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Jacob C, Meier F, Neidhardt K, Jugl S, Walker J, Braun S, Augustin M. Epidemiology and costs of psoriatic arthritis in Germany—a retrospective claims data analysis. Poster presented at: 45th Congress of the German Society for Rheumatology; September 3-6, 2017; Stuttgart, Germany.

Kaufman S, Hughes J, Duhig A. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX. *Silver Medal Winner*.

Kohlscheen K, Jacob C, Altevers J, Mittendorf T. Utilization and evaluation of Delphi panels in German AMNOG assessments. Poster presented at: ISPOR20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Krinke K, Borchert K, Braun S, Mittendorf T. The impact of patient preference studies in the German healthcare system. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Kuchenbecker U, Günther J, Mittendorf T. Application of mixed-method study designs in health- economic-related studies. A narrative review. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Kulp W, Reinartz MT. AMNOG dossiers as a challenge for pharmaceutical companies: is there a correlation between volumes and added medical benefit? Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Lankford M, Willey J, Buettner A, Britton S, Scharf M, Dreicer R. Prescribing preferences of US oncologists for patients with metastatic urothelial carcinoma at first recurrence: impact of novel agents. Poster presented at: Genitourinary Cancers Symposium; February 16-18, 2017; Orlando, FL.

Laurenz A, Sprenger R, von Eiff C, et al. Pneumokokken-konjugatimpfung—impfraten und impfzeitpunkt bei kindern des geburtsjahrgangs 2013 auf basis von daten der gesetzlichen krankenversicherung vor umstellung auf das 2+1-schema. [Pneumococcal conjugate vaccination—vaccination rates and time of vaccination in children of the birth cohort 2013 based on data from the statutory health insurance before conversion to the 2 + 1 scheme.] Poster presented at: Deutscher Kongress für Kinder und Jugendmedizin [German Congress for Children and Adolescent Medicine] 2017; September 20-23, 2017; Cologne, Germany.

Liu T, Benjamin N, Popelar B. A1C levels and factors associated with glycemic control among patients with diabetes mellitus in the US. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Liu T, Ruiz K, Colby J. Estimation of survival outcomes for use in oncology value frameworks. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Lokhandwala T, Bhor M, Stafkey-Mailey D, Chen H, Elliott BM. Comparison of treatment characteristics between patients diagnosed with immune thrombocytopenia (ITP) and treated with thrombopoietin receptor agonists (TPO-RA). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL.

Maas C, Kuchenbecker U, Kontekakis A. Cost and operational efficiency comparison of an integrated vs. a multi-step system for extracorporeal photopheresis in Germany. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

McLeod K. Remote therapy management of patients on automated peritoneal dialysis demonstrates cost savings in Germany and Italy. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

McLeod K, Duhig A, Ogbonnaya A, Quillen A, Yue B. Prospective study of real-world outcomes in the treatment of neurogenic orthostatic hypotension with droxidopa. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX.

Meise D, Kohlscheen KM, Jacob C, Braun S. Application of balancing techniques in studies utilizing German administrative claims data. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Mezzio D, Kiselica A, Nguyen V, O'Day K. Immediate discounts versus delayed rebates: a survey of US payers. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Moreland K, Kugel M, Liu T. Burden of post-operative nausea or vomiting associated with acute postoperative pain treatment. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX.

Nguyen V, Mezzio D, Kiselica A, O'Day K. Relative versus absolute risk framing in healthcare decision-making: a survey of U.S. payers. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO. *Gold Medal Winner.*

O'Day K, Brown D. Cohort analysis methods to estimate the budget impact of oncology treatments by line of therapy. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

O'Day K, Brown D. Cost impact of elotuzumab in second-line+ vs third-line+ relapsed refractory multiple myeloma in a commercial health plan. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO.

O'Day K, Campbell D, Meyer K. Do NICE appeals make a difference? Impact of appeals on appraisal outcomes. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

O'Day K, Campbell D, Meyer K. When the outcome of an appraisal is not nice: a review of NICE appeals. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

O'Day K, Meyers K. Economic impact of treating severe hemophilia A patients with plasma-derived factor-VIII/VWF versus recombinant factor-VIII in the United States. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Oderda GM, Morland K, Iqbal SU, Soergel DG, Kugel M, Liu S, Habib AS, Senagore AJ. Burden of postoperative nausea or vomiting associated with acute postoperative pain treatment. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX.

Ogbonnaya A, Hennenfent K, Eaddy M. Evaluation of treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL). Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Ogbonnaya A, Lokhandwala T, Duhig A. Does the commercial availability of clobazam affect healthcare resource utilization and costs among patients with Lennox-Gastaut syndrome? Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Panettieri RA, Corren J, Gabriel S, Ruiz KM, Sawchyn B, Colby JA, Mendelson M. Reduction in corticosteroid use among patients receiving omalizumab in real-world settings: a systematic literature review of non-randomized studies. Poster presented at: 2016 American Academy of Allergy, Asthma and Immunology Annual Meeting; March 4-7, 2016; Los Angeles, CA.

Parcher B, Shamseddine N, Walters T, Campbell C. US payer assessment of late-stage clinical trials involving digital health technologies and pharmaceutical manufacturers. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Popelar B, Jackson J, Duhig A, Sarnes M, Kaufman S. FDAMA 114 for the exchange of healthcare economic information: manufacturer experiences, attitudes, and perceptions of current legislation and future directions. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO. *Bronze Medal Winner.*

Popelar B, Sarnes M, Duhig A, Kaufman S, Jackson J. FDAMA 114 for the exchange of healthcare economic information: payer experiences, attitudes, and perceptions of current legislation and future directions. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO. *Silver Medal Winner*.

Romanus D, Raju A, Farrelly E, Luptakova K, Blazer M, Hari P. Predictors of treatment with triplet first-line therapy among transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) in routine clinical care. Poster presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Luptakova K, Blazer M, Hari P. Triplet therapy and overall survival in routine practice among transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) in the United States (US). Poster presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Noga S, Blazer M, Hari P. Treatment patterns and outcomes by line of therapy (LOT) in a large United States (US) cohort of transplant-ineligible patients with multiple myeloma in the era of novel agents. Poster presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Farrelly E, Skacel T, Blazer M, Hari P. Newly diagnosed multiple myeloma (NDMM): effect of age, renal insufficiency, and cardiovascular disease on overall survival and treatment patterns among stem cell transplant-ineligible patients in the United States (US). Poster presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Romanus D, Raju A, Yong C, Farrelly E, Luptakova K, Labotka R, Noga S, Blazer M, Hari P. Association between treatment regimen type in second-line therapy and duration of therapy and time to next treatment in a United States (US) relapsed/refractory multiple myeloma (RRMM) cohort. Poster presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.

Ruban C. Assessing the healthcare cost of diabetic non-small cell lung cancer patients compared to non-small cell lung cancer patients. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Ruban C. Assessing the utilization of diabetic non-small cell lung cancer patients compared to non-small cell lung cancer patients. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Ruban C. Investigation of demographic differences for non-small cell lung cancer patients with and without type 2 diabetes. Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Sarnes E, Cadarette S, Gittings K, Kulp W, Ruiz K, Wissinger E. A comparison of health technology (HTA) requirements for systematic literature reviews (SLRs). Poster presented at: ISPOR 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.

Senagore AJ, Habib AS, Morland K, Iqbal SU, Soergel DG, Kugel M, Liu S, Oderda GM. Predictors of postoperative nausea and vomiting associated with opioid-treated acute postoperative pain. Poster presented at: PAINWeek 2017; September 5-9, 2017; Las Vegas, NV.

Stafkey-Mailey D, Bhor M, Lokhandwala T, Elliott B. Adherence, persistence, and dosing patterns of eltrombopag for treatment of immune thrombocytopenia. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO.

Stafkey-Mailey D, Roy A, Lokhandwala T, Yuan J, Landsman-Blumberg P, Siddiqui A, Ghaznawi F. Evaluation of treatment patterns among patients with newly diagnosed, persistent, and chronic immune thrombocytopenia (ITP) treated with eltrombopag in a real-world setting in the US. Poster presented at: 59th American Society of Hematology Meeting; December 9-12, 2017; Atlanta, GA.

Stafkey-Mailey D, Wang W, Murty S, Shetty S. Validation of an algorithm to identify death in administrative claims data. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX. *Gold Medal Winner*.

Stafkey-Mailey D, Yue B. Treatment patterns among patients diagnosed with advanced melanoma in a commercially insured population. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Ta J, Bonine N, Harrington A, Shih V, Stafkey-Mailey D, Fuldeore RM, Yue B, Gillard P, Banks E. Healthcare resource utilization and costs of surgery for the treatment of uterine fibroids. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX.

Templin C, Billig S, Damen D, Kulp W. German AMNOG benefit assessment: the type of appropriate comparator makes the difference. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Templin C, Erwes KL, Italia N, Kulp W. Transition from orphan disease to full assessment in the German AMNOG system: key learnings from pioneers. Poster presented at: ISPOR 20th Annual European Congress; November 4-8, 2017; Glasgow, Scotland.

Tennant L, Gittings K, Migliaccio-Walle K, Campbell C, Danavar A. Payer perceptions and utilization of the Institute for Clinical and Economic Review (ICER) value assessment framework. Poster presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of migraine prophylaxis treatments using likelihood of being helped or harmed. Poster presented at: Congress of the International Headache Society; September 5-8, 2017; Vancouver, Canada.

Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of migraine prophylaxis treatments using likelihood of being helped or harmed. Poster presented at: European Headache Federation Congress; December 1-3, 2017; Rome, Italy.

Wang W, Shetty S, Murty S, Stafkey-Mailey D. The direct cost of cardiovascular disease-related death in patients with type 2 diabetes mellitus in a Medicare population. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 16-19, 2017; Dallas, TX. *Bronze Medal Winner*.

Yue B, Lankford M, Landsman-Blumberg P. Estimating healthcare costs for advanced metastatic bladder cancer patients who are lost to follow-up: applications of the Kaplan-Meier sampling average (KMSA). Poster presented at: American Society of Clinical Oncology 2017 Quality Care Symposium; March 3-4, 2017; Orlando, FL.

2016

[Return to Posters](#)

[Return to Publications](#)

Abdel-Sattar M, Corey L, Shields S, Snow J, Denno M. Drug pricing in the United States: payers evaluate strategies proposed by presidential candidates to lower drug costs. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA. *Gold Medal Winner*.

Abdel-Sattar M, Donne L, Rugani M, Kaufman S, McLaughlin T, Jackson J. Understanding the hepatitis C patient journey: insights from a patient panel in the United States. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Abdel-Sattar M, McCart M. Clinical pharmacy medication therapy management and patient follow-up to improve real-world adherence to novel oral anticoagulants: a single-center prospective study. Poster presented at: Academy of Managed Care Pharmacy's 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA. *Silver Medal Winner*.

Agashe V, O'Day K, Arvin-Berod C, Meyer K, Bramley T. Potential impact of the Cancer Drugs Fund reform on orphan cancers. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Altevers J, Prosser C, Körber F, Wetzka S, Tafalla M, Braun S. Komplikationen bei Keuchhusten in Deutschland—ergebnisse einer schadendatenbankanalyse. [Complications associated with pertussis in Germany—results from a claims database analysis.] Poster presented at: 13 Kongress für Infektionskrankheiten und Tropenmedizin [Congress for Infectious Diseases and Tropical Medicine]; June 15-18, 2016; Würzburg, Germany.

Bell J, Galaznik A, Farrelly E, Blazer M, Shih H-C, Ogbannaya A, Eaddy M, Dezube B. Treatment patterns and outcomes among patients with higher-risk myelodysplastic syndromes treated in a real-world setting: electronic medical record-based data. *Blood*. 2016;128:5540.

Borchert K, Altevers J, Braun S, Mittendorf T. The value of patient reported outcomes in German AMNOG dossiers. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Boswell K, Mody L, Sawchyn B, Sarnes E. Value, utility, and challenges with the Academy of Managed Care Pharmacy (AMCP) format dossier: implications of version 4.0 (v4.0). Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD. *Gold Medal Winner*.

Bozkaya D, Migliaccio-Walle K, O'Day K. Assessing prescription drug value in the United States: a hypothetical example comparing ASCO and ICER framework outcomes. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Bozkaya D, O'Day K. Budget impact analysis of ibrutinib for patients with first-line chronic lymphocytic leukemia. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Brown D. Retrospective database analysis on anaphylaxis and patient concordance in the United States. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Patient and caregiver reported problems in the utilisation of epinephrine auto-injectors for management of severe allergic reactions. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting; October 13-15, 2016; Rome, Italy.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Retrospective database analysis on anaphylaxis and patient concordance in the United States. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting; October 13-15, 2016; Rome, Italy.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Weaknesses of treatment guidelines for the management of anaphylaxis and healthcare utilization following an anaphylaxis event. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting; October 13-15, 2016; Rome, Italy.

Brown D, Saathoff F, Lehnigk U, Karjalainen M, Locklear JC. Weaknesses of treatment guidelines for the management of anaphylaxis and health care utilization following an anaphylaxis event. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Campbell D, Mezzio D, Campbell C. Payer perceptions on the value of cost-per-outcome data in select disease states. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA.

Clark R, Campbell C, Meyer K, Bramley T. 2015 update of health technology assessment decisions across the globe: a focus on oncology. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC. *ISPOR Award Finalist*.

Clark R, Meyer K, Campbell C. Health technology assessment decisions for novel psoriasis and psoriatic arthritis agents: results, rationale, and trends. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Coutinho A, Blumberg P, Eaddy M. Use of joinpoint regression to define phases of care in patients with advanced melanoma: an evaluation from metastatic diagnosis until death. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Eaddy M, Cross N, Hanna D. Patient comfortability in administering C1 esterase inhibitor therapy for hereditary angioedema: an evaluation of patient activation and adherence. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Eaddy M, Cross N, Hanna D. Predictors of low patient activation when initiating C1 esterase inhibitor therapy for hereditary angioedema. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

François C, Houle C, Duhig A. Development of a neurogenic orthostatic hypotension activities of daily living (NOH ADL) scale. Poster presented at: American Academy of Neurology; April 15-21, 2016; Vancouver, BC.

François C, McLeod K, Duhig A, Ogbonnaya A, Quillen A, Cannon J, Padilla B, Shiao CA, Biaggioni I. Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension. Poster presented at: 20th International Congress of Parkinson's Disease and Movement Disorders; June 19-23, 2016; Berlin, Germany.

Friedman M, Snow J, McCart M. Plan sponsor perceptions on the influence of quality metrics on formulary coverage decisions. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA. *Bronze Medal Winner*.

Guptill JT, Allen J, Runken MC, Eaddy M, Lunacsek O. A comparative assessment of IVIG therapy in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA.

Hari P, Linh MT, Yong C, Noga SJ, Farrelly E, Raju A, Seal B, Labotka R, Blazer M, Jhaveri M, Romanus D. Duration of second-line treatment (2LT) and overall survival (OS) in multiple myeloma (MM). Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Huang M-Y, Prosser C, Landsman-Blumberg P, et al. The healthcare utilisation and cost of prolonged-release fampridine without disease-modifying therapies in patients with multiple sclerosis throughout Germany during 2011–2013. Poster presented at: 2nd Congress of the European Academy of Neurology; May 28-31, 2016; Copenhagen, Denmark.

Jacob C, Altevers J, Haas J, Hardt T, Erath F, Braun S. Retrospective claims database analysis to explore differences in heart failure patients with and without iron deficiency or anemia. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Jacob C, Meier F, Neidhardt K, Jugl S, Walker J, Braun S, Augustin M. Epidemiology and costs of psoriasis in Germany—a retrospective claims data analysis. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Jhaveri M, Romanus D, Raju A, Seal B, Farrelly E, Yong C, Noga SJ, Labotka R, Blazer M, Hari P. Real-world prescribing patterns in U.S. multiple myeloma (MM) patients refractory to lenalidomide in the front line. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Khalaf K. Cost effectiveness of onabotulinumtoxinA versus PTNS and SNS for the treatment of overactive bladder from the US payer perspective. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Krüger K, von Hinüber U, Meier F, Meise D, Braun S, Tian H, Neidhardt K, Jugl SM, Borchert K. Ankylosing spondylitis is associated with significant increases in healthcare resource utilisation and costs in a German real

world setting. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. Antibiotic treatment failure in adults with community-acquired bacterial pneumonia: an analysis of a large US claims database. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. Patterns of antibiotic treatment failure in pediatric community-acquired bacterial pneumonia in the USA. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Landsman-Blumberg P, Carroll C, Murty S, Slaff S. The relationship between macrolide-resistant *Streptococcus pneumoniae* and treatment failure in adults with community-acquired bacterial pneumonia by CDC region in the US. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Liu T, Jackson J, Khalaf K, Meyer K, Brown D. Price elasticity of demand for new oral anticoagulant agents among patients with non-valvular atrial fibrillation. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Maiese B, Cadarette S, Campbell D, Arvin-Berod C. Findings of a literature review in support of a patient count model (PCM) for hepatitis C virus (HCV) in the EU5. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Meyer K, Brown D, Sarnes E, Hughes J, O'Day K. Payer utilization of economic models in the AMCP format for formulary submissions: a web-based survey. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Ng-Mak DS, O'Day K, Chuang CC, Friedman ML, Rajagopalan K, Loebel A. Cost savings associated with improved adherence among patients with schizophrenia using lurasidone. Poster presented at: American Psychiatric Association Annual Meeting; May 14-18, 2016; Atlanta, GA.

O'Day K, Campbell D. Cost-utility analysis of exercise for the prevention of cancer. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

O'Day K, Campbell D. Results from a model to forecast the current and future number of patients eligible for treatment of refractory advanced nonsmall cell lung cancer (NSCLC) in France, Germany, Italy and Spain. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

O'Day K, Campbell D. What's the matter with average cost-effectiveness ratios? A simple graphical explanation. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

O'Day K, Meyer K, Bramley T. Defining end-of-life: is the short life expectancy criterion biased against young people and children? Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

O'Malley P, Lee A, O'Day K, Friedman M. Multiple sclerosis relapse-related costs of oral disease-modifying therapies in Denmark: an economic analysis comparing delayed-release dimethyl fumarate, fingolimod, and teriflunomide. Poster presented at: 2nd Congress of the European Academy of Neurology; May 28-31, 2016; Copenhagen, Denmark.

Ogbonnaya A, Duhig A, Farrelly E, Che Shih H, François C, Biaggioni I, Shibao CA, Ziemann A. Impact of neurogenic orthostatic hypotension on healthcare utilization and costs associated with falls in Parkinson's disease. Poster presented at: 20th International Congress of Parkinson's Disease and Movement Disorders; June 19-23, 2016; Berlin, Germany.

Ogbonnaya A, Eaddy M. Treatment patterns with topical rosacea treatment. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A. Healthcare resource utilization among commercially insured clobazam-treated patients with Lennox-Gastaut syndrome. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA.

Ogbonnaya A, Lokhandwala T, Landsman-Blumberg P, Duhig A. Healthcare resource utilization and projected long-term cost savings following clobazam initiation in patients with Lennox-Gastaut syndrome. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 3-6, 2016; National Harbor, MD.

Popelar B. Patterns and predictors of repository corticotropin injection therapy use in patients with sarcoidosis. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA.

Popelar B. Real-world treatment patterns and demographic, clinical, and economic characteristics of systemic lupus erythematosus (SLE) patients initiating repository corticotropin injection therapy. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA.

Prosser C, Altevors J, Hickstein L, Walker J, Braun S. Influence of validation of outpatient diagnoses on incidence and prevalence estimates using health insurance data. Poster presented at: AGENS Methodenworkshop 2016; March 3-4, 2016; Munich, Germany.

Prosser C, Haas J, Wakeford C, Landsman-Blumberg P, Braun S. Relapse rates and healthcare resource use of therapy for persistent and non-persistent multiple sclerosis patients in Germany—a real world analysis. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Romanus D, Raju A, Seal B, Farrelly E, Yong C, Noga SJ, Jhaveri M, Labotka R, Blazer M, Hari P. The clinical course of relapsed or refractory multiple myeloma (RRMM) U.S. patients receiving two or more lines of therapy. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Romanus D, Raju A, Yong C, Seal B, Farrelly E, Labotka R, Jhaveri M, Noga SJ, Blazer M, Hari P. Practice patterns and outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) in the United States (US). Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Romanus D, Raju A, Yong C, Seal B, Farrelly E, Noga SJ, Jhaveri M, Labotka R, Blazer M, Hari P. Duration of therapy in U.S. patients treated for relapsed/refractory multiple myeloma (RRMM) in the real world. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Sarnes E, Shields K. Evaluating “value” in metastatic colorectal cancer treatments: trends in the evidence. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Sarnes E, Shields K, Kaufman S, Meyer K. Global value dossiers (GVDs): how to ensure the value isn't lost in translation. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Shah MV, Maiese BA, Eaddy MT, Lunacsek O, Pham A, Wan GJ. Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) + IV opioids or IV opioids alone for postoperative pain. Poster presented at: Annual Congress of Enhanced Recovery and Perioperative Medicine (American Society for Enhanced Recovery); April 20-22, 2016; Washington, DC.

Stafkey-Mailey D. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Stafkey-Mailey D. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Stein J, Haas J, Ong S, Borchert K, Hardt T, Lechat E, Nip KT, Foaerster D, Braun S, Baumgart DC. Oral versus intravenous iron treatment in patients with inflammatory bowel disease and iron deficiency and/or anaemia in Germany. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Templin C, Italia N, Damen D, Kulp W. Patient individual therapy as appropriate comparator in AMNOG-dossiers in the field of oncology: status quo and strategic implications for pharmaceutical companies. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Theidel U, Löpmeier J, Mittendorf T. Impact of trial design on price discounts after early benefit assessment (AMNOG) in Germany. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

Theidel U, Väättäin S, Martikainen M, Soini E, Hardt T, Doehner W. Budget impact of IV iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. Poster presented at: Heart Failure 2016 and 3rd World Congress on Acute Heart Failure; May 21-24, 2016; Florence Italy.

Vegesna A, Panettieri RA, Gabriel S, Ruiz KM, Colby JA, Maiese BA, Corren J. Patient-reported outcomes (PROs) in patients receiving omalizumab: a systematic literature review. Poster presented at: American Academy of Allergy, Asthma and Immunology Annual Meeting; March 4-7, 2016; Los Angeles, CA.

Walters T, Parcher B, Campbell C, Shah M. Appraising the value of digital health technologies from the managed care perspective: insights for evidence assessment and reimbursement in the U.S. Poster presented at: Academy of Managed Care Pharmacy 28th Annual Meeting and Expo; April 19-22, 2016; San Francisco, CA. *First Interactive Digital Poster*.

Williamson T, Carlton R, Khalaf K, Lennert B, Cameron J. Cost and budget impact of topical treatments for the inflammatory papules and pustules of mild to moderate rosacea in the managed care setting. Poster presented at: ISPOR 21st Annual Meeting; May 21-25, 2016; Washington, DC.

Yong C, Seal B, Farrelly E, Romanus D, Jhaveri M, Noga SJ, Raju A, Blazer M, Labotka R, Hari P. Practice patterns and outcomes in US patients with relapsed/refractory multiple myeloma (RRMM) and comorbid renal dysfunction and/or cardiovascular disease. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Zischka M, Sauer A, Günzel F, Italia N, Kulp W. Are criteria commonly used in the benefit assessment of drugs also applicable to medical devices? A systematic literature review. Poster presented at: ISPOR 19th Annual European Congress; October 29–November 2, 2016; Vienna, Austria.

2015

[Return to Posters](#)

[Return to Publications](#)

Abdel-Sattar M, Denno M. Clinical pharmacy medication therapy management to improve real-world adherence to novel oral anticoagulants: results of a retrospective descriptive study. Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Aigbogun MS, Liu S, Kamat S, Shah M, Hartry A, Duhig A, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the United States. Poster presented at: 28th Annual US Psychiatric and Mental Health Congress; September 10-13, 2015; San Diego, CA.

Allen L, Denno M, Jackson J. Trends in medication adherence: the payer perspective. Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Altevers J, Borchert K, Mittendorf T, Braun S. Prevalence and incidence estimations in German AMNOG applications—the role of real-world evidence (RWE). Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Altevers J, Borchert K, Mittendorf T, Braun S. Use of real-world evidence in German AMNOG applications. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Altevers J, Borchert K, Mittendorf T, Braun S. Use of real-world evidence in German AMNOG applications. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Bloudek L, Eaddy M. Estimating cost per month of progression free survival (PFS) from a payer perspective: comparing commonly used treatment regimens for previously treated, i.e., relapsed and/or refractory multiple myeloma (RRMM). Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Borchert K, Haas J, Mittendorf T, Braun S. Real world evidence in oncology—status quo in Germany. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Bozkaya D, Migliaccio-Walle K. The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Bozkaya D, Migliaccio-Walle K. The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Bozkaya D, Migliaccio-Walle K. Estimation of the budget impact of rifaximin treatment in patients with irritable bowel syndrome. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Carlton R, Campbell C, Raju A, Eaddy M. Expected costs and projected annual budget impact of treatment of varicose veins with polidocanol endovenous microfoam 1%. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 26-29, 2015; Orlando, FL.

Carlton R, Eaddy M. Cost of treatment of radiopharmaceutical and chemotherapy for the treatment of castration-resistant prostate cancer with bone metastases in hospital setting. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Clark R, Carlton R, Meyer K. Economic impact of avoidable drug wastage in patients admitted to the hospital for an acute COPD exacerbation. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Clark R, Meyer K, Bramley T. Trends in health technology assessment decisions across the globe: a focus on hepatitis C. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Corren J, Gabriel S, Karagiannis T, Ruiz K, Sawchyn B, Colby JA, Mendelson M. Exacerbations, emergency visits, and hospitalizations in patients receiving omalizumab in real-world settings: a systematic literature review of non-randomized studies. Poster presented at: CHEST Annual Meeting 2015; October 24-28, 2015; Montreal, Canada.

Corren J, Gabriel S, Karagiannis T, Ruiz K, Sawchyn B, Colby JA, Mendelson M. Pulmonary function and rescue medication use in patients receiving omalizumab in real-world settings: a systematic literature review of non-randomized studies. Poster presented at: CHEST Annual Meeting 2015; October 24-28, 2015; Montreal, Canada.

Dandappanavar A, O'Day K. Budget impact analysis of ibrutinib for patients with previously treated chronic lymphocytic leukemia. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 26-29, 2015; Orlando, FL.

Denno M, Klein C, Lennert B. Analyzing the burden of hepatitis C using an outcomes evaluation tool within an integrated delivery network. Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Fernandez-Lopez S, Kazzaz D, Bashir M, McLaughlin T. Assessment of pharmacists' views on biosimilar naming conventions. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 26-29, 2015; Orlando, FL.

Haas J, Jacob C, Braun S. Comparative effectiveness of granulocyte colony-stimulating factors (G-CSF) for reducing incidence of febrile neutropenia (FN)-related hospitalization: a retrospective. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Inuzuka Y, Prosser C, Wakeford C, Kinter E, Landsman-Blumberg P, Braun S. Relapse rates among multiple sclerosis patients treated with different disease-modifying therapies in Germany. Poster presented at: 8th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; November 19-21, 2015; Seoul, Korea.

Jacob C, Meise D, Mittendorf T, Braun S. The use of real-world evidence to support market access of medical devices—implications for the German setting. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Kish J, Bloudek L. Modeling the budget impact of panobinostat for the treatment of relapsed/refractory multiple myeloma from the perspective of a U.S. health plan. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 26-29, 2015; Orlando, FL.

Kish J, Eaddy M. Cost of care for gastric cancer in patients with and without metastases. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Kish J, Eaddy M. Patterns of care in the workup and management of nonmetastatic and metastatic colorectal cancer. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Kish J, Lunacsek O, Eaddy M, Willey J. The importance of duration of treatment and therapy discontinuation rates in third-line relapsed/refractory multiple myeloma patients treated in U.S. community oncology practice. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 26-29, 2015; Orlando, FL.

Knight J, Campbell D, Meyer K, Clark R. Analysis of health technology assessment in 7 Asia Oceania countries/regions: comparison of evidentiary requirements for standard and orphan drugs. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Lee A, Liu Y, Gleissner E, Prosser C, Kinter E, Landsman-Blumberg P, Braun S. Treatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in Germany. Poster presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 7-10, 2015; Barcelona, Spain.

Lee A, Liu Y, Gleissner E, Prosser C, Kinter E, Landsman-Blumberg P, Braun S. Treatment costs and patterns in patients with multiple sclerosis treated with prolonged-release fampridine in Germany. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Lennert B, Eaddy M. The use of interquartile deviation in establishing Delphi panel consensus: a prioritization of intravenous immunoglobulin utilization. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

McLeod K. Use of simulation to assess the impact of a remote monitoring system. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Meyer K, Clark R. The impact of endoscopic linear stapling device stability in thoracic surgery: a Delphi panel approach. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Morland K, Carroll C. The importance of anchor based minimal clinically important difference (MCID) to health technology assessment of established intranasal allergic rhinitis treatments. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Morland K, Eaddy M. Evaluating the cost of treating bladder cancer with and without metastases. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O'Day K, Campbell D. Cost-utility analysis of chocolate consumption for prevention of cardiometabolic disease. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O'Day K, Campbell D. Patient count forecasts of advanced non-small cell lung cancer: results from the UK, Germany, France, Italy and Spain (EU-5). Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O'Day K, Campbell D. The expanded number needed to treat: applying the concept of NNT to continuous health economic outcomes. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, Popelar B, Tang H, Balk M. Budget impact analysis of enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) from a US payer perspective. Poster presented at: American Urological Association Annual Meeting; May 15-19, 2015; New Orleans, LA.

O'Day K, Liu S, Bozkaya D. A method to evaluate uncertainty due to unknown parameter correlation in stochastic decision models. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O'Day K, Popelar B. Budget impact analysis of enzalutamide for treatment of metastatic castration-resistant prostate cancer from a U.S. payer perspective. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Ogbonnaya A, Kish J, Eaddy M. Rate of adverse event-related treatment changes and healthcare costs associated with topical rosacea treatment. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Pelton S, Shea K, Farkouh R, Strutton D, Braun S, Jacob C, Klok R, Gruen ES, Weycker D. Rates of pneumonia among children and adults with chronic medical conditions in Germany. Poster presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25-28, 2015; Copenhagen, Denmark.

Popelar B, Walters T, Houle C, Duhig A. Use of work productivity endpoints in clinical studies: a review by disease state and measurement type. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Prosser C, Altevers J, Braun S. Incidence and prevalence estimations based on claims data—new methodological considerations. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Prosser C, Landsman-Blumberg P, Braun S. Treatment costs and patterns in patients with multiple sclerosis treated with prolonged-release fampridine in Germany. Poster presented at: ISPOR 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Raju A, D'Souza A. Hypoglycemia rates and healthcare costs in patients with type 2 diabetes mellitus (T2DM) treated with 2nd line linagliptin or sulfonylurea after metformin. Poster presented at: Academy of Managed Care Pharmacy 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA.

Watson C, Prosser C, Braun S, Landsman-Blumberg P, Naoshy S. Health care resource utilization before and after natalizumab initiation among multiple sclerosis patients in Germany. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Albers H, Peplies J, Sadlo A, et al. Determinanten der patientenzufriedenheit von jugendlichen und jungen erwachsenen mit chronisch entzündlichen darmerkrankungen (CED). [Determinants of patient satisfaction of adolescents and young adults with chronic inflammatory bowel disease.] *Zeitschrift für Palliativmedizin [J Palliat Med]*. 2014;15(3).

Bendell JC, Lankford M, Britton S, Buettner A, Green MR, Neely D, Scharf M. Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for choice of therapy after failure of first-line FOLFOX + bevacizumab (FFB) in patients with metastatic colorectal cancer (mCRC). Poster presented at: 2014 Gastrointestinal Cancers Symposium; January 16-18, 2014; San Francisco, California.

Bozkaya D, Barrett AC, Migliaccio-Walle K. Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy. Poster presented at: The Liver Meeting®, AASLD 65th Annual Meeting; November 7-11, 2014; Boston, MA.

Bozkaya D, Migliaccio K, Bramley T. Evaluation of patient and financial outcomes associated with advanced infertility treatment options. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA.

Campbell C, Popelar B, Dandappanavar A, Knight J, O'Day K. Cost-effectiveness analysis of coffee consumption for prevention of all-cause mortality in the United States. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Carlton R, Campbell C, Raju A, Eaddy M. Evaluating the cost-effectiveness of interventional therapies used in the treatment of chronic venous disease. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA. *Silver Medal Winner*.

Carlton R, Clark R. Healthcare resource utilization and rehospitalization costs of nebulized arformoterol for the treatment of chronic obstructive pulmonary disease. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Carlton R, Zagadailov E, Bramley T. Comorbidity cost savings over 2 years of treatment with phentermine and topiramate extended-release (PHEN/TPM ER) in an overweight and obese population. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Chaudhari S, McLaughlin T, Morlock R, Shah MV, Cameron A, Ogale S. Extending targeted therapy beyond first-line chemotherapy backbone: real-world treatment patterns and outcomes in patients with metastatic colorectal cancer (mCRC). Poster presented at: European Society for Medical Oncology 16th World Congress on Gastrointestinal Cancer; June 25-28, 2014; Barcelona, Spain.

D'Souza AO, Morland K, Eaddy M. Treatment patterns and cost of care for patients with pancreatic cancer. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Factors influencing US payer coverage of elective biomarker diagnostics. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Factors that influence health plan decision-making in the coverage of biomarker diagnostic tests. Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Payer familiarity with oncology biomarkers, their companion diagnostics, and specific plan coverage practices: results of a focus group. Poster

presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

Denno M, Jackson J. Payers perspective on the future of genetic testing and personalized medicine. Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

Denno M, Klein C, Campbell C. Evaluation of outcomes in patients with overactive bladder within an integrated healthcare delivery system using a treatment patterns analyzer. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA.

Denno M, Popelar B, Jackson J, Lennert B. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

Drees L, Theidel U, Campbell CM, Popelar BV, O'Day K, Mittendorf T. Cost-effectiveness analysis of coffee consumption for prevention of all-cause mortality in Germany. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Faria C, Jackson J, Lunacsek O. A comparison of time to treatment failure in metastatic breast cancer patients receiving therapy with eribulin mesylate, either with or without dosing modifications. Poster presented at: Breast Cancer Coordinated Care 2014; February 20-22, 2014; Washington, DC.

Faria C, Jackson J, Lunacsek O, Hennenfent KL. Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: American Society of Clinical Oncology 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Faria C, Knoth R, Jackson J, Lunacsek O, Hennenfent K. Impact of anthracycline on progression-free survival and time-to-treatment failure in patients with metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Faria C, Knoth R, Jackson J, Lunacsek O, Hennenfent K. Impact of the duration of prior taxanes on progression-free survival and time-to-treatment failure in patients with metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Jacob C, Annoni E, Haas JS, Witthohn A, Braun S, Grünert J, Winking M, Franke J. Claims data analysis on the annual frequency and incremental cost of reoperations in instrumental spinal surgeries in Germany. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Green MR, Willey J, Buettner A, Lankford M, Neely DB, Ramalingam SS. Molecular testing prior to first-line therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC): a survey of United States (US) medical oncologists (MOs). Poster presented at: American Society of Clinical Oncology 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Gueron B, Kish J, O'Day K, Martel MJ, Manley Daumont M. Patient count projections for advanced melanoma by line of therapy and other clinical characteristics in EU countries: results from the UK, Germany, France, Italy, and Spain (EU-5). Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Haas JS, Wutzler P, Braun S. Burden of disease caused by influenza in Germany—a retrospective claims database analysis. Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Jacob C, Bechtel B, Engel S, et al. Kosten schwerer asthma-exazerbationen in Deutschland—eine empirische analyse. [Costs of severe asthma exacerbations in Germany—an empirical analysis.] Poster presented at:

dggö—Jahrestagung [Annual Conference of the German Society for Health Economics]; March 17-18, 2014; Munich, Germany.

Jacob C, Bechtel B, Engel S, et al. Kosten und ressourcennutzung im gesundheitswesen von asthma in Deutschland—eine schadensdatenbasierte analyse. [Cost and healthcare resource utilization (HRU) of asthma in Germany—a claims data based analysis.] Poster presented at: dggö—Jahrestagung [Annual Conference of the German Society for Health Economics]; March 17-18, 2014; Munich, Germany.

Jacob C, Brasseur P, Haas JS, Braun S. Cost comparison of surgical and non-surgical treated lumbar spinal stenosis patients. Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Jacob C, Prosser C, Lobermeyer K, Volk J, Braun S. Versorgungsbedarf bei allergie-immuntherapie-patienten in Deutschland: aggregierte ergebnisse von drei erhebungen im versorgungsalltag. [Need for care for allergy immunotherapy patients in Germany: aggregated results of three surveys in daily routine care.] Poster presented at: 9 Deutscher Allergie Kongress [9th Annual German Allergy Congress]; October 2-4, 2014; Wiesbaden, Germany.

Knight J, Floyd J, Denno M, Allen L, Duhig A, Jackson J. Managed care perspectives on accountable care organization implementation: focus on oncology. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA. *Bronze Medal Winner.*

Lokhandwala T, Dann R, Johnson M, D'Souza AO. Costs of the diagnostic workup for lung cancer: a Medicare claims analysis. Poster presented at: 2014 Multidisciplinary Symposium in Thoracic Oncology; October 30-November 1, 2014; Chicago, IL.

Lunacsek O, Bramley T. The economic burden of end-of-life care in metastatic breast cancer. Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

Meyer, K, O'Day K. Cost-effectiveness analysis of lurasidone vs. quetiapine XR in patients with bipolar depression. Poster presented at: ISPOR 19th Annual International Meeting; Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

O'Day K, Campbell C, Popelar B. Cost-utility analysis of coffee consumption for prevention of chronic disease and cancer in the United States. Poster presented at: ISPOR 19th Annual International Meeting; Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

O'Day K, Campbell C, Popelar B, McLaughlin T. The health economic impact of coffee consumption on prevention of chronic disease and cancer in the United States. Poster presented at: ISPOR 19th Annual International Meeting; Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

O'Day K, Meyer K. Budget impact model of eslicarbazepine acetate for refractory partial-onset epilepsy in a US health insurance plan. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA.

O'Day K, Meyer K. Subcutaneous peginterferon beta-1a reduces relapse-associated costs in patients with relapsing-remitting multiple sclerosis. Poster presented at: Academy of Managed Care Pharmacy 26th Annual Meeting and Expo; April 1-4, 2014; Tampa, FL.

O'Day K, Velez F, Meyer K. Cost-effectiveness of eslicarbazepine acetate in refractory partial-onset epilepsy. Poster presented at: 68th Annual American Epilepsy Society Meeting; December 5-9, 2014; Seattle, WA.

Prosser C, Jacob C, Lobermeyer K, Volk J, Braun S. Gründe für eine allergie-immuntherapie bei patienten mit allergischer rhinitis. [Reasons to opt for allergy immunotherapy in patients with allergic rhinitis.] Poster presented at: 9 Deutscher Allergie Kongress [9th Annual German Allergy Congress]; October 2-4, 2014; Wiesbaden, Germany.

Rodby R, Umanath K, Niecestro R, Jackson J, Dwyer J, Lewis J. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Poster presented at: National Kidney Foundation Spring Clinical Meeting; April 22, 2014; Las Vegas, NV.

Rouleau A, Guiraud-Diawara A, Landsman-Blumberg PB, Lokhandwala T, Stafkey-Mailey D, Verpillat P. Assessing balance in baseline characteristics using different propensity-adjusted methods for bipolar I mixed disorder patients initiating asenapine vs other oral atypical antipsychotics. Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Ryan CJ, Buettner A, Britton SL, Lankford M, Neely DB, Green MR. Prospective evaluation of prescribing preferences (PPrefs) of US-based oncologists in the postdocetaxel mCRPC patient (Pt). Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Ryan CJ, Green MR, Britton S, Buettner A, Lankford M, Neely D. Prospective evaluation of prescribing preferences (PPrefs) by US-based oncologists in the post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) patient. Poster presented at: 2014 Genitourinary Cancers Symposium; January 30–February 1, 2014; San Francisco, CA.

Ryan CJ, Green MR, Britton S, Buettner A, Lankford M, Neely D. Second-line prescribing preferences (PPrefs) of US-based medical oncologists (MOs) following first-line TKI use in patients with metastatic clear cell renal cell carcinoma (mccRCC). Poster presented at: 2014 Genitourinary Cancers Symposium; January 30–February 1, 2014; San Francisco, CA.

Seal BS, Xia F, Germino F, Rietschel P, Asche CV, D'Souza AO, Morland K, Eaddy M. An evaluation of national treatment trends in pancreatic cancer. Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Senbetta M, Dandappanavar A, Schenkel B, O'Day K. Ibrutinib therapy for patients with relapsed or refractory chronic lymphocytic leukemia: a budget impact analysis from a US payer perspective. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.

Shah NP, Buettner A, Lankford M, Willey J, Neely D, Green MR. Trends in first-line tyrosine kinase inhibitor prescribing preferences among United States-based hematology-oncology physicians for patients with chronic-phase chronic myelogenous leukemia. Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Stafkey-Mailey D, Seal BS, Xia F, Rietschel P, Germino R, Asche CV, Zagadailov E, Eaddy M. An evaluation of national treatment trends and survival in GIST. Poster presented at: American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30–June 3, 2014; Chicago, IL.

Stafkey-Mailey D, Zagadailov E, Eaddy M. Treatment patterns and cost of care for patients with gastrointestinal stromal tumor (GIST) treated with imatinib. Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Theidel U, Wahlers K, Mittendorf T. AMNOG benefit assessment for oncologic and orphan drugs in Germany—implications for price discounts. Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.

Zagadailov E, Carlton R, Bramley T. Budget impact of phentermine and topiramate extended-release (PHEN/TPM ER) in overweight and obese patients with comorbid prediabetes or type 2 diabetes mellitus (T2DM). Poster presented at: ISPOR 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

Zagadailov E, Duhig A, Denno M. The current state of patient-reported outcomes in managed care: payer perceptions of PROs and other measures of benefit. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 8-9, 2014; Boston, MA. *Bronze Medal Winner*.

Zagadailov E, Farrelly E, Eaddy M, Stafkey-Mailey D. Evaluating costs and utilization of prostate cancer patients with bone metastases in the outpatient hospital setting. Poster presented at: ISPOR 19th Annual International Meeting; Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.

2013

[Return to Posters](#)

[Return to Publications](#)

Bramley T. Cost-effectiveness of various combinations of human papillomavirus (HPV)-based testing, including genotyping for HPV 16/18, for cervical cancer screening. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T. Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T, Zagadailov E. The potential cost savings associated with preventing the development of hypertension, diabetes, and dyslipidemia in an overweight and obese population. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R. Cost of completing 1 year of treatment with phentermine/topiramate extended release in an overweight and obese population. Poster presented at: Obesity Society Conference; November 11-16, 2013; Atlanta, GA.

Carlton R, Bramley T. Cost analysis model between the cobas BRAF test and Sanger sequencing when treating malignant melanoma based on the presence of V600 mutations. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R, Clark R, Regan T. The burden of secondary cardiovascular disease in commercial and Medicare patients: a managed care perspective. Poster presented at: Academy of Managed Care Pharmacy 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.

Choti MA, Green MR, Corral M, Wong SL, Thomas M, Eaddy M. American medical oncology physician (AMOP) preferences for combined modality therapy beginning with systemic management in patients with liver-limited metastatic colorectal cancer (II-MCRC). Poster presented at: Gastrointestinal Cancers Symposium (ASCO GI); January 24-26, 2013; San Francisco, CA.

Claßen M, Albers H, Peplies J, et al. Expectations and satisfaction of CED teenagers and young adults with care—results from a survey of CEDATA patients. Poster presented at: 28 Jahrestagung der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); March 20-23, 2013; Heidelberg, Germany.

Consaul J. Methods to detect adverse drug reactions using automated healthcare databases. Poster presented at: Academy of Managed Care Pharmacy 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.

Denno M, Dandappanavar A, Raju A, Clark R, Campbell C, Regan T, Jackson J, Skodny P. Systematic literature review and meta-analysis of B-cell therapies in systemic lupus erythematosus. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Jacob C, Wüstenberg E, Lobermeyer K, Volk J, Mittendorf T. Need for care in specific immunotherapy in Germany: results of a market research analysis in everyday care. Poster presented at: 8 Deutscher Allergie Kongress; September 5-7, 2013; Bochum, Germany.

Li Y, Suh KH, Chen W, Wei ZJ, Higuchi K. Patterns in asthma medication treatment in the US. Poster presented at: ISPOR 16th Annual European Congress; November 2-6, 2013; Dublin Ireland.

Stafkey-Mailey D, Eaddy M. Treatment patterns and costs of patients with gastrointestinal stromal tumor (GIST) receiving first-line imatinib. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Theidel U, Mittendorf T, Mueller-Schwefe GH, Ueberall MA. Utilization patterns for treatment with strong opioids for chronic back pain in Germany. Poster presented at: ISPOR 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

2012

[Return to Posters](#)

[Return to Publications](#)

Altevers J, Sadlo A, Bauer A, et al. Quality of care of young people with inflammatory bowel disease (CED)—validation of a patient satisfaction questionnaire. Poster presented at: 7 Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi); September 26-29, 2012; Regensburg, Germany.

Bakhai A, Greiner W, Mittendorf T, Berto P, Campbell D, Sandberg A, Oberdiek A, Zamorano JL. Assessment of patient satisfaction with chronic treatment using the European Patient Survey in Atrial Fibrillation (EUPS-AF). Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Bokemeyer B, Helwig U, Stallmach A, Teich N, Halle R, Düffelmeyer M, Prenzler A, Mittendorf T, Hartmann H. Low levels of glucocorticoid use in early Crohn's disease in Germany. Poster presented at: 7th Congress of European Crohn's and Colitis Organisation; February 16-18, 2012; Barcelona, Spain.

Bordoni R, Gilmore JW, Haislip S, et al. Factors influencing hypomethylating agent (HMA) choice in patients with myelodysplastic syndromes (MDS) seen in a community practice. Poster presented at: Second Annual Association for Value-Based Cancer Care Conference; March 29-31, 2012; Houston, TX.

Bramley T, Bruno A. Patterns of treatment failure among patients receiving anticholinergics for overactive bladder (OAB) treated in a managed care setting. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Bruns H, Peplies J, Altevers J, et al. Determinants of medication adherence in chronically ill adolescents. Poster presented at: 57 Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS); September 16-20, 2012; Braunschweig, Germany.

Claßen M, Peplies J, Altevers J, et al. Transition of CED patients—initial analyses of a survey in CEDATA patients. Poster presented at: 27 Jahrestagung der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); April 12-14, 2012; Vienna, Austria.

Damm O, Leppert F, Greiner W. Cost-of-illness of common cancer types—results of a health insurance claims data analysis. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

D'Souza A, Bramley T, Carlton R. A conjoint analysis of willingness to pay to avoid metastatic breast cancer side effects. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Eddy M. Comparing the management and cost of hospitalized prostate cancer patients with and without bone metastases. Poster presented at: MASCC/ISOO 2012 International Symposium on Supportive Care in Cancer; June 28-30, 2012; New York, NY.

Eddy M. Comparing the use and cost of radiopharmaceuticals in prostate cancer patients with and without bone metastasis. Poster presented at: ISPOR 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Eddy M. Evaluating the inpatient hospitalization costs of treating prostate cancer patients. Poster presented at: ISPOR 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Jackson J, Chen L, Sail K, et al. Monitoring patterns and subsequent outcomes among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community

setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.

Lennert B. Anticoagulants for stroke prophylaxis in a commercially insured atrial fibrillation population. Poster presented at: Academy of Managed Care Pharmacy 24th Annual Meeting and Expo; April 18-20, 2012; San Francisco, CA.

McGee N. Healthy technology assessment evidence criteria: what types of evidence should be presented for products used to screen for disease in the United States? Poster presented at: ISPOR 15th Annual European Congress; November 5, 2012; Berlin, Germany.

Meyer K. Discontinuation rates among atypical antipsychotics for schizophrenia: an indirect treatment comparison. Poster presented at: Academy of Managed Care Pharmacy 2012 Educational Conference; October 4, 2012; Cincinnati, OH.

Mittendorf T, Zamorano JL, Bakhai A, Berto P, Leach N, Sandberg A, Oberdiek A, Greiner W. Out-of-pocket financial burden in atrial fibrillation and potential impact on care: comparison across five European countries using the European Patient Survey in Atrial Fibrillation (EUPS-AF). Poster presented at: ISPOR 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

O'Day K, Bramley T. Sensitivity analysis versus uncertainty analysis in health economic decision making. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Peplies J, Bruns H, Altevors J, et al. Transition of chronically ill adolescents—first results of a survey of young patients with chronic inflammatory bowel disease (CED). Poster presented at: 57 Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS); September 16-21, 2012; Braunschweig, Germany.

Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F. Long-term costs and outcomes of patients with schizophrenia who have previously failed an atypical antipsychotic. Poster presented at: 25th Annual U.S. Psychiatric and Mental Health Congress; November 8-11, 2012; San Diego, CA.

Rajagopalan K, O'Day K, Meyer K, Hsu J, Pikalov A. Economic impact of relapse-related hospitalization in adults with schizophrenia: results from a 12-month, double-blind lurasidone vs quetiapine XR study. Poster presented at: American Psychiatric Association 165th Annual Meeting; May 5-9, 2012; Philadelphia, PA.

Sail K, Chen L, Jackson J, Ericson S, et al. Treatment patterns among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.

Seal B, Asche C, Puto K, Allen P. Patient-reported outcomes (PROs) and tolerability of therapeutic agents in patients with metastatic prostate cancer (MPC): a systematic literature review. Poster presented at: ISPOR 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Seal B, Sullivan SD, Ramsey SD, et al. Comparing the management and cost of hospitalized prostate cancer patients with and without bone metastases. Poster presented at: Multinational Association of Supportive Cancer Care International Symposium on Supportive Cancer Care; June 28-30, 2012; New York City, NY.

Shah M. Cost-effectiveness of select first-line chemotherapy regimens in the treatment of nonsquamous non-small cell lung cancer patients in the outpatient setting. Poster presented at: Academy of Managed Care Pharmacy 24th Annual Meeting and Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Disease-specific costs and resource utilization associated with the initiation of insulin therapy within a type II diabetes mellitus population. Poster presented at: Academy of Managed Care Pharmacy 24th Annual Meeting and Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Outcomes after initiation of fluticasone propionate-salmeterol combination versus anti-cholinergics in patients with moderate exacerbations of COPD. Poster presented at: Academy of Managed Care Pharmacy 24th Annual Meeting and Expo; April 18-20, 2012; San Francisco, CA.

Shah M, Gruschkus S, Dhamane A. Economic evaluation of reduced futile 1st line therapy in metastatic renal cell carcinoma patients using early angiogenesis-specific imaging. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Sikirica V, Fridman M, Bruno A, Hodgkins P, Erder M. Factors associated with the use of psychotropic concomitant medication (PCM) for attention-deficit/hyperactivity disorder (ADHD). Poster presented at: European Network for Hyperkinetic Disorders 2nd International ADHD Conference; May 23-25, 2012; Barcelona, Spain.

Tomeczkowski J, Theidel U, Mittendorf T, Fleischmann J, Tapprich C. Data analyses on prevalence and treatment of acute myeloid leukaemia in Germany. Poster presented at: ISPOR 15th Annual European Congress; November 6, 2012; Berlin, Germany.

2011

[Return to Posters](#)

[Return to Publications](#)

Barocas D, Gallager J, Colayco D, Schwartz B, Heap K, Globe D. Utilization of immediate postoperative instillation of intravesical chemotherapy: a quality-of-care concern in older patients with non-muscle-invasive bladder cancer. Poster presented at: 12th Annual meeting of the Society of Urologic Oncology in Conjunction with the World Urological Oncology Federation; November 30–December 2, 2011; Rockville, MD.

Barocas DA, Globe D, Colayco D, Gilmore A, Bramley T. Humanistic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer (NMIBC). Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Boswell KA, Wang J, Shah MV, Apro VS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen-receptor positive (ER+) advanced breast cancer: a review of the literature. Poster presented at: ISPOR 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Bowles D, Wasiak R, Lindemann M, Van Nooten F, Meinhardt M, Greiner W. Burden of illness in patients with neural tube defects in Germany. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Brixner D, Eaddy M, Parkinson J. Applications in using large databases. Xcenda's short course. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Carlton R, Regan T, Rice G. Lower daily average consumption and greater prescription cost savings of armodafinil compared with modafinil: a 12-Month Retrospective Database Analysis. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Damm O, Horn J, Kretschmar M, et al. Estimating the potential cost-effectiveness of human papillo-mavirus (HPV) vaccination in Germany using a dynamic transmission model. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Damm O, Rose MA, Greiner W, et al. Cost-effectiveness of vaccinating children aged 2–17 years with intranasal live attenuated influenza vaccine (LAIV) in Germany. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Dexter F, Yang J, Carlton R, Bramley T, Harb G. Cost-effectiveness analysis of antiarrhythmic therapies for the treatment of supraventricular tachycardia and surgically induced tachycardias and hypertension. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting event in patients with breast cancer receiving low emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.

Foran J. Treatment of higher-risk myelodysplastic syndrome (MDS) by American hematology-oncology providers (AHOPs): changes in 1st-line treatment preferences over time in relation to cytogenetics & survival data from randomized studies. Poster presented at: 2011 Annual Meeting of the American Society of Hematology; December 12, 2011; San Diego, CA.

Gerson LB, Balu S, McLaughlin T, Lunacsek O, Jackson J. Examination of resource utilization patterns across subgroups of gastroesophageal reflux disease patients. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Jain G, Roy A, Harikrishnan V, Yu S, Dabbous OH. Association between work productivity and severity of depression among full-time employees as measured by the WPAI & HPQ. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Kruep E, Gruschkus S, Goodwin B, Chaudhari S. Impact of length of 5 ARI therapy on clinical outcomes and costs in a population of managed care patients with benign prostatic hyperplasia. Poster presented at: American Urological Association; May 14-19, 2011; Washington, DC.

Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. Willingness to pay for a reduction in risk of treatment side effects in patients with metastatic breast cancer. Poster presented at: ISPOR 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Larsen S, McLaughlin T, Allen P, Farrelly E, Sarnes M, LaFrance N. Real world use of diagnostic procedures in renal cell carcinoma. Poster presented at: Society of Nuclear Medicine Annual Meeting; June 6, 2011; San Antonio, TX.

Lawrence C, Roy A, Harikrishnan V, Uy S, Dabbous OH. The association between self-perceived cognitive difficulties and level of depression among employees with current depression. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Lee CT, Globe D, Colayco D, Gilmore A, Bramley T. Economic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Lee C, Gruschkus S, Colayco D, Bramley T, Globe D. Treatment patterns and costs of treating non-muscle-invasive bladder cancer. Poster presented at: 12th Annual meeting of the Society of Urologic Oncology in conjunction with the World Urological Oncology Federation; November 30–December 2, 2011; Rockville, MD.

O'Day K, Globe D, Gruschkus SK, Peterson P. Novel methods for characterizing uncertainty in economic analysis. Poster presented at: ISPOR 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

O'Day K, McLaughlin T, Bramley T. Is it time to eliminate the ICER? Using net benefits to report the results of deterministic cost-effectiveness analyses. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Peters C, Drees A, Leppert F, et al. Productivity of telemedical services: a state of the art analysis of input and output factors. Poster presented at: 21 International RESER Conference; September 7-10, 2011; Hamburg, Germany.

Polonsky W, Rosenstock J, Gilmore A, Wei W, Chaudhari S, Riddle M. Patient reported outcomes using twice-daily insulin aspart premixed vs insulin glargine plus 1 prandial insulin glulisine or stepwise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents. Poster presented at: American Diabetes Association 70th Scientific Sessions Abstract; June 24-28, 2011; San Diego, CA.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT₃ receptor antagonist selection within triple antiemetic regimens on the risk of uncontrolled chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.

Shah M. Venous Thromboembolism prophylaxis patterns in a large oncology center. Poster presented at: MASCC/ISOO 2011 International Symposium; June 23-25, 2011; Athens, Greece.

Shah M, Chaudhari S, McLaughlin T, et al. The cost of corticosteroid-associated adverse events in systemic lupus erythematosus. Poster presented at: ISPOR 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Theidel U, Asseburg C, Giannitsis E, Katus H. PCV70 cost effectiveness of ticagrelor in the treatment of acute coronary syndrome in Germany. *Value Health*. 2011;14(7):A376-A377. Poster presented at: ISPOR 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Ye X, Shah M, Rupnow M, Hammond J. Readmission rates and costs associated with fibrin sealant use among patients undergoing orthopedic surgery. Poster presented at: ISPOR 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

2010

[Return to Posters](#)

[Return to Publications](#)

Bordoni R, Feinberg BA, Gilmore JW, et al. Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2010; Chicago, IL.

Braun S, Zeidler J, Linder R, Ahrens S, Manouguian M, Greiner W. Cost of attention deficit/hyperactivity disorder in Germany. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Brixner D, Eaddy M, Parkinson J. Real-world data methods: applications in using large retrospective databases. Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Crawford ED, Moul JW, Pettaway C, Sutton S, Poston S, Kruep E. Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2010; Chicago, IL.

Dhamane AD, Martin B, Brixner D, Hudson TJ, Said Q. Assessment of metabolic monitoring of patients prescribed second-generation antipsychotics (SGAs) using electronic medical record (EMR) data. Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Eaddy M, Chen L, DuBois R, Davies EH. A comparison of intravenous and oral formulations of fludarabine in the treatment of Chronic Lymphocytic Leukemia (CLL) Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Ejzykowicz F, Regan T, Gratz-Levenson G. Chronic heart failure: adherence to guidelines by physicians and adherence to therapy by patients in metropolitan vs non-metropolitan areas. Poster presented at: Academy of Managed Care Pharmacy 2010 Educational Conference; October 13-15, 2010; St. Louis, MO.

Ejzykowicz F, Schoof-Knauer PJ, Gratz-Levenson GR, Regan T. Physician adherence to clinical guidelines for chronic heart failure and acute myocardial infarction: metropolitan vs. non-metropolitan area practices. Poster presented at: National Rural Health Association Annual Conference 2010; May 18, 2010; Savannah, GA. Slides 1-25.

Feinberg B, Schwartzberg LS, Gilmore J, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting event in patients with hematologic malignancies receiving chemotherapy. Poster presented at: 52nd American Society of Hematology Annual Meeting and Exposition; December 4-7, 2010; Orlando, FL.

Green MR, Wozniak AJ, Willey J, Lemke KE, West HJ. Plans of American medical oncologists (AMOs) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2010; Chicago, IL.

Mass N, Bruno B, Greiner W. PO-Onko 02.42, ACT-FASTER: an epidemiological prospective cohort study to describe treatment patterns of Fulvestrant and exemestane in postmenopausal patients with advanced HR+ breast cancer under real-life conditions in Germany. Poster presented at: 58th Congress of the German Society of Gynecology and Obstetrics; October 5-8, 2010; Munich, Germany.

Mauceri E, Jackson J, Inman M, Bramer S, Bienkowski C, Doyle JJ. Assessment of a worksite cardiometabolic intervention program: impact on hypertension awareness and control. Poster presented at: Forum 10, Disease Management Association of America: Care Continuum Alliance Annual Meeting; October 13-15, 2010; Washington, DC. *Won best poster.*

O'Day K, Meissner B, Bramley T. Ruling out extendedly dominated options in excel using an ICER matrix. Xcenda's Short Course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

O'Day K, Meissner B, Bramley T. The cost-effectiveness sensitivity curve: quantifying the effect of individual parameter uncertainty in a probabilistic model. Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Rice G, Carlton R, Regan T. The Financial impact of a Daily Average Consumption (DACON) analysis in a US Pharmacy Benefit Management (PBM) company. Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Shenolikar R, Burch S, Cantrell C, Gilmore A, Eaddy M. Sensitivity of medication use and outcomes to formulary controls in the elderly: a review of the literature. Xcenda's short course. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Sroczyński G, Schnell-Inderst P, Muehlberger N, et al. HPV-based primary cervical cancer screening in Germany. Cost-effectiveness results from a decision-analytic modeling study. Poster presented at: ISPOR 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Willey J, Lemke KE, Williams ME, Green MR, Lonial S. Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2010; Chicago, IL.

Yu E, Gilmore J, Gilmore AS, et al. Patient reported symptoms and treatment patterns of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer in a US-community oncology setting. Poster presented at: European Society for Medical Oncology Congress; October 8-12, 2010; Milan, Italy.

2009

[Return to Posters](#)

[Return to Publications](#)

Claes C, Mittendorf T, Kuchenbecker U, Rose M, Reinert R. Cost-effectiveness of switching strategies from a 7-valent to a 13-valent pneumococcal conjugate vaccine. Poster presented at: ISPOR 12th Annual European Congress; October 24-27, 2009; Paris, France.

Jackson J, Kohn-Parrott KA, Parker C, et al. Chrysler BPSZ Study Poster: Improvements in blood pressure control and lifestyle modifications through a unique, employer-based hypertension management program (BP

success zone: you auto know). Poster presented at: American Occupational Health Conference; April 26-29, 2009; San Diego, CA.

Mauceri E, Bienkowski C, Hanson KA, Doyle JJ, Jackson J, Bramer S. Cardio Mission Health Poster: A health outcomes assessment of an on-site employer cardiometabolic intervention program. Poster presented at: American Occupational Health Conference; April 26-29, 2009; San Diego, CA.

Prenzler A, Mittendorf T, Kuchenbecker U, Montag T, Mueller-Busch C. Palliative care and its reimbursement for outpatient services in Germany—a survey among office-based physicians. Poster presented at: ISPOR 12th Annual European Congress; October 24-27, 2009; Paris, France.

2008

[Return to Posters](#)

[Return to Publications](#)

Eidt D, Mittendorf T, von der Schulenburg JM. Medication costs of patients with cystic fibrosis (CF) in Germany. Poster presented at: ISPOR 11th Annual European Congress; November 2008; Athens, Greece.

Jackson J, Kohn-Parrott KA, Parker C, et al. Chrysler BPSZ Study Poster: A health outcome assessment of the introductory blood pressure success zone at Chrysler LLC. Poster presented at: American Occupational Health Conference; April 13-16, 2008; New York, NY.

2005

[Return to Posters](#)

[Return to Publications](#)

Crivera C, Varghese S, Faruqi R, Kaliner M, Bramley T, Chiao E. Reasons for non-adherence to Inhaled Corticosteroid (ICS) therapy in persistent asthma. Poster presented at: American Thoracic Society International Conference; May 20-25, 2005; San Diego, CA.

Gehling R, Crivera C, Szwarcberg J, Bramley T, Chiao E, Vishalpura T. Application of a Delphi technique to determine management patterns of inhaled corticosteroid-induced oropharyngeal side effects. Poster presented at: Western Society of Asthma, Allergy, and Immunology Annual Meeting; January 23-27, 2005; Kauai, HI.

Goldstein JL, Senagore A, Delaney C, Matuszewski K, Chiao E. The inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. Poster presented at: Digestive Disease Week; May 14-19, 2005; Chicago, IL.

Kaliner M, Crivera C, Szwarcberg J, Bramley T, Chiao E. Physician responses to oropharyngeal adverse events caused by inhaled corticosteroids in adults with asthma. Poster presented at: American Academy of Allergy, Asthma, and Immunology 61st Annual Meeting; March 18-22, 2005; San Antonio, TX.

Katon WJ, Cantrell CR, Sokol MC, Gdovin JM, Chiao E. Impact of increased antidepressant adherence on comorbid medication use and economic outcomes. Poster presented at: Society of General Internal Medicine Annual Meeting; May 11-14, 2005; New Orleans, LA.

Vargo J, Bramley T, Meyer K, Nightengale B. Practice efficiency for colonoscopy can be improved by utilizing a sedation agent with a recovery profile that is superior to meperidine and midazolam: results of a Monte Carlo cost simulation model. Poster presented at: Digestive Disease Week; May 14-19, 2005; Chicago, IL.

2004

[Return to Posters](#)

[Return to Publications](#)

Frankum LE, Nightengale BS, Russo CL, Sarnes MW. Pharmacoeconomic analysis of antimycotic agents in the treatment of onychomycosis. Poster presented at: Academy of Managed Care Pharmacy; April 2, 2004; San Francisco, CA.

Grant D, Frieson S, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of a diabetes disease management program in a Medicaid program. Poster presented at: Disease Management Association of America 6th Annual Disease Management Leadership Forum; October 20-23, 2004; Orlando, FL.

Patric K, Stickles J, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of diabetes disease management in a Medicaid population enrolled in a network model managed care organization. Poster presented at: Disease Management Association of America (DMAA) 6th Annual Disease Management Leadership Forum; October 20-23, 2004; Orlando, FL.

Rosenfeld WE, Bramley TJ, Meyer K. Patient compliance with topiramate vs. other antiepileptic drugs: a claims database analysis. Poster presented at: American Epilepsy Society; December 3-8, 2004; New Orleans, LA.

Sarnes MW, Eaddy MT, Hill L, Mauch R, Regan T. The Medication Use Evaluation (MUE) software: a depression/anxiety quality improvement tool for managed care. Poster presented at: Academy of Managed Care Pharmacy; April 2, 2004; San Francisco, CA.

2003

[Return to Posters](#)

[Return to Publications](#)

Bramley T, Eaddy M, Mauch R, Regan T. Treatment patterns and time to treatment discontinuation with SSRIs: comparison of a controlled-release formulation of paroxetine and immediate-release SSRIs. Poster presented at: Disease Management Association of America, 5th Annual Disease Management Leadership Forum; October 12-15, 2003; Chicago, IL.

Frechette A, Jackson JH, Frech F. Determinants of uncontrolled blood pressure in a hypertensive population. Poster presented at: American Academy of Nurse Practitioners 18th Annual National Conference; June 29–July 1, 2003; Anaheim, CA.

Jackson JH, Frechette A, Farrelly E, Frech F. Modeling coronary heart disease risk reduction through improvement in blood pressure control. Poster presented at: American Academy of Nurse Practitioners 18th Annual National Conference; June 29–July 1, 2003; Anaheim, CA.

Regan T, Lennert B, Eaddy M. Incorporating compliance and persistency outcomes into disease management: the national depression/anxiety managed care database study. Poster presented at: Disease Management Association of America, 5th Annual Disease Management Leadership Forum; October 12-15, 2003; Chicago, IL.

Sheehan D, Eaddy M, Sullivan L. Evaluating the economic consequences of SSRI drop-outs in depression. Poster presented at: ISPOR; May 2003; Crystal City, VA.

2002

[Return to Posters](#)

[Return to Publications](#)

Frechette A, Jackson JH, Hibler S, et al. The need for improved blood pressure control within the African-American population: a multi-site assessment. Poster presented at: American College of Clinical Pharmacy Spring Practice and Research Forum; April 7-10, 2002; Savannah, GA.

Grogg A, Eaddy M, Mauch R, Maue S. The effects of antipsychotic partial compliance on resource utilization in a schizophrenia and bipolar population. Poster presented at: 42nd Annual New Clinical Drug Evaluation Unit Meeting; June 12, 2002; Boca Raton, FL.

Grogg A, Eaddy M, Mauch R, Maue S. The effects of atypical and oral conventional antipsychotics on the compliance of mental health patients. Poster presented at: American Psychiatric Association 2002 Institute on Psychiatric Services Meeting; October 9-13, 2002; Chicago, IL.

Jackson JH, Farrelly E, Frechette A. Clinical and economic advantages of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy 2002 Educational Conference; October 11, 2002; Washington, DC.

Jackson JH, Farrelly E, Frechette A, Lennert B, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in a hypertensive population. Poster presented at: American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Godly P. Economic impact of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy 14th Annual Meeting and Showcase; April 3-6, 2002; Salt Lake City, UT.

Jackson JH, Farrelly E, Ziska D, et al. Heart Failure therapies within managed care. Poster presented at: American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Ziska D, Frech F, Hibler S. Heart failure therapies within managed care. Poster presented at: 6th Annual Scientific Meeting of the Heart Failure Society of America; September 23, 2002; Boca Raton, FL.

Jackson JH, Farrelly E, Ziska D, Lennert B, Mullany L, Frech F. Heart failure therapies within managed care. Poster presented at: American College of Clinical Pharmacy 2002 Annual Meeting; October 23, 2002; Albuquerque, NM.

Jackson JH, Maue SK, Godly P. Prevalence of elevated systolic blood pressure in the U.S. Poster presented at: American Heart Association's Asia Pacific Scientific Forum; April 23-26, 2002; Honolulu, HI.

Maue SK, Godly P. Assessing the prescription burden of hypertensive diabetes patients within managed care plans. Poster presented at: American Diabetes Association 62nd Annual Meeting and Scientific Sessions; June 14-18, 2002; San Francisco, CA.

2001

[Return to Posters](#)

[Return to Publications](#)

Godley PJ, Nikam PT, Yokoyama KK, Maue SK, Woodward BW. Blood pressure control within the Scott and White health plan through primary care provider-focused interventions. Poster presented at: American Society of Health-Systems Pharmacists Mid-Year Clinical Meeting; December 3-7, 2001; New Orleans, LA.

Lennert B, Maves T, Maue SK, Jackson JH. Identifying opportunities to improve clinical outcomes in hypertension: collaboration between pharmacy and quality improvement departments at touchpoint. Poster presented at: 2001 Pharmacy Society of Wisconsin Educational Conference; April 26-27, 2001; Madison, WI.

Maue SK, Farrelly EW, Frech F. The need for improved blood pressure control within the diabetic hypertensive population. Poster presented at: President's Poster Reception at American Diabetes Association 61st Scientific Sessions; June 22-26, 2001; Philadelphia, PA.

Maue SK, Konerman JP, Sarnes MW. Identifying opportunities to improve clinical outcomes for high risk hypertensive patients. Poster presented at: American Society of Health-Systems Pharmacists Annual Meeting 2001; June 3-6, 2001; Los Angeles, CA.

Maue SK, Lennert B, Godley PJ, Berney S. Assessing quality improvement in hypertension care to meet HEDIS 2000 standards. Poster presented at: 13th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; April 18-21, 2001; Tampa, FL.

Nightengale BS. The disease burden and cost of illness related to VRI. Poster presented at: Symposium held during Academy of Managed Care Pharmacy Educational Conference: Managing the Cold War: Costs and Complications of Respiratory Illness; October 19, 2001; Dallas, TX.

Nightengale BS, Maue SK, Farrelly EW, Frech F. Identifying hypertension patients for quality improvement: is HEDIS enough? Poster presented at: 13th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; April 18-21, 2001; Tampa, FL.

Woo A, DeWolf W, Maue SK. Which standard for blood pressure control? WHO or JNC-VI? Poster presented at: American Society of Hypertension 16th Scientific Meeting; May 15-19, 2001; San Francisco, CA.

2000

[Return to Posters](#)

[Return to Publications](#)

Fraser M, Mofsen R, Maue SK, Farrelly E. A quality improvement initiative for patients with behavioral disorders in the long-term care environment. Poster presented at: American Geriatrics Society Annual Meeting; May 17-21, 2000; Nashville, TN.

Maue SK, Farrelly E. Quality improvement opportunities for hypertension care in a managed care setting. Poster presented at: American Society of Health-Systems Pharmacists Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.

Maue SK, Gillis CT, Frech FH, Doan Q, Farrelly EW. Identifying opportunities to improve clinical outcomes for hypertensive patients with diabetes in a managed care setting. Poster presented at: American Society of Hypertension 15th Scientific Meeting; May 16-20, 2000; New York, NY.

Pham H, Godley PJ, Rohack J, Maue SK. Quality of hypertension care among diabetics in a managed care setting: scope for improvement. Poster presented at: American Society of Health-Systems Pharmacists Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.

Pham HT, Godley PJ, Rohack J, Woodward B, Nightengale BS. HEDIS 2000 hypertension improvement program within a managed care organization. Poster presented at: American Society of Health-Systems Pharmacists Annual Meeting; June 4-7, 2000; Philadelphia, PA.

Sapienza S, Sacco P, Floyd KM, DiCesare J, Doan Q. Hypertension management in long-term care: opportunities for quality improvement. Poster presented at: American Medical Directors Association Annual Symposium; March 16-19, 2000; San Francisco, CA.

1999

[Return to Posters](#)

[Return to Publications](#)

Fraser M, Mofsen R, Kernodle SJ. A quality improvement initiative for patients with dementia. Poster presented at: American Medical Directors Association Annual Meeting; March 4-7, 1999; Orlando, FL.

Fraser M, Mofsen R, Maue SK, Farrelly E. A quality improvement initiative for patients with behavioral disorders in the long-term care environment. Poster presented at: University of Florida Pharmacy Health Care Administration Transatlantic Geriatrics Annual Meeting; September 1-3, 1999; Paris, France.

Nightengale BS, Crumly JM, Kernodle SJ, Jacobs EW. Dosing trends and associated schizophrenia related health care costs from a state Medicaid perspective: risperidone versus olanzapine. Poster presented at: American Psychiatric Association Annual Meeting; January 1999.

Rapp KL, Collette A, Mauch RP, Floyd KM. A prescription for balancing quality and cost in the changing reimbursement environment. Poster presented at: American Medical Directors Association Meeting; March 4-7, 1999; Orlando, FL.

1997

[Return to Posters](#)

[Return to Publications](#)

Assessing the outcomes associated with implementing an H2 antagonist outcomes management program in a long-term care population. Poster presented at: American Society of Consultant Pharmacists 28th Annual Meeting and Exhibition; November 15, 1997; Philadelphia, PA.

Description of a health outcomes management program in a long-term care population. Poster presented at: American Society of Consultant Pharmacists 28th Annual Meeting and Exhibition; November 15, 1997; Philadelphia, PA.

Mauch RP, Floyd KM. Health outcomes management program. Poster presented at: American Medical Directors Association Meeting; February 15, 1997; Phoenix, AZ.

Mauch RP, Tuell KT, Floyd KM. Assessing the impact of a heart failure health outcomes management program in a long-term care environment. Poster presented at: American Society of Consultant Pharmacist 28th Annual Meeting and Exhibition; November 1997; Philadelphia, PA.

Relationship of consultant type and prescription utilization in Florida long-term care facilities. Poster presented at: 24th Annual Meeting and Exposition of the American Society of Consultant Pharmacists; November 12, 1993; New Orleans, LA.